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Abstract
Background:
Vitamin D has sparked the researchers and public health interest because its 
deficiency and insufficiency have the potential to impact enormously on many aspects 
of human health.
This paper presents research investigating vitamin D status among pre- and post­
menopausal healthy Saudi women, examining the influence of lifestyle factors on 
vitamin D levels, and evaluating associated effects of vitamin D on musculoskeletal 
health in these healthy women.
Subjects and methods:
As part of the investigation, a total of 449 healthy Saudi women [age 20-82 years] 
were randomly recruited from the city of Jeddah, medically examined and provided 
urine and blood samples for assessment of biochemical parameters. Socio­
demographic and lifestyle information such as sun exposure and physical activity was 
obtained using a standardized questionnaire. Musculoskeletal pain information was 
obtained through another designed questionnaire. Physical performance functions 
were assessed by the following three tests: get up and go (GUG), 8 -feet walk (8 FW), 
and five-time sit to stand (5-STS). Bone mineral density (BMD) was determined 
using dual x-ray absorptiometry (DXA).
Results:
The mean age was 29.1[SD 5.6] and 58.8 [SD 5.9] years for pre-and post-menopausal 
women, respectively. A total of 8 6 % of women studied were vitamin D deficient 
(serum 25(OH) D <50 nmol/L) and 20% exhibited severe vitamin D deficiency 
(25(OH) D <12.5 nmol/L). The mean serum 25(OH)D was 22.6 [19.8] and 35.0 [22.1] 
nmol/L for pre-and post-menopausal women, respectively. Based on World Health
Organization (WHO) criteria, a total of 29% of all women were osteopenic at the 
lumbar spine, and 29% at the femoral neck. The percentage of osteoporosis at lumbar 
spine site was higher than that at femur neck, being 9.1% and 4.1% respectively. 
Obesity was prevalent in 39% of the women studied. The mean body mass index was
25.9 [5.4] and 31.5 [5.7] kg/m^ for pre-and post-menopausal women, respectively. 
Although vitamin D deficiency was highly prevalent in the studied population, it was 
not associated with physical performance, a strong predictor of future disability. 
About 86.4% of women complained of bone pain, however it was not correlated to 
vitamin D.
Conclusion:
Despite abundant sun shine almost all year round, vitamin D deficiency is highly 
prevalent in Saudi Arabia. Limited sun exposure due to excessive heat and/or 
conservative clothes and obesity are among the factors contributing to this public 
health issue in the area. Given the high prevalence of vitamin D deficiency in our 
population, additional research examining the interaction between vitamin D, lifestyle 
factors and musculoskeletal health are warranted.
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CHAPTER I
REVIEW OF THE LITERATURE
1.1 Introduction
Vitamin D has been the subject of considerable research and debate in recent 
years. This fat-soluble vitamin, which may better be classed as a steroid hormone, has 
sparked this interest partly due to its unique duality of sourcing both from dietary 
intake and skin’s synthesis through the exposure to the sun’s ultraviolet radiation and 
in part because of its extensive role in human health. Serum 25-hydroxyvitamin Dg 
[25(0H)Dg] levels are used to measure the adequacy of vitamin D status. The 
consensus among researchers is that 25(OH)D concentrations of at least 75 nmol/L 
are optimal (Holick et al., 2011).
1.2 Vitamin D
Vitamin D is unique among the vitamins due to the ability of human’s skin to 
synthesize it via the exposing to ultraviolet radiation (UVR). This characteristic, in 
addition to the fact that it can act on specific target tissues through vitamin D 
receptors (VDRs), beside the feedback regulation of its production by serum (Ca) and 
phosphorus (PO4 ), make it more accurately classified as a hormone (Plum & DeLuca, 
2010). Vitamin D is available in two forms: ergocalciferol (vitamin D2 ) and 
cholecalciferol (vitamin Dg). The production of most of our vitamin Dg takes place in 
the skin but food is another important source as well. Vitamin D2 and Dg undergo 
similar main steps as they are metabolized. Both forms are used in supplements and 
the fortification of food. Without a numerical subscript, the term ‘vitamin D’ is used 
to represent either D2 or Dg or both. Vitamin D is inert compound and must undergo 
obligate hydroxylation twice in order to form 1,25-dihydroxyvitamin Dg 
(l,25(OH)2Dg), its biologically active hormone. Vitamin D is transported in the blood 
by the vitamin D binding protein (DBP), which is a specific binding protein for 
vitamin D and its metabolites (Christakos et al., 2010). Vitamin D binding protein is
produced in the liver and has a high affinity for 25(OH)D (Haddad, 1999). Figure 
l.lprovides a simplified diagrammatic display of vitamin D sources, synthesis, and 
activation in the human body (Deeb et al., 2007).
7-dehydrocholesterol 
(pro-Vltamin D,)
sunlight (UVB) 
exposure
pre-Vitamin D3
isomerized in the 
epidermal basal layer
dietary sources
intestinal absorption of natural and 
fortified foods and supplements
Vitamin D 
binds to DBP hydroxylated by liver 25-hydroxylase 
(250H ase)
2 5 (O H )D
hydroxylated by 
kidney 1a-hydroxylase 
(laO H ase)  
la,25(pH)^ D )
Intestine: increases 
Ca’ "^ and P04
bone: increases 
bone resorption
Figure 1.1: Vitamin D sources and metabolism
Adapted from (Deeb et al., 2007)
1.3 Sources of vitamin D
Worldwide, most individuals have low vitamin D status (Holick, 2007). This 
may stem from lack of clarity about the sources and conversion of vitamin D into a 
form which is physiologically useful. For instance, some educators and nutritionists 
think that a normal healthy diet will supply adequate amounts of the vitamin 
(Cashman, 2012). However, others disagree, arguing that if vitamin D was a standard 
part of typical dietary intake, the current high rates of vitamin D deficiency and 
insufficiency would not be observed.
1.3.1 Food Sources
The amount of vitamin D which comes from a normal diet is not large, with 
significant amounts (10-25 pg) of vitamin D3 found only in oily fish like salmon, 
herring, tuna, sardines, and cod liver oil (NIH, 2011; O'Mahony et al., 2011). Small 
amounts (0.5-2.5 pg) of vitamin D3 are also present in eggs, beef liver, and meat, 
while vitamin D2 is found in wild mushrooms. Apart from fish, the vitamin D found 
naturally in food is low in general. Instead, products fortified with vitamin D provide 
the vast majority of human dietary intake of vitamin D in the United States of 
America, Canada, and several other countries (Calvo et al., 2004). When research 
showed the vital importance of vitamin D for health, a policy of vitamin D 
fortification of some foods was introduced in the United States of America, Canada, 
and several other countries (Calvo et al., 2004). In developing countries, vitamin D is 
even less common in diets because foods naturally containing vitamin D are not as 
accessible and there is a lack of regulation about fortifying foods with vitamin D. 
Table 1.1 shows the vitamin D contents of several dietary sources (NIH, 2011; 
O'Mahony et al., 2011). Two units are used to express the vitamin D intake from food 
and supplements: international units (lU) or micrograms (pg). 1 pg of vitamin D has
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the biological activity of 40 lU. For every 100 lU of vitamin D ingested the 
circulating level of 25(OH) D increases by Ing/ml (lng/ml= 2.5nmol/L) (Lappe, 
2011).
Table 1.1: Selected food sources of vitamin D (O’Mahony et al., 2011)
Source Vitamin D content (Ills)
Cod liver oil, 1 teaspoon 400-1000
Salmon, fi-esh wild (3.5 oz) 600-1000
Salmon, fi-esh farmed (3.5 oz) 100-250
Sardines, canned (3.5 oz) 300
Mackerel, canned (3.5 oz) 250
Tuna, canned (3.5 oz) 236
Mushroom, fi-esh (3.5 oz) 1 0 0
Egg yolk 2 0
Fortified milk ( 8  oz) 1 0 0
Fortified orange juice ( 8  oz) 1 0 0
lUs = International Units
1.3.2 Dietary supplements
With the awareness of the widespread nature of vitamin D deficiency 
worldwide has came an increase in the availability of vitamin D supplements. The 
form of vitamin D in fortified foods and supplements may be one of two forms: D2 
(ergocalciferol) or D3 (cholecalciferol). Vitamin D2  is manufactured by the ultraviolet 
beta (UVB) irradiation of ergosterol extracted in yeast, and vitamin D3 is 
manufactured by the irradiation of 7-dehydrocholesterol (7-DHC) of lanolin in wool 
fat (Holick, 2005). Both vitamin D2 and D3 increase serum 25(OH)D levels however, 
currently there is a reformulation of many supplements, replacing vitamin D2 with 
vitamin D 3 .  This could be due to the effectiveness of vitamin D 3  in raising serum 
25(OH)D and maintaining those levels for a longer time than vitamin D2 (Armas et 
al., 2004). By centering on the differences in side chain between the two forms of 
vitamin D (D2  has an additional methyl group on carbon 24), this difference directly 
affects the rate of conversion of D2 to serum 25(OH)D, and also its affinity for 
vitamin DBF and VDRs, which are all critical steps in the activation of vitamin D
(Houghton & Vieth, 2006). Once the two steps of hydroxylation process has been 
completed and l,25(OH)2D has been formed, an additional step occurs that involves 
24 hydroxylation at the kidney to form l,24,25(OH)3D. Once l,24,25(OH)3D2 has 
been formed, ergocalciferol is deactivated, and irretrievable. In contrast, 
1,24,25(0H)3D3 retains its capacity to bind to the VDRs and still requires an 
additional side chain oxidation to become deactivated. Thus, this additional step gives 
advantage for D3 to remain biologically active, and maintain vitamin D status (Armas 
et al., 2004; Houghton & Vieth, 2006).
1.3.3 Sunlight
On a global level, individuals get 90% of their vitamin D requirement 
primarily through skin exposure to adequate sunlight (Holick, 2006). During sunlight 
exposure, the UVB radiation with energies of 290-315nm is absorbed by 7-DHC 
(provitamin D 3 )  that resides in the epidermis to form previtamin D 3  (Holick, 2007). 
The concentrations of previtamin D3 in the skin reaches its maximum within hours 
(Bikle, 2009). Previtamin D 3 ,  an unstable compound, is quickly converted to form the 
more stable vitamin D3 via heat. This is a purely photochemical reaction where no 
enzymes are involved. The conversion of previtamin D3 to vitamin D3 is the last step 
in the synthesis of vitamin D3 in human skin. Vitamin D3 diffuses from the epidermis 
into the blood bound to vitamin D binding protein (Haddad, 1999), and is transported 
to the liver. Upon reaching the liver, vitamin D3 is converted to 25(OH)D and then to 
1,25(0H)2D in the kidneys (Holick, 2007). Exposure to higher doses of UVR does not 
cause vitamin D intoxication. Instead previtamin D3 absorbs the sunlight and is 
converted to other inactive photoproducts such as tachysterol and lumisterol which 
are sloughed off with the skin rather than continuing on the pathway to 25(OH)D
production (Bikle, 2009). However, these compounds may be converted back when 
the concentrations of previtamin D3 decreases (Bikle, 2009).
The recommendation for adequate vitamin D synthesis from sunlight is 5-30 
minutes of sun exposure to the face, arms, hands, and back from the hours of 1 0  am to 
3 pm in all seasons except winter without the use of sunscreen (Holick, 2007). 
However this does not apply in all geographical locations (Al-Daghri et al., 2012). 
Skin exposure of the whole body to one minimal erythemal dose (MED), the time 
taken for UVR to cause a slight reddening to the skin 24 hours after exposure, raises 
the blood level of 25(OH)D equivalent to ingesting of 20,000 lU of vitamin D. Age 
and skin type can affect the amount of vitamin D3 produced in response to sunlight 
(Armas et al., 2007). Aging is associated with decreased amount of 7-DHC and 
increased skin pigmentation acts as a natural sunscreen, both cause decrease in 
previtamin D3 for a given dose of UVB (Armas et al., 2007).
1.3.3.1 Factors affecting cutaneous vitamin D synthesis
The availability and absorption of UVB required for cutaneous vitamin D 
synthesis is influenced by a number of environmental and personal factors (Tsiaras & 
Weinstock, 2011). Season, latitude, and time of day affect the amount of UVB 
radiation reaching the earth’s surface and, therefore, affect cutaneous vitamin D 
synthesis. The UVB required for vitamin D production decreases during the winter 
and in high latitude regions. Personal skin pigmentation also affects vitamin D 
production. Melanin (natural sunscreen) absorbs UVR and prevents the photons from 
entering other skin cells. As the melanin increases in the skin, the synthesis of 
previtamin D3 decreases for a given dose of UVB (Armas et al., 2007). Although, 
sunscreens are beneficial in preventing skin cancer, it prevents vitamin D synthesis in 
the skin as well (Tsiaras & Weinstock, 2011). Using a sunscreen with sun protection
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factor of 30, for example, reduces cutaneous production of previtamin D3 by more 
than 95% (Holick et al., 2011). Ultraviolet energy is reduced when there is complete 
cloud cover and when there is shade (including shade caused by extreme pollution) 
(Tsiaras & Weinstock, 2011). Moreover, indoor exposure to sunlight through a 
window does not produce vitamin D because UVR does not penetrate glass. Clothing 
(veils and concealing clothing) is a physical barrier between solar radiation and the 
skin. Clothing absorbs UVR, preventing vitamin D synthesis (Tsiaras & Weinstock, 
2011).
1.4 Vitamin D metabolism
Vitamin D3 synthesized in the skin after exposure to UVB radiation is 
transported mainly via DBF, whereas vitamin D ingested from the diet is transported 
primarily by chylomicrons in the bloodstream (Haddad, 1999). Whether orally 
ingested or endogenously synthesized, vitamin D is inert and does not have any 
significant biological activity before it is metabolized into the active hormonal form 
(Holick, 2005). This occurs in two steps within the liver and kidneys.
In the liver, vitamin D undergoes the first hydroxylation by one or more 
cytochrome P450 vitamin D-25-hydroxylase (25-OHase) to form 25(OH)D, also 
known as; 25-hydroxycholecalciferol or calcidiol (Lehmann & Meurer, 2010). Both 
dietary intake (including nutritional supplements and fortified foods) and cutaneous 
synthesis of vitamin D contribute to serum 25(OH)D, which is the most plentiful 
circulating precursor of active vitamin D. Serum 25(OH)D is the most widely 
accepted indicator of vitamin D status of the individual (Holick, 2007). Although it is 
biologically inactive, the desired range is >75 nmol/L for overall health and disease 
prevention (Vieth et al., 2007) however, this cutoff value is still debatable. This form
of vitamin D has a correlation with secondary hyperparathyroidism, rickets, and 
osteomalacia (Holick, 2006).
From the liver, 25 (OH) D is released back into the bloodstream where it is 
transported bound to DBF to the kidney and other tissues. In the kidney, 25(OH)D 
undergoes the second hydroxylation to produce l,25(OH)2D also known as 1,25- 
dihydroxycholecalciferol or calcitriol, the most potent vitamin D metabolite 
(Lehmann & Meurer, 2010). This reaction is catalyzed by the enzyme 25(OH)D-l-a- 
hydroxylase (1-a-OHase) in the proximal tubular epithelial cells of the kidney 
(Feldman et al., 2010). The renal production of l,25(OH)2D is stimulated by PTH, 
low serum calcium (Ca) and low phosphorus (PO4 ) concentrations (Christakos et al., 
2010).
In normal human plasma, l,25(OH)2D circulates at around 1000-fold lower 
concentrations than 25(OH)D (Cannell & Hollis, 2008) and the half-life of 
1,25(0H)2D is only 15 hours, compared to 15 days for 25(OH)D (Jones, 2008). 
Although the kidney is the major source for circulating l,25(OH)2D, many tissues 
outside the kidney also produce this active hormone (Bikle, 2009). This l,25(OH)2D 
does not enter the circulation and is therefore not measured as part of the serum 
concentration. Extra-renal production of l,25(OH)2D is not controlled by calcium but 
is dependent on an adequate supply of 25(OH)D reaching the tissues (Bikle, 2009). 
High concentrations of l,25(OH)2D inhibit 1-OHase and stimulate 24-hydroxylase 
(24-OHase) enzyme activity in the kidney, which acts to degrade 25(OH)D and 
1,25(0H)2D to calcitroic acid for excretion (Prosser & Jones, 2004). The 24-OHase 
enzyme produces 24,25(OH)2D and l,24,25(OH)2D, intermediates in the degradation 
of 1,25(0H)2D to calcitroic acid, a water-soluble, biologically inert metabolite, which 
is excreted in the bile (Prosser & Jones, 2004).
1.5 Vitamin D actions
Once 1,25(0H)2D is formed in the kidneys, it is transported to organs and 
tissues bound to DBP where it acts in both genomic or non-genomic manner 
(Lehmann & Meurer, 2010). It mediates its biological effects by binding to VDRs, 
which are located in the nuclei or membrane of target cells. The VDR, a 
phosphorprotein which binds the hormone with high affinity and regulates the 
expression of genes, is expressed by cells in most organs such as the brain, heart, skin, 
colon, pancreas, and breast (Adams & Hewison, 2010).
The primary function of vitamin D is to maintain serum Ca levels within a 
normal range so as to support bone health (Holick, 2010b). Vitamin D is necessary for 
Ca absorption, bone mineralization, and the prevention of rickets and osteomalacia. 
The active form of the vitamin accomplishes its function through the interaction with 
three organs.
In the intestine, l,25(OH)2D enhances the active transport of Ca and PO4  from 
the lumen of the intestine to the blood (Holick, 2010). When serum Ca levels start to 
decrease, the parathyroid glands is stimulated to secrete PTH, which then increases 
renal l,25(OH)2D production. The l,25(OH)2D interacts with nuclear VDRs in the 
intestinal cells activating genes for calcium binding protein (calbindin) and other 
proteins involved in Ca and P0 4  transport across the cell membranes, through the 
cells, and into circulation to maintain s-Ca levels (Holick, 2005).
In the case of inadequate dietary Ca to maintain serum Ca concentrations, 
1,25(0H)2D and PTH work together to stimulate re-absorption of Ca from the renal 
tubules and mobilize Ca from the skeleton to maintain normal serum Ca levels 
(DeLuca, 2004).
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Once 1,25(0H)2D has completed its aetion, it decreases its own synthesis 
through two mechanisms (Figure 1.2 below): first, increased serum Ca and PO4  will 
decrease the synthesis of PTH that decreases the production of l,25(OH)2D. 
Secondly, increased l,25(OH)2D level will inhibit the stimulation of PTH from the 
parathyroid glands which
in turn will inhibit 1 -a-OHase activity and preventing further production of 
1,25(0H)2D (Feldman et al., 2008). In addition, increased l,25(OH)2D levels will 
stimulate the expression of 24-OHase which converts l,25(OH)2D along with 
25(OH)D to biologically inactive calcitroic acid which is excreted in the bile.
Parathyroids
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Figure 1.2: Regulation of l,25(OH)2D synthesis
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1.6 Vitamin D and Health
Vitamin D is thought to play a part in several diseases and conditions or has 
the potential to do so because of the presence of VDRs on most organs and tissues in 
the human body (Zittermann & Gutierrez, 2010) and the influence of vitamin D on up 
to one third of human genes (Holick et al., 2011). Vitamin D ’s role in bone health is 
well known, with rickets in infants and children and osteomalaeia in adults being the 
traditional conditions associated with severe and prolonged deficiency of the vitamin 
(Holick, 2006). They are characterized by defective mineralization leading to a 
reduction in the amount of mineralized bone and reduced bone strength. In addition to 
the calcemic role, the essential role of vitamin D in muscle function, circulatory, 
immune, endocrine, and nervous systems has emerged in recent years (Zittermann & 
Gutierrez, 2010).
1.7 Optimal vitamin D levels for health
There is some controversy regarding what is considered ‘normal’ or ‘optimal’ 
levels of vitamin D for health. There are several classifications of deficiency and 
insufficiency, but the most widely-used criteria for speeifying levels of vitamin D 
status were proposed by Holick: serum 25(OH)D <50nmol/L considered as deficient, 
52-72 nmol/L as insufficient, and values >75nmol/L as sufficient (Holick, 2009). 
Vitamin D deficiency can be further classified as severe (<12.5nmol/L), moderate 
(12.5-25nmol/L), and mild (25-50nmol/L) (Lips, 2004). Other researchers and 
experts in the field proposed different cutoffs for vitamin D deficiency and 
insufficiency, however they all agreed that serum 25(OH)D<50nmol/L is the cutoff 
for deficiency (Binkley et al., 2010; Holick et al., 2011). The reason of agreement on 
this cutoff value of deficiency is based on the traditional function of vitamin D in 
mineral homeostasis.
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A relationship between PTH concentrations and serum 25(OH)D has been 
found in several studies. Of those studies which were evidence-based, most pointed to 
a plateau in the levels of PTH concentrations when the level of 25(OH)D is greater 
than 75 nmol/L and secondary hyperparathyroidism is at a minimum level (Dawson- 
Hughes et al., 2005). Thus this cutoff value was chosen to maximize vitamin D’s 
effect on Ca and bone metabolism and is the minimum for non-traditional effect of 
vitamin D on cell health (Holick et al., 2011; Vieth, 2011). Using these parameters, 
there are approximately 1 billion people around the world who have deficient or 
insuffieient levels of vitamin D (Holick, 2007).
1.8 Groups at risk for vitamin D deficiency
Acquiring enough vitamin D purely from natural food sources is very difficult. 
It is essential to eat foods fortified with vitamin D and to be exposed to sunlight in 
order to maintain sufficient vitamin D levels. While this is enough for many people, 
other groups may need dietary supplements to reach their daily recommended amount 
of vitamin D.
1.8.1 Infants
Human fetal status of vitamin D depends on the mothers. If the mother is 
vitamin D deficient, her fetus will show this deficiency that may persist throughout 
the developmental period (Hollis & Wagner, 2004). Exclusively breastfed infants will 
be at high risk for vitamin D deficiency unless supplemented, because human milk 
contains very little vitamin D (Hollis & Wagner, 2004).
1.8.2 Elderly
The elderly are at higher risk for vitamin D deficiency because of the reduced 
amount of 7-DHC as a result of aging (Tsiaras & Weinstoek, 2011). Other 
consequence of aging process is the impaired hydroxylation in the liver and reduced
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ability of the kidneys to convert vitamin D to its active hormone form (Mosekilde,
2005). Poor dietary intake of vitamin D, decreased exposure to sunlight, and 
excessive use of sun protection on the sites exposed to sunlight may contribute to 
vitamin D deficiency among the elderly (Heaney, 2006).
1.8.3 Obese
More and more research points to a connection between obesity and changes 
in the vitamin D endocrine system. There is an inverse relationship between body fat 
mass and serum 25(OH)D concentration (Arunabh et al., 2003); the reduetion in the 
latter is due to the decreased bioavailability of vitamin D from cutaneous and dietary 
sources because of its deposition in body fat compartments (Wortsman et al., 2000). 
Although obese people have higher fat contents, they have lower levels of vitamin D.
1.8.4 Reduced dietary intake
Having a lower dietary intake of vitamin D than recommended also 
contributes to vitamin D deficiency (Laillou et al., 2013). Vitamin D deficient diets 
are associated with milk allergy, lactose intolerance, and strict vegetarianism (Smith, 
2006; Persson et al., 2013). Due to low vitamin D fortification of food in Saudi 
Arabia, the dietary intake of vitamin D is approximately one-tenth of that in the USA 
(Madani & Kumosani, 2001).
1.8.5 Limited sun exposure
Vitamin D deficiency is also more likely in people whose exposure to sunlight 
is lower than normal, including people who always wear sun protection outside or 
who seldom spend any time outdoors, women whose religious beliefs call for 
conservative clothing, and people whose jobs prevent exposure to the sun. Excessive 
heat which causes sun avoidance, and covering up with clothing for both men and 
women may cause vitamin D defieiency in the Gulf area (El-Hajj Fuleihan, 2009).
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1.8.6 Renal and liver diseases
Also at a higher risk for developing vitamin D deficiency are individuals 
suffering from renal and hepatic diseases (Holick, 2007), those with diseases affecting 
intestinal absorption and individuals taking medications which have an effect on 
vitamin D and bone metabolism (i.e. corticosteroids, anticonvulsants, weight reducing 
drugs) (Grober et al., 2011).
1.9 Recommended intake of vitamin D
In 2010, the Institute of Medicine (lOM) announced an increase in the 
Recommended Dietary Allowance (RDA) from 400 lU to 600 lU for individuals aged 
1 to 71 years, although this amount is still seen by many in the research community as 
insufficient. Consequently, it is quite likely that people eating fortified foods still have 
inadequate vitamin D levels and recommendations to raise the vitamin D status can be 
applied to everyone (Forrest & Stuhldreher, 2011). A vitamin D intake of at least 
1000 lU/day is recommended for all healthy individuals to maintain a sufficient serum 
25(OH)D level if they do not expose themselves to the sun (Holick et al., 2012). 
Serum 25(OH)D concentrations are inversely assoeiated with PTH concentrations. 
This led some researchers to define vitamin D sufficiency by using as a biochemical 
criterion the 25(OH)D concentrations needed to suppress PTH to its plateau level. 
Many investigators have estimated this level to be 75 nmol/L or higher (Dawson- 
Hughes et al., 2005; Holick et al., 2011). However, these cut-off values are under 
continuous discussion and debate.
1.10 Vitamin D toxicity
It is not likely that excessive sun exposure will lead to vitamin D toxicity, 
since the prolonged heat on the skin causes photo-degradation of previtamin D3 as it
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forms (Holick, 2008). Similarly, toxicity from a high level of dietary vitamin D is 
unlikely to occur unless cod liver oil is consumed in large amounts. However, high 
dose intake of vitamin D through supplements may lead to toxicity and hypercalcemia 
(Vieth, 2010). Vitamin D intoxication symptoms include nausea and vomiting, 
dehydration, and renal failure (lOM, 1997). Hypercaleemia, hypercalciuria, and 
elevated serum 25(OH)D are the main biochemical findings of vitamin D 
intoxications (Vieth, 2010). Vitamin D toxicity may occur when 25(OH) D serum 
levels are higher than 375 nmol/L (Holick, 2007).
1.11 Vitamin D status in Saudi Arabia
Vitamin D deficiency is a global problem, with a high prevalence in the 
developed and developing countries as well (van Schoor & Lips, 2011). Studies of 
healthy adults in Western countries found low vitamin D levels to be highly prevalent 
(Kauppinen-Makelin et al., 2001; Lips et al., 2001). What was also clear in these 
studies was the key effect that seasonal variations and latitude have on serum 25(OH) 
D levels (Kull et al., 2009; Lagunova et al., 2009).
The climate of the Middle East is hot and arid, and its latitudinal location 
supplies UVB rays almost year round, for over eight hours daily, which is sufficient 
for vitamin D synthesis. However, despite this abundant sunlight, some of the lowest 
levels of vitamin D and the highest rates of hypovitaminosis D world-wide are seen in 
the Middle East (Arabi et al., 2010). Excessive heat and avoidance of heat strokes 
may be the reasons for limited sun exposure and thus low vitamin D levels. Clearly 
then, since synthesis of Vitamin D in the skin is restricted, dietary and supplementary 
vitamin D becomes essential to maintain serum 25(OH)D levels. In a number of 
countries, some vitamin D fortified foods are available (i.e. milk, cereal, margarine).
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However, milk is fortified with vitamin D in Saudi Arabia, it is not sufficient to 
prevent vitamin D deficiency.
In spite of living in a country with an abundance of sunshine all year, 
individuals of all ages in Saudi Arabia are affected by this serious public health issue, 
including newborns, infants, children and teenagers, expectant mothers, adults, and 
the elderly. The widespread nature of the problem may be explained by several factors 
including, but not limited to: inadequate exposure to sunlight because of cultural 
practices and very high temperatures, dark pigmentation of the skin, obesity, low 
vitamin D dietary supplementation, and lack of government regulation for vitamin D 
fortification of food (El-Hajj Fuleihan, 2009).
Saudi mothers and their newborns were found to have reduced levels of 
25(OH)D (Erfan et al., 1997). Among the factors contributing to vitamin D deficiency 
and rickets in infants in this region were exclusive breast feeding, lower maternal 
educational status and limited exposure to sunlight (Al-Mustafa et al., 2007). 
Hypovitaminosis D affects older children as well. A random sample of 433 Saudi 
girls, 12-15 years of age found that 81% had 25(OH) D levels below 25 nmol/L, 40% 
had below 12.5 nmol/L, and 61% had no symptoms or rickets (Siddiqui & Kamfar,
2007). Another study of 331 Saudi children between the ages of 6  and 17 found a 
prevalence of vitamin D deficiency (<25nmol/L) in 83% of the subjects (153 boys and 
178 girls) (Al-Othman et al., 2012).
Similar results have been seen in adults. Some of the earliest research carried 
out in the region studied a small sample of 59 apparently healthy university students 
aged 18 to 26 and 24 elderly people with a mean age of 62±13 yr, and found a mean 
25(OH)D level varying between 9 and 29 nmol/L (Sedrani et al., 1983). The vitamin 
D level was considerably lower in the elderly than that in the students, both male and
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female, and was significantly lower in males than in females. Even more disturbing is 
a study conducted in the Eastern Province of Saudi Arabia on 71 ambulatory primary 
health-care patients (87% women). Their mean 25(OH)D concentration was found to 
be 19 nmol/L, with levels below 75 nmol/L found in 100% of the subjects and below 
50 nmol/L in 97% (Eledrisi et al., 2007).
Research has shown that vitamin D deficiency or insufficiency affects almost 
everyone. Several studies identified a high prevalence of vitamin D insufficiency in 
healthy Saudi subjects (Ghannam et al., 1999; Al-Turki et al., 2008). Ardawi et al. 
evaluated 1172 healthy pre- and post-menopausal women randomly selected from the 
community and found that 45.6% of them (38.3% pre, 50.9% post) exhibited vitamin 
D deficiency 25(OH)D < 25 nmol/L. The authors concluded that obesity, limited sun 
exposure, and poor dietary vitamin D supplementation were among the factors 
contributing to the deficiency in this group (Ardawi et al., 2011).
1.12 Bone
1.12.1 Bone physiology:
The skeleton is a highly specialized and dynamie organ that undergoes 
continuous regeneration. Throughout life, bones are continuously undergoing 
modeling as they adapt to varying biomechanical forces (Clarke, 2008). Remodeling 
of bones also occurs to replace bone which is old and micro-damaged with new, 
mechanically stronger bone, facilitating the preservation of bone strength (Baron, 
2008). Different functions are carried out by the skeleton. Bones of the skeleton 
provide the rest of the body structural support, protect vital internal organs and 
structures, and allow movement and locomotion by being an attachment for muscles 
and ligaments (Clarke, 2008). In order to achieve maximum functionality and 
maintain strength even under exposure to strain, bone tissue is both hard and elastic at
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the same time. Additionally, the skeleton serve as a major reservoir of calcium, 
phosphate, and other ions (Barrère et al., 2006).
1.12.2 Bone anatomy:
According to shape, bone can be categorized into three main types: long 
(tubular) bones such as the femur, humerus, and radius; short bones represented by 
the vertebras, carpal, and tarsal, as well as flat bones such as the skull, ribs, and 
scapula. The flat bones act as protective covering for the vital organs they surround. 
The function of both the long and short bones is to act as levers for the muscles, 
enabling locomotion and other forms of movement (Clarke, 2008).
The anatomy of long bones shows a cylindrieal tube in the center (diaphysis), with 
wider regions at each end (epiphysis) and a transition area in between (metaphysis) 
(Figure 1.3). Dense cortical bone largely makes up the diaphysis, while trabecular 
meshwork bone enclosed by a comparatively thin casing of dense cortical bone make 
up the metaphysis and epiphysis. Bone has two surfaces: an inner endosteal surface 
and an outer periosteal surface. Taken as a whole, the skeleton of an adult human is 
composed of 20% trabecular bone and 80% cortical bone (Clarke, 2008). Different 
bones and skeletal sites within bones have different ratios of cortical to trabecular 
bone. For example, the bones of the vertebra are composed of trabecular and cortical 
bone in a ratio of 75:25.
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Figure 1.3: Anatomy of long bone
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1.12.3 Composition of bone:
Bone is a specialized comiective tissue composed of organic matrix, cells and 
minerals. Bone organic matrix contains approximately 90% type I collagen and 10% 
different non-collagenous proteins (Robey & Boskey, 2008). Matrix maturation is 
associated with expression of alkaline phosphatase and other proteins, including 
osteocalcin and osteopontin. The mineral composition of bone consists mainly of 
hydroxyapatite (Clarke, 2008). The tensile strength of collagen and the hardness of 
hydroxyapatite combine to give bone its great strength.
1.12.4 Bone cells:
Bone has three distinct cell types: osteoblasts, osteocytes, and osteoclasts (Clarke,
2008). Figure 1.4 below presents the three types of bone cells.
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Figure 1.4: Bone cells
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1.12.4.1 Osteoblasts:
Osteoblasts, mononuclear cells, are bone-forming cells which are derived from 
mesenchymal precursor cells in the bone marrow (Silva & Branco, 2011). As the bone 
matrix is being formed, some of the osteoblasts are entrapped in it and these are now 
referred to as osteocytes. Other osteoblasts, which remain as thin cells covering the 
surface, are referred to as lining cells. Osteoblasts are responsible for osteoclasts 
regulation (Silva & Branco, 2011). Osteoblasts produce macrophage colony 
stimulating factor (m-CSF), receptor activator of nuclear factor Kappa B ligand 
(RANKL), as well as osteoprotegerin (OPG) (Silva & Branco, 2011). The production 
of RANKL is increased and the production of OPG is decreased when hormones and 
local factors act on the osteoblastic cells. The rate at which bone breaks down is 
dietated by the balance between RANKL and OPG expression (Jabbar et al., 2011).
Besides their role in osteoclasts regulation, osteoblasts play a part in the 
deposition of bone matrix (Silva & Branco, 2011). In normal situations, similar 
amounts of non-collagenous protein and collagen are synthesized and secreted by 
osteoblasts. As osteoblasts begin to differentiate, collagen type I is produeed, forming 
the primary structural bone matrix component. Playing an important role in the 
stabilization of the matrix are osteopontin, a non-collagenous matrix protein, and
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alkaline phosphatase. An additional non-collagenous protein that is produced almost 
only in bone is osteocalcin. This protein, which is up-regulated late in the 
differentiation process, is involved in the regulation of matrix mineralization (Neve et 
al., 2013).
1.12.4.2 Osteoclasts:
Derived from the mononuclear precursor cell line of hematopoietic stem cells, 
osteoclasts are the cells involved in bone resorption (Silva & Branco, 2011). 
Macrophage CSF expression by osteoblasts is required for progenitor cells to 
differentiate into preosteoclasts. Active osteoclasts, multi-nucleated cells, are 
characterized by a ruffled border which contains molecules that transport hydrogen 
ions from the cells to the surface of the bone, where they can dissolve the bone 
matrix’s mineral component. The ruffled border also secretes enzymes such as 
cathepsin K to break down the part of the matrix made up primarily of type I collagen 
(Boyce & Xing, 2007). Osteoclast formation, activation and activity are controlled by 
different growth factors, hormones, and cytokines. Osteoclasts mature, differentiate 
and become active when RANKL is expressed on osteoblast cells and binds to its 
receptor, RANK, on preosteoclast. OPG, a membrane bound and secreted protein, 
binding to RANKL inhibits osteoclastogenesis and bone resorption (Clarke, 2008).
When 1,25(0H)2D is recognized by its receptor in osteoblasts, this will cause 
an increase in the expression of RANKL. Thereafter, RANKL binds to its receptor 
RANK on preosteoclasts, which induces preosteoclasts to become mature osteoclasts. 
Mature osteoclasts cause bone resorption and release of minerals from the bone 
(Feldman et al., 2008). l,25(OH)2D also down regulates the production of OPG from 
osteoblasts which can bind to RANKL to block its interaction with RANK and
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thereby prevents the maturation of preosteoclasts. Thus l,25(OH)2D favors bone 
resorption (Holick, 2010).
1.12.4.3 Osteocytes:
Osteocytes, which are derived from osteoblasts, are cells shaped like stars 
surrounded by a thin ring of cytoplasm. They are initially present on the surface of 
bone but subsequently become encased within bone. These are the most abundant 
cells in bone, communicating with each other and with the surrounding medium 
through extensions of their plasma membrane. Mechanosensation is the primary 
function of osteocytes (Riddle & Donahue, 2009). Osteocytes transduce stress signals 
from bending or stretching of bone into biologic activity. The osteocyte has a role in 
the maintenance of bone matrix, which is facilitated by the transport of material and 
fluid via the canaliculi. Osteocytes express osteocalcin, sclerostin as well as several 
other bone matrix proteins (Rochefort et al., 2010).
1.12.5 Bone modeling and remodeling:
There is a dynamic interaction between bone modeling, which occurs during 
bone growth and development, and remodeling, which occurs during bone repair and 
aging. This interplay results in a continuous fluctuation in the skeleton (Borer, 2005). 
The growth of bone typically takes place on the exterior or periosteal bone surface, 
resulting in increased bone width (Clarke, 2008). Conversely, remodeling activity 
takes place on the interior or endosteal bone surface.
In the process known as modeling, the overall shape of bones changes due to 
physiologic or mechanical factors, causing the skeleton to gradually adjust to the 
forces that it encounters. The removal or addition of bone to the suitable surface by 
independent action of osteoblasts and osteoclasts as a reaction to biomechanical 
forces may widen bones or change their axis. During this process, bone formation and
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resorption occur separately. At any bone surface modeling involves osteoclast 
activation and subsequent resorption of bone, or it involves osteoblast activation and 
subsequent formation of bone, but not both at the same location (Seeman, 2009). 
Nearly all the skeleton is replaced in the first year of life, but in adulthood, bone 
modeling occurs less frequently than remodeling in normal subjects (Kobayashi et al.,
2003).
Remodeling is a continuous lifelong process responsible for maintaining bone 
strength and mineral homeostasis. In addition, the process of bone remodeling is 
essential for healthy bones because it repairs microfi*actures, which are due to 
repetitive stress, by forming new bone and resorbing old bone (Rockville, 2004). 
Approximately 10% of the skeleton is renewed each year by remodeling which is 
crucial for maintaining the skeleton quality (Seeman, 2009). The bone remodeling 
unit, composed of a tightly coupled group of osteoclasts and osteoblasts, continuously 
removes separate packets of old bone, replacing them with newly synthesized protein 
matrix, which is then mineralized to create new bone. The imbalance in the activity 
between these two types of cells results in weakening of bones (osteopenia) and over 
time bones become brittle and prone to fracture (osteoporosis) (Sambrook & Cooper,
2006). The overall equilibrium between the osteoclasts and osteoblasts may be shaped 
by systemic hormones such as PTH, vitamin D, and other steroid hormones and local 
mediators such as cytokines and growth factors (Seibel, 2005).
In adult life, bone remodeling occurs in an orderly sequence of bone 
resorption, lasting about ten days, followed by a phase of bone formation that takes up 
to three months to complete (Seibel, 2005) (Figure 1.5). Compared to cortical bone, 
trabecular bone is remodeled more often. This may explain the higher incidence of 
metabolic bone diseases like osteoporosis in bones such as the distal forearm, spine,
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and hip, which have relatively large amounts of trabecular bone (Kontulainen et al., 
2002). Bone remodeling accelerates in early postmenopausal women and then 
eontinues at a slower rate in subsequent years, but is still higher than in 
premenopausal women.
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Figure 1.5: Bone remodeling cycle
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1.12.6 Peak Bone Mass:
Peak bone mass (PBM) is defined as the maximum bone mass or bone mineral 
density (BMD) attained by an individual throughout life (Carmona, 2004). The 
attainment of higher BMD at a young age reduces the risk of osteoporosis and related 
fractures occurring later in life (Heaney et al., 2000). Bone mass accumulates through 
childhood and adolescence until PBM is reached during the third decade of life in 
most populations. Bone mass remains relatively stable during the third and fourth 
decade of life with only a small decline. In women there is then a more precipitous 
drop in bone mass that occurs after menopause (Harris et al., 2006).
There are numerous factors that influence the attainment of PBM and genetics 
accounts for approximately 60-80% of PBM attained (Krall & Dawson-Hughes, 1993; 
Stewart & Ralston, 2000). Barthe et al have shown that young daughters of women 
with osteoporosis have a lower than normal BMD for their age (Barthe et al., 1998). 
Numerous protective and detrimental factors influence an individual’s ability to attain 
their PBM. The modifiable protective factors include, but are not limited to, physical 
activity and proper dietary habits including sufficient Ca and vitamin D intake 
(Lanham-New et al., 2007). In examining the attainment of PBM, Heaney et al. 
(2000) identified load bearing exercise (e.g. jumping and dancing), Ca and vitamin D 
intake, as factors that can assist an individual in achieving their predetermined full 
genetic potential of bone mass.
The negative modifiable factors can include caffeine, smoking, and improper 
management of endocrine dysfunction (NOT, 2013). Proper growth and maintenance 
of BMD depends on proper endocrine function in both males and females. 
Disruptions in normal endocrine function can occur because of disease, diet, 
excessive exercise, or drug use. Later age at onset of menarche, and thus a later and
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shorter exposure to estrogen, has also been associated with lower BMD (Clarke & 
Khosla, 2010). Most of these factors are also involved in the maintenance of bone 
mass during adulthood as well as in bone loss later in life, although in variable 
proportions compared with their role in PBM acquisition.
1.13 Osteoporosis:
Osteoporosis is a skeletal disease characterized by low bone mass and micro- 
architectural deterioration of bone tissue, resulting in compromised bone strength and 
increased susceptibility to fracture (WHO, 2003). Figure 1.6 below shows the 
difference between normal and osteoporotic bone. Bone mass in later life is a result of 
PBM attained and subsequent bone loss. Measures of decreased bone density are 
clearly related to fracture risk both in postmenopausal women, and older men (NOF, 
2013). It is anticipated that one in three women will suffer an osteoporotic fracture 
after the age of 50 in her remaining life (Steurer et al., 2011; NOF, 2013). For men the 
picture is only slightly better with one out of every five men having a fracture related 
to osteoporosis in their lifetime (NOF, 2012). Because osteoporosis often develops 
without clear symptoms, fragility fractures can occur before the detection of bone 
loss. The most common fracture sites are the wrist, hip and vertebrae (Melton, 2003). 
These fractures result in significant reduction of mobility and quality of life for 
patients (Brooks, 2006). There is also an association between major fractures and 
increased mortality after the fracture. Osteoporosis treatment and the direct costs 
associated with an osteoporotic fracture are staggering. As the number of older people 
increases, the direct cost of health expenditure on osteoporotic fractures is predicted 
to rise as well (Melton, 2003).
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fFigure 1.6: Normal bone in the left side of the picture & osteoporotic bone on
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1.13.1 Definition of osteoporosis
The WHO in 1994 has standardized the interpretation of BMD results, based 
on a comparison of a subject’s BMD with the mean for a normal young adult 
population of the same race and gender (Kanis, 1994). The subject’s BMD is 
calculated as a T-score, which is the number of standard deviations above or below 
the mean BMD for normal young adults as follows:
Normal: BMD value that is higher than 1 standard deviation below the young adult 
female reference mean (T-score -1 and above).
Osteopenia: BMD value more than 1 standard deviation below the young female 
adult mean, but less than 2.5 SD below this value (T-score < -1 and > -2.5 SD). 
Osteoporosis: BMD value 2.5 SD or more below the young female adult mean (T- 
score < -2.5 SD) (WHO, 2003).
1.13.2 Risk Factors for Osteoporosis
There are two main categories of risk factors for osteoporosis: modifiable and 
non-modifiable. The most important non-modifiable factors are heredity, age, gender, 
previous fragility fracture or family history of fractures (Steurer et al., 2011). 
Osteoporosis-related risk factors related to lifestyle are those which can be modified
28
and include smoking, low body mass index, sedentary lifestyle, diet low in Ca, high 
alcohol consumption, and low levels of vitamin D due to low dietary intake or lack of 
sunlight exposure (NOF, 2013). Secondary osteoporosis can be caused by long-term 
use of medications such as corticosteroids and certain medical conditions such as 
rheumatoid arthritis, celiac disease and other chronic gastrointestinal conditions, over- 
active thyroid or parathyroid glands, and chronie hepatic or renal diseases (NOF, 
2013). Changes in lifestyle and corrections of secondary osteoporosis eauses may 
improve BMD and decrease the risk of fractures if deteeted early (Francis et al.,
2004).
1.13.3 Burden of osteoporosis in Saudi Arabia
Osteoporosis is a health problem around the world because the condition leads 
to fraetures. As life expectancy increases, so does the burden of fractures. The Middle 
East is no exception: with a steadily aging population, the burden of osteoporosis is 
expected to increase (Cooper et al., 1992). Currently, the population of Saudi Arabia 
is approximately 25.7 million. Of this number, 10% is 50 years of age or above and 
2% is 70 or above. By 2050, it is estimated that the total population of Saudi Arabia 
will increase to 40 million, of which 31% will be 50 or above and 8 % will be 70 or 
above (IGF, 2011). In the absence of reliable national data, recent research reports 
estimated the prevalence of osteoporosis to be between 23-34% in postmenopausal 
Saudi women above 50 years of age (El-Desouki, 1999; Ardawi et al., 2005; Greer et 
al., 2008).
In Saudi Arabia, research has been done to assess BMD (Ghannam et al., 
1999) and adjust the means to that found in Western populations (Ardawi et al.,
2005). In all of these studies, which were carried out mainly on female populations, 
researchers found BMD values lower than the standard established for the
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US/European reference data. For instance, in the study done by Ardawi and 
colleagues, the prevalence of osteoporosis in Saudi women 50 years old or above was 
44.5% when the US/European manufacturer’s reference values of DXA were used 
compared to only 28.2% using the Saudi reference values (Ardawi et al., 2005).
The first step in being proactive in the prevention, early diagnosis and 
treatment of osteoporosis is being aware of the risk factors. Many middle-aged and 
elderly Saudi women do not know the risk factors for osteoporosis (Al-Shahrani et al., 
2010). There are well-known risk factors for the disease in other populations. 
However, research indicates that there are additional risk factors in the Middle East, 
especially in the Gulf region, which are significant. These additional factors, which 
include vitamin D deficiency, a high number of pregnancies, and prolonged lactation 
period, may explain the findings of lower axial BMD in women in the region 
compared to those in Europe and North America (Ghannam et al., 1999; Hammoudeh 
et al., 2005).
The incidence of osteoporosis and the risk of fi’actures can be greatly reduced 
through healthy lifestyle measures. Optimal bone health can be achieved through a 
balanced diet rich in calcium and vitamin D, regular muscle-strengthening and 
weight-bearing exercise, reduced intake of alcohol, cessation of smoking and 
prevention of falls (NOF, 2010).
1.14 Bone Minerals 
1.14.1 Calcium
Calcium is an essential mineral in the human body, playing a role in bone 
formation and metabolism. More than 99% of the total Ca in the body is present in the 
bones and teeth as calcium-phosphate complexes, principally as hydroxyapatite 
(Caio[P0 4 ]6 [OH]2), which is the main constituent of bone (Favus et al., 2006). The
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rest of the Ca is present in blood, extracellular fluid, muscle and other tissues and 
cells. In addition to being a fundamental element of hydroxyapatite in bones, Ca plays 
an essential role in the regulation of numerous body functions: muscle contraction, 
intracellular signaling, neuromuscular activity, hormone secretion, blood clotting and 
enzyme activity (Favus et al., 2006).
1.14.1.1 Calcium Sources
Conversely to vitamin D, it is important that individual’s diet contain Ca since 
the body cannot produce this mineral and it is lost daily from our bodies. Food and 
dietary supplements are the only sources for the ingested Ca. Classically Ca is 
associated with dairy products; milk and its products are a rich source for Ca and 
contribute to the major share of Ca in the diet (Price et al., 2012). Vegetables, grains, 
legumes, and fhiits are other sources for Ca. Among groups of people who do not 
consume or rarely consume dairy products, such as vegans, those who are lactose 
intolerant, or allergic to milk, Ca-fortified foods such as beverages and cereals are an 
alternative source of Ca. For those unable to consume enough dietary Ca, supplements 
are available to compensate for adequate daily Ca requirements. Calcium supplements 
are available without a prescription in a wide range of preparations and in different 
amounts. For adults younger than 50 years, the National Osteoporosis Foundation 
recommends a calcium intake of 1000 mg/day. A Ca intake of at least 1200mg/day is 
recommended for all individuals aged over 50 years of age (NOF, 2010).
1.14.1.2 Calcium absorption:
Across the intestinal mucosa, Ca is absorbed by passive diffusion and by 
active transport. The rate of absorption is affected by the amount of Ca ingested (Ross 
et al., 2011). Passive diffusion occurs during high Ca intake throughout the length of
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the intestine. In the case of low dietary intake, Ca absorption occurs in the duodenum 
by active transport and is dependent on vitamin D. Caleitriol acts to raise the number 
of Ca binding proteins (CaBPs) present in mucosal cells, optimizing active Ca 
absorption (Bronner, 2003). Without vitamin D, the small intestine absorbs no more 
than 10-15% of dietary Ca and the efficieney of absorption increases to 30-40% with 
sufficient vitamin D (Holick, 2007). However, several other factors affect Ca 
absorption and excretion including, but not limited to, sodium, protein, and caffeine 
(Branca & Valtuena, 2001).
1.14.1.3 The regulatory hormones of blood calcium
At a metabolic level, Ca is one of the most aetive minerals and its metabolism 
is closely regulated. The concentration of Ca in the blood is tightly eontrolled, 
explaining the lack of a correlation between Ca intake and its serum levels. Calcium is 
constantly entering and leaving the blood through exchange between three organs: 
intestine, kidneys, and bone. The transport of Ca in this system is controlled by two 
main hormones and their receptors: PTH, and the aetive form of vitamin D: 
1,25(0H)2D, as well as serum Ca and the calcium sensing receptors (CaSRs) 
(Peacock, 2010). One of the many key factors leading to osteoporosis and bone mass 
reduction is chronic deficiency of Ca stemming from insufficient intake or reduced 
intestinal absorption and inereased urinary excretion of Ca. A decrease in serum Ca 
inactivates CaSRs in the parathyroid glands and increases PTH secretion, which in 
turn increases Ca re-absorption and resorption in the kidneys and bone, respectively 
(Peacock, 2010). PTH also stimulates the production of l,25(OH)2D in the kidney, 
which in turn accelerates the rate of absorption of calcium in the intestine and the 
mobilization in the bone. These actions result in a normalization of serum Ca
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concentration levels. The reference range of serum Ca ranges from 2.2- 2.6 mmol/L 
for healthy adults (Ross et ah, 2011).
1.14.1.4 Calcium and bone health:
Peak bone mass is reached by the end of adolescence for the most part, with 
final stages of aecumulation oeeurring between the second and third decade of life 
(Heaney, 2009). It is essential to try to accumulate the maximum amount of bone by 
early adulthood. This is because an increased PBM may reduce the risk of conditions 
such as osteoporosis in later years. A person’s PBM is determined largely by genetic 
factors, but lifestyle factors such as diet ean also play an important role in 
accumulating and preserving bone mass during this time (Lanham-New et ah, 2007). 
Some reports suggested that, it would be hard to meet the existing dietary 
recommendations for Ca without eating dairy foods. Beside the higher Ca content, 
these foods include vitamin D (if the dairy products are fortified) (Weaver, 2010). 
Dietary consumption of Ca and vitamin D promotes healthy bones by lowering 
circulating PTH levels, thereby increasing bone mineralization and lowering bone 
turnover rates (Heaney, 2009).
Fractional Ca absorption fluctuates throughout life, with the highest rates 
occurring during growth, thus low Ca intakes during growth will affect peak bone 
mass (Lanham-New, 2008). Nieves et ah (1995) predicted that hip BMD would 
increase by 6 % if the intake of Ca is raised from 800 to 1200 mg/d during adolescence 
(Nieves et ah, 1995). Evidence from epidemiological studies suggests that the risk of 
fractures could be reduced by as much as 60% by high (mg/d) Ca consumption 
throughout life (Heaney, 2009). Numerous studies have examined the relationship 
between bone health and dairy product consumption. A positive assoeiation between 
the consumption of dairy products and BMD has been documented (Heaney, 2009).
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Opotowasky and Bilezikian (2003), reported greater hip BMD in premenopausal and 
postmenopausal women who had higher Ca intake during adolescence. A 
retrospective study of women between the ages of 20 and 49 indicated that the 
consumption of milk in childhood and adolescence seems to be associated with BMD 
and a lower risk of fractures (Kalkwarf et al., 2003).
Beside the well known effect of estrogen loss on bone remodeling, estrogen 
decline during the menopause is associated with a negative Ca balance (Cranney et 
al., 2007). Postmenopausal effects include a decrease in intestinal Ca absorption and 
an increase of renal excretion of Ca compared to before menopause, which leads to an 
inerease in Ca requirements to maintain bone health (Nordin et al., 2004). The effect 
of Ca supplements on reducing the rate of postmenopausal (5 or more years) bone loss 
is well established (Dawson-Hughes et al., 1990). Previous studies suggest that Ca 
supplementation reduces the rate of bone loss and may lower the fracture risk in 
women after menopause (Reid et al., 1995; Shea et al., 2004). The use of 500 mg/day 
of Ca supplements (with vitamin D), was found to significantly reduce the loss of 
femur, spine, and total body BMD compared to placebo in postmenopausal women 
aged 65 years and older (Dawson-Hughes et al., 1997). However, this improvement 
may decrease over time (Nordin, 2009). The use of Ca supplements in a daily dose of 
1200 mg, maintained normal serum Ca levels and suppressed PTH in postmenopausal 
women for more than 5 years aged between 50-65 years old (Fazlini et al., 2013). A 
review of more than 20 studies by Nordin found that the annual rate of bone loss in 
postmenopausal women who were treated with Ca supplementation was significantly 
lower than in untreated women (Nordin, 1997; Nordin, 2009).
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1.14.2 Phosphorus:
Phosphorus ( P O 4 )  is the second most plentiful mineral in the body, after Ca. 
Phosphorus works closely with Ca in the development of strong teeth and bones. 
Body tissues need P O 4  for growth, repair, and maintenance (Bemdt & Kumar, 2007). 
In order to stay healthy throughout life, bones and teeth need to undergo re­
mineralization, a process which requires a balance of important minerals including 
phosphorus (Shaikh et al., 2008). The skeleton contains approximately 85% of the 
body’s P 0 4  as hydroxyapatite, with the other 15% present in the extracellular fluids 
and soft tissues. Most of the P O 4  in whole blood is in the phospholipids of red blood 
cells and plasma lipoprotein, and only 1 mmol/L is found as inorganic phosphate 
which can be measured in plasma and serum (Razzaque, 2009). The reference range 
of serum P O 4  ranges from 0.85- 1.65 mmol/L for healthy adults (Goldman, 2011).
Phosphorus deficiency is uncommon as most people’s diets are rich in PO4 . 
Phosphorus is abundant in food, as many foods can contain both natural and added 
PO4 . As a rule, dairy products and protein-dense foods have the highest amount of 
PO4 , while fruits and vegetables provide the least (Uribarri, 2009). The 
gastrointestinal traet absorbs most dietary PO4  in all segments of the intestines (Favus 
et al., 2006). Dietary consumption does not affect how efficiently PO4  is absorbed. 
While not a necessary factor in the absorption of PO4  (Williams & DeLuca, 2007), 
vitamin D does increase its absorption to some degree. The absorption of PO4  occurs 
both through passive diffusion related to the concentration in the intestinal lumen (i.e. 
higher after a meal) and active transport which is stimulated by l,25(OH)2D 
(Williams & DeLuca, 2007).
The principal hormones responsible for the regulation of P O 4  eoneentrations 
are fibroblast growth factor 23 (FGF23), and PTH (Peacock, 2010). An increase in
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serum PO4  stimulates FGF23, which is an important regulator of PO4  homeostasis. It 
targets the kidney to increase urinary PO4  excretion by reducing its re-absorption and 
suppressing the production of l,25(OH)2 D, which decrease intestinal PO4  absorption 
(Clarke, 2011). The overall effect is to normalize PO4  levels. PTH plays a key role in 
PO4  homeostasis as well. An increase in serum PTH increases both the excretion of 
PO4  in the urine, and mobilizing it from the bone. PTH also increases the production 
of 1,25(0H)2D in the kidneys, which in turn increases intestinal PO4  absorption and 
reduces its renal excretion (Peacock, 2010). The effect of l,25(OH)2D on urinary PO4  
excretion is indirect; an increase in serum Ca concentration, which is mediated by 
1,25(0H)2D, suppresses PTH secretion, which, in turn, enhances PO4  re-absorption 
(Shimada et al., 2004).
1.15 Assessing bone strength and bone turnover
1.15.1 Bone Mineral Density measurement:
The end point used to evaluate bone strength is bone fracture (Martin & 
Correa, 2010). Bone mineral density and fraeture risk are strongly inversely 
associated and the relationship is highly predictive (Martin & Correa, 2010). Since 
osteoporosis is characterized by low bone mass, the key way to diagnose it is through 
quantifying BMD. Although, there is variety of methods to assess BMD, dual energy 
X- ray absorptiometry (DXA) is eonsidered the ‘gold standard’ (Knapp, 2009). The 
DXA is an non-invasive, fast and accurate method of measuring BMD expressed as 
grams of mineral per unit projected area of the bone (Andreoli et al., 2009). Using 
DXA, the risk of fracture can be estimated and patients undergoing treatment can be 
monitored. Spine column and proximal femur scans represent the majority of the 
clinical measurements performed using DXA (Hans et al., 2006).
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The WHO defined osteopenia and osteoporosis on the basis of T-score (which 
is the difference between the measured BMD and the mean value of young adults, 
expressed in standard deviation (SD) for a normal population of the same gender and 
ethnicity) (WHO, 2003). Alongside the T-score, another useful way of expressing 
BMD is the Z-score. Instead of comparing the subject’s BMD with the young normal 
mean as in T-score, the Z-score is comparing it to the mean BMD expected for a 
healthy normal subject matched for age, gender, and ethnic origin (WHO, 2003).
1.15.2 Bone Turnover Markers:
The normal process of bone remodeling facilitates the repair of micro fractures 
and the maintenance of skeletal strength. Over the past 20 years, several bioehemical 
bone turnover markers (BTM’s) have been developed that reflect the overall activity 
of osteoblasts and osteoclasts (Naylor & Eastell, 2012). Biochemical markers of bone 
turnover can be measured in serum and/or urine to provide a clinical picture of bone 
turnover by measuring the levels of bone formation and resorption. There are several 
sources of technical variability which need to be controlled for. These include 
specimen choice and mode of collection, and appropriate preparation of the patient 
(Seibel, 2005). The preeision of analysis can be seriously affected if specimens are 
not properly collected, handled and/or stored. It is also essential to use the same 
laboratory for serial measurements because even if identical procedures are used, 
results of assays can fluctuate significantly in different laboratories (Seibel, 2005). 
These measurements are comparatively inexpensive, generally available and 
noninvasive. There is a significant overlap in the BTM’s values of patients with 
osteoporosis and those without, so bone markers are not used for the diagnosis of the 
disease (Seibel, 2003). Nevertheless, BTM’s provide a useful way to estimate bone 
turnover rates and identify individuals undergoing rapid bone loss (Naylor & Eastell,
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2012). The combination of reduced BMD and high BTM’s is a better predictor of 
fractures than either risk factor alone. Consequently, BTM’s are now considered 
another tool to use in the assessment of the risk of fracture (Naylor & Eastell, 2012). 
Recommendations for the use of BTM’s have been published by the lOF (Delmas et 
al., 2000). The risk of osteoporotic fractures doubles with elevated levels of bone 
resorption markers. Therefore, for patients in whom clinical risk factors and BMD are 
insufficient to make a treatment decision, these BTM’s can be used to estimate the 
risk of fracture.
1.15.2.1 Markers of bone formation:
Markers of bone formation are reflective of osteoblast function and are 
released into the bloodstream when bone formation oceurs. When bone is formed, 
osteoblasts synthesize type I collagen as the precursor procollagen molecule with 
extension peptides in the carboxy (C) and amino (N) ends of the molecule. During the 
metabolism of extracellular collagen, proteases cleave these extension peptides, 
forming N-terminal (PfNP) and C-terminal (PICP) propeptides of type I eollagen, 
which can be measured in the bloodstream (Seibel, 2005). The amount of each 
propeptide in serum is considered to be proportional to the level of newly synthesized 
collagen. Non-eollagenous proteins are also released by osteoblasts. One of these is 
osteocalcin, the most plentiful non-eollagenous protein found in bone, and its clinical 
measurement can be used as an indication of osteoblastic activity (Cepelak & 
Cvoriscec, 2009). Osteoblasts secrete osteocalein during osteoid synthesis, and this 
protein plays a role chiefly in the mineralization of bone. Although most of it is 
deposited in the bone matrix, a small fraction is released in the circulation where it 
can be detected by immunoassays.
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1.15.2.2 Markers of bone resorption:
During bone resorption, osteoclasts break down the extracellular matrix and a 
range of collagen degradation products are released into the bloodstream. Bone 
resorption can then be indieated by measuring the levels of these products of collagen 
breakdown. These specific peptides are degradation products of the non-helical region 
of type I collagen in the aminoterminal region (NTX) and the carboxy-terminal region 
(CTX) produced by osteoclasts during bone resorption. Table 1.2 lists some more 
commonly measured BTM’s (Cepelak & Cvoriscec, 2009).
Table 1.2: Clinically useful bone turnover markers 
Bone formation
Osteocalcin (OC)
Bone specific alkaline phosphatase (BALP)
N-terminal propeptides of type 1 procollagen (PINP)
C-terminal propeptides of type 1 procollagen (PICP)
Bone resorption 
Pyridinoline (PYD)
Deoxypyridinoline (DPD)
N-terminal cross-linking telopeptides of type I collagen (NTX)
C-terminal cross-linking telopeptides of type I collagen (CTX)
Adapted from (Cepelak & Cvoriscec, 2009)
In their position paper on the utility of BTMs, the International Osteoporosis 
Foundation suggested that a good estimate of dynamic bone activity could be 
achieved by measuring the PINP, and the CTX in clinical studies (Vasikaran et al.,
2011). These markers both assess the turnover of type 1 collagen, with PINP 
measuring the synthesis of collagen and CTX measuring its breakdown. The IGF have 
actually cited PINP and CTX as the ‘reference standards for bone formation and
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resorption’, respectively (Vasikaran et al., 2011). This is due in part to the wide 
availability of easy-to-use enzyme-linked immunosorbent assays (ELISAs) and 
minimal pre-analytical variability.
1.16 Parathyroid hormone:
Parathyroid Hormone is the most important regulator of Ca and P O 4  
homeostasis. There are primarily two types of cells which make up the human 
parathyroid: chief cells (the main cell type) and oxyphilic cells. Chief cells have an 
important role in the synthesis and secretion of PTH (Bjorklund & Heilman, 2012). 
The cleavage of PTH to an 84 amino acid protein occurs in the parathyroid gland. 
Here it awaits release, being stored with fragments in secretory granules. The 
circulating 1-84 amino acid protein, upon release, has a half-life of 2-4 minutes 
(Schmitt et al., 1996). Binding to PTH reeeptors found throughout the body, PTH is 
subsequently cleaved into N-terminal, C-terminal, and mid-region PTH fragments. 
These then undergo metabolism in the liver and kidney (Goodman et al., 2002). PTH 
assays are commonly used for the differential diagnosis of calcium homeostasis 
disorders. Its reference range is between 1.6-6.89 pmol/L (Ravel, 1995).
The major regulator of both the synthesis and secretion of PTH is low 
concentration of serum Ca (Silva et al., 2011). There is an inverse relationship 
between PTH secretion and serum calcium. Low serum Ca levels increase the 
production of PTH in an attempt to correct calcium levels, while increased Ca levels 
suppress PTH secretion. l,25(OH)2D independently interacts with the VDRs in the 
parathyroid gland, resulting in an inhibition of PTH gene transcription. By interacting 
with its three major target organs (bone, kidney, and intestine), PTH is primarily 
responsible for the regulation of Ca homeostasis.
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In the kidney, PTH increases Ca re-absorption and PO4  excretion. Another 
important effeet of PTH in the kidney is to stimulate l,25(OH)2 D synthesis, which 
exerts control over the intestinal absorption of Ca (Murray et al., 2005). Thus the 
effect of PTH is indirect on the intestine where PTH stimulates the renal 1 -OHase, 
which enhances the conversion of 25(OH)D in its active metabolite l,25(OH)2D, 
which in turn increases the intestinal absorption of Ca and PO4  (Holick, 2010).
In the bone, PTH enhances the release of Ca and P O 4  (bone resorption) from 
bone by stimulating osteoclasts indirectly. Since osteoclasts do not have receptors for 
PTH, it binds to its membrane receptors on mature osteoblasts instead. This binding 
induces osteoblasts to increase their expression of RANKL and inhibits their 
expression of O P G .  The binding of RANKL to RANK (facilitated by the decreased 
amount of O P G )  stimulates the activation of osteoclasts which enhances bone 
resorption and the release of Ca and P O 4  from bone (Favus & Goltzman, 2008).
Parathyroid hormone plays an important role in the regulation of bone 
metabolism. Continuous excessive secretion of PTH, common especially in 
hyperparathyroidism, leads to higher bone turnover and deerease bone’s minerals 
(Poole & Reeve, 2005). Continuously elevated serum PTH levels, then, may result in 
bone loss and increased risk of fractures.
1.17 Summary
As a public health problem, inadequate vitamin D status causing vitamin D 
deficiency and insufficiency have the potential to impact enormously on many aspects 
of human health. Vitamin D insufficiency is associated with suboptimal calcium 
absorption (Heaney et al., 2003) and increased parathyroid hormone (PTH) levels, 
which lead to increased bone resorption, and increased risk of fracture (Dawson- 
Hughes et al., 2005). In addition to the effect on bone links have been found between
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inadequate vitamin D levels and cardiovascular disease, cancer and other diseases 
currently prevalent in our society (Lappe, 2011).
Information about the vitamin D status of different populations is widely 
available, but comparatively little research has been done to determine the vitamin D 
status of the Saudi population. This is due to Saudi Arabia being considered a sunny 
country and it being assumed that ambulatory Saudis at least, almost by default, must 
have adequate vitamin D status simply due to high sun exposures. Earlier and recent 
studies, however, have not supported this theory (Sedrani et al., 1983; Al-Jurayyan et 
al., 2002; Al-Mustafa et al., 2007; Al-Turki et al., 2008; Ardawi et al., 2011; Al-Elq,
2012). It appears that inadequate vitamin D status may be a problem not only in 
countries with reduced sun exposure or in non-ambulatory populations, but also in 
populations of ambulatory healthy adults in a sunny country such as Saudi Arabia.
A major recent area of research regarding vitamin D is the part it plays in 
maintaining muscle strength. A number of large clinical studies have found a 
relationship between inadequate levels of vitamin D and reduced muscle strength 
(Pfeifer et al., 2000; Bischoff-Ferrari et al., 2004b). Nevertheless, no research has 
been done on the link between muscle strength and physical performance and vitamin 
D in the Saudi population. Decreased muscle strength leads to reduced balance and 
increased body sway (Bischoff-Ferrari, 2012), resulting in a higher risk of falls and 
fractures (Bischoff-Ferrari et al., 2009), which makes it a serious health issue. 
Considering the fact that 80% of the population studied in Jeddah (Western region of 
Saudi Arabia) had vitamin D deficiency with overall vitamin D levels below 
50nmol/L (Ardawi et al., 2011), there is a need to fill the clear gap in what we know 
about muscle strength and its relationship with vitamin D status in the Saudi 
population.
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Worldwide, one of the main causes of disability and one of the most 
widespread reasons to seek primary care is musculoskeletal pain. Recent research has 
found that vitamin D deficiency is prevalent in people suffering from musculoskeletal 
pain (Plotnikoff & Quigley, 2003). The association of vitamin D with muscle 
weakness and regional pain disorders like low back pain may be explained by the 
identification of the vitamin D receptors in muscle tissues (Plotnikoff & Quigley, 
2003). There is little research to date looking into the link between vitamin D and 
musculoskeletal pain among Saudis (A1 Faraj & A1 Mutairi, 2003).
Osteoporosis is a significant public health concern and a costly condition 
globally. The aging of the population is the chief reason for the number of 
osteoporotie fi*actures; however, a sedentary lifestyle and an unhealthy diet also have 
an effect on the incidence of fi'actures (NOF, 2013). Sixty to eighty percent of a 
person’s total bone mass is genetically determined (Hunter et al., 2001). The rest of 
the bone mass is determined by nutrition (Bonjour et al., 2009) and lifestyle factors, 
such as physical activity (Sugiyama et al., 2002). The role of lifestyle faetors (such as 
parity, physical activity, sun exposure, smoking, veiling, etc.) in vitamin D status and 
bone health, especially in healthy Saudi women, is less clear, however.
Therefore, this thesis paper aims to describe the vitamin D status in a sample 
of randomly selected ambulatory healthy pre and post-menopausal Saudi women 
living in the Jeddah area (Western region of Saudi Arabia) and to examine 
associations with lifestyle factors and musculoskeletal health in this population.
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1.18 Objectives of the research:
1.18.1 To describe the extent of vitamin D deficiency and insufficiency in a sample of 
randomly selected healthy pre-and post-menopausal Saudi women.
• To investigate the impact of age and skin pigmentation on serum 25(OH) D.
• To investigate the impact of lifestyle factors on serum 25(OH) D in these 
healthy women.
1.18.2 To describe the extent of osteopenia and osteoporosis in a sample of randomly 
seleeted healthy pre-and post-menopausal Saudi women.
• To investigate the impact of age, age at menarche, and menopausal duration
• To investigate the impact of body weight, height, and BMI
• To investigate the impact of lifestyle factors on BMD
1.18.3 To examine the interaction between vitamin D status and bone mineral density 
and bone turnover markers in a sample of randomly selected healthy pre-and post­
menopausal Saudi women.
• To investigate the association between serum 25(OH)D and PTH
• To investigate the association between serum 25(OH)D and BMD
• To investigate the association between serum 25(OH)D and BTM’s
1.18.4 To describe the extent of overweight and obesity among pre-and 
postmenopausal healthy Saudi women
• To examine the assoeiation between serum 25(OH)D and adiposity measures
• To examine the association between PTH and adiposity measures
• To examine the association between BMI categories and BMD
1.18.5 To describe the interaction between vitamin D and musculoskeletal health 
among pre-and postmenopausal healthy Saudi women
• To assess if an association exists between serum 25(OH) D and muscle 
strength/function (8 -FW, GUG, 5-STS) in pre and post-menopausal women.
• To assess if non-specific musculoskeletal pain is associated with serum 
25(OH) D
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1.19 Hypotheses of the research:
1.19.1 Low levels of serum 25(OH)D are more prevalent in postmenopausal women 
than premenopausal women.
1.19.2 Bone mineral density is higher in premenopausal women than postmenopausal 
women.
1.19.3 Vitamin D status has an effect on bone mineral density and bone turnover 
markers in both groups of women.
1.19.4 Obese and overweight women have lower serum 25(OH)D levels and higher 
bone mineral densities than normal weight women.
1.19.5 Low serum 25(OH)D levels are associated with poor physical performance 
measures and non-specific musculoskeletal pain in both groups of the studied women.
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CHAPTER II
SUBJECTS AND METHODS
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2.1 Human research ethics and recruitment
This cross-sectional study was conducted in the city of Jeddah (in the western 
region of Saudi Arabia). The Jeddah community is composed of a diverse population 
representing most Saudis because of its strategic location between Madinah and 
Makkah (Muslim holy cities). A representative sample size was calculated using the 
sample-size determination option in Epi-Info Statistical Package (version 6 ; USD, 
West Park Place, Stone Mountain, G A, USA). The sample size was ealculated to be 
384 subjects and the calculation power was 98.9%. Subjects were recruited from 
primary health care centers (PHCCs) scattered around the city of Jeddah and through 
advertisement to ensure that the average health status of the studied subjects will 
reflect a randomly selected adult population.
A multi-stage sampling technique was adopted. In stage I, two PHCCs were 
selected from each of the seven geographical sectors of the Jeddah area. In stage 2, 
systematic random samples were used of the selected PHCCs to select the files of 
women among the registered population. In stage 3, all women in the selected age 
group among selected files were contacted for possible recruitment to the study 
according to the predefined criteria of inelusion which is any healthy women (not 
pregnant or lactating at the time of inclusion in the study) 20 years and older (Table 
2.1). Then, women who agreed to participate in the study were asked to visit a special 
clinic at the Center of Excellence for Osteoporosis Research (CEOR), King Abdulaziz 
University (KAU), Jeddah, Saudi Arabia to be enrolled in the study. A reminder eall, 
with the time of attendance required for the participant was also made to all 
partieipants 1 week prior to the data collection.
The study was approved by CEOR’s Human Ethics Research Committee and a 
written informed consent (Appendix d) was obtained from all women participating in
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the present study. Once collected, data for each participant was tagged with a unique
4-digit code and the information was stored in a locked cabinet in the researcher’s 
office to ensure complete confidentiality.
Table 2.1: Exclusion criteria 
The following women were excluded from this study
K* Women having any of the following diseases
- Hepatic - Renal
- Cancer - Osteoporosis
- Endocrine disorders
- Gastrointestinal disorders
- Rheumatoid arthritis
- Any disease interferes with vitamin D and bone metabolism 
Women using any of the following medications
- Glucocorticoids - Bisphosphonates
- Anticonvulsants - Aromatase inhibitors
- Anticoagulants - Calcitonin
- Any others interfere with vitamin D and bone metabolism 
Women who had any of the following conditions
- Oophorectomy
- Pregnancy at time of the study
- Lactating
- Menstrual irregularities
2.2 Subject selection
Over a period of 6 months (April - September 2010), a total of 761 Saudi 
women were recruited. Upon enrollment, subjects completed a health history 
questionnaire to determine their eligibility for the study (Appendix c). Only healthy 
women with no diseases or use of medications known to affect vitamin D and/or bone 
metabolism were included in the study. No pregnant or lactating women were
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included in the current study. The designed exclusion criteria for the current study are 
present in Table 2.1.
After excluding women with diseases and medications known to affect bone 
metabolism, pregnant or lactating women, and those who declined due to personal 
reasons (Figure 2.1), only 464 women were eligible and agreed to participate. Pre­
menopause was defined as the time before menopause (regular menses in past 9 
months) and with serum follieular stimulating hormone (FSH) levels <15 mlU/L. 
Postmenopausal women are defined as those who had their last menstrual period at 
least one year before the date of scanning (with no pregnancy). The levels of FSH of 
postmenopausal women were >15 mlU/L. The classification of menstrual status was 
confirmed by measuring FSH (Reame et al., 2000) in CEOR’s lab. Further exclusion 
was done based on the biochemical results (up-normal levels of liver or renal funetion 
tests and FSH). A total 449 women were included in the present study, 226 
premenopausal women aging from 20-39 years and 223 postmenopausal women 
aging from 50-82 years.
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Eligible 
(n = 464)
Approached 
(n = 761)
Prescreened on phone 
(n = 734)
Further exclusion based on biochemical results
(n=15)
Unreachable (n = 19) 
Declined participation (n = 8)
Excluded:
Not meeting inclusion criteria (n = 242) 
Declined further participants (n = 28)
A total of women included (n = 449) 
Premenopausal (n= 226) 
Postmenopausal (n = 223)
Figure 2.1 Flowchart of participation
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2.3 Data collection and Measurement
During the study, each woman came to the center once, at which time the researcher 
met with her. During the visit, each participant went through the following seven 
measurement ‘ stations ’ :
• Basic anthropometric data (weight and height)
• Socio-demographic data
• Life style information
• Bone and muscle pain questionnaire
• Three physical performance measures
• Bone mineral density measurement (DXA)
• Specimen collection
With the exception of the stations involved in blood collection, anthropometric 
measurement, and DXA, the main researcher ran each of the stations, explaining to 
participants what they needed to do at that station. In order to ensure a smooth flow of 
participants, on a typical day, four to five women were given appointments to visit the 
center at intervals of half an hour. This reduced delays for participants and 
inconvenience. The researcher explained to each woman the objectives of the study 
and participants signed the consent form, after which they could proceed through the 
measurement stations in no particular order.
As part of quality assurance, there was a checklist stapled to the front of each 
participant’s file, listing all data collection measures and required forms to be filled 
out. As each participant finished a particular station, the researcher recorded station 
completion on the list. When the participant was ready to leave at the end of the data 
collection process, the researcher was able to check this list to make sure that the 
participant had not missed any of the stations, thereby lowering the likelihood of
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missing data. Pretesting of the questionnaires was also carried out prior to the actual 
data collection in order to ensure standardization and reliability of the questionnaires. 
The questionnaires were then revised and finalized on the basis of the pretest results. 
2.4. Participants Data
2.4.1 Anthropometry
In order to obtain the body mass index of the participants, the center’s physician 
obtained height and weight measurements. Subjects were weighed (while wearing 
light clothes and no shoes) on a balance beam scale in kilograms (kg). Standing height 
was measured (with no shoes) using stadiometer in centimeters (cm) (Detecto, USA). 
Body mass index (BMI) was calculated as weight (kg) / height (m^). Normal weight is 
defined as BMI between 18.5-24.99, over weight as BMI > 25, and obese as BMI > 
30 on the basis of International Obesity Classification (NOG, 2009). Waist 
circumference (midway between the lower rib margin and the iliac crest), hip 
circumference (the maximal circumference over the buttocks) were measured, and 
waist to hip ratio (WHR) as waist (cm) / hip (cm) was calculated.
2.4.2 Socio-demographics
Information on participant socio-demographics such as age, marital status, residential 
area, educational level, income, occupation, and type of accommodation was collected 
from each woman at the beginning of the questionnaire, which was used to collect 
information on participants lifestyle (Appendix a).
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2.4.3 Reproductive history
Assessment of reproductive history included age at menarche, number of pregnancies, 
history of breastfeeding, and age at menopause was obtained by self-report at the 
interview time. Menstrual status was defined, based on each woman’s report and 
confirmed by FSH measurements. The number of pregnancies was calculated as the 
sum of all a woman’s pregnancies of at least 6  months’ duration. Women who had 
had at least one pregnancy reported whether they had ever breastfed. The average of 
total breastfeeding month’s were calculated.
2.4.4 Collection of lifestyle data:
2.4.4.1 Smoking habits:
Information on participants smoking habits was also collected. Participants were 
asked to identify whether they were smokers or non-smokers. If they were current 
smokers, additional information about the number of cigarettes or bubbly bubbly they 
currently smoked and the number of years they had smoked was also recorded.
2.4.4.2 Physical activity:
Subjects were asked about the type(s) of physical activity they were practicing and the 
amount of time they spent per day/week and the number of times a week they were 
physically active (short of breath and sweating) for > 2 0  minutes.
2.4.4.3 Sunlight exposure:
There are several methods used to measure the extent of exposure to UV light, among 
them the use of bio-film badges (Diffey, 1984). Another method is a questionnaire to 
collect information about the time participants spend outside and their sun protection 
behaviors. In the current study, participants were asked to answer a short 
questionnaire with information related to their outdoor UV exposure and steps to
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protect themselves from the sun over the last month which was filled out by the 
researcher. The period of one month was used because research has indicated that the 
use of shorter term recall times like this is a more reliable method of collecting this 
type of data compared to questionnaires which require longer term recall (Godar, 
2005). The sunlight exposure information was obtained by asking the subjects about 
the extent of exposure to sunlight, the average duration during a day, and the use of 
sunscreen. Assessments of the participant’s skin color was obtained and recorded by 
the researcher based on the Fitzpatrick scale (Figure 2.2) (Fitzpatrick, 1975).
Type I: Extremely fair skin, always bums, and never tans.
Type II: Fair skin, always bums, and tans minimally.
Type III: Medium skin, bums moderately, tans gradually to light brown.
Type IV: Olive skin, bums minimally, always tans to moderately brown.
Type V: Dark brown skin, rarely bums, and tans profusely to dark.
Type VI: Deeply pigmented dark brown to black skin that never bums
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Figure 2.2: Skin tone chart
Copyright © Available at (Fitzpatrick, 1975)
2.4.4.4 Veiling style:
All women in Saudi Arabia maintain conservative clothing style due to cultural and 
religious belief while being outdoors. This veiling style ranged from partially covered 
allowing face and hands exposed to the sun to totally covered, including face and 
hands. Information about veiling style while being outdoors was obtained from all 
women participated in the current study.
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2.5 Physical performance Measures
One objective way to assess a participant’s functional ability is the use of physical 
performance measures. Research has shown that future disability can be reliably 
predicted by impaired function on physical performance tests (Guralnik et al., 1994; 
Lusardi et al., 2003). In addition to creating social and environmental obstacles, 
disability is a sign of physiological limitations. People with a physical disability often 
cannot perform common essential daily activities like getting dressed, walking, and 
doing household chores without assistance (Lusardi et al., 2003). Future falls in the 
elderly may be predicted by various balance tests (Morris et al., 2007). The simple ' 8  
feet gait speed test', 'get-up and go test', and 'sit-to-stand test' are some which have 
been used for this purpose (Guralnik et al., 2000). The following three short physical 
performance tests were measured by the main researcher following a standard 
protocol, outlined below:
2.5.1 Eight foot walk Test:
An eight-foot walk (8 FW) (2.4 m) was selected to test comfortable walking speed by 
recording how much time was required to cover the 8 -feet distance. Among the 
elderly, both healthy and fi*ail, functional walking performance can be measured 
effectively by gait speed at a usual or comfortable self-selected walking speed 
(Guralnik et al., 2000). An unobstructed 8 -feet course was measured, with the start 
and finish lines clearly marked. To begin, participants were asked to place both feet 
together at the start line. Timing was started as soon as either foot was placed down 
on the floor beyond the start line. Participants were told to walk at their usual speed 
(not race) to the finish line. They were asked to imagine they were just walking down 
the street to go shopping, and to continue walking past the other end of the tape before 
they stopped. As soon as either foot was put on the floor beyond the finish line, timing
56
was stopped. The test was then repeated, with the participants being asked to line up 
their feet and walk back along the same course past the tape at the other end (Guralnik 
et al., 2000). Participant performed two trials of the 8 FW test with a 1 minute rest 
period between the trials.
2.5.2 Get Up and Go Test:
The get-up and go (GUG) test was used as an assessment of functional mobility in the 
study participants (Podsiadlo & Richardson, 1991). Functional mobility involves 
motor skills required for people to live independently. These include walking a short 
distance quickly (e.g. to answer a ringing telephone), changing direction while 
walking, and getting up from and returning to a seated position (e.g. to/from a chair, 
bed, or toilet) (Shumway-Cook et al., 2000). The test was performed with the use of a 
straight-back chair placed next to a wall. Participants were instructed to sit 
comfortably in the chair with their back to the chair and their arms resting on the arm 
rests. Then they were asked to move as quickly as safely able to rise from the chair 
and walk a distance of ten feet (3m), turn around, walk back to the chair and sit down 
again (Figure 2.3). Timing began when the subject started to rise from the chair and 
ended when she returned to the chair and sat down (Lusardi et al., 2003). Participant 
performed two trials of the GUG with a 1 minute rest period between the trials. The 
rationale for including this test is that get-up-and-go speeds exceeding 2 0  seconds 
have been shown to predict an increased risk of falls in older adults (Lusardi et al., 
2003).
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Figure 2.3: Get up and go test 
2.5.3 Five Times Sit To Stand Test:
The five times sit-to-stand (5-STS) test appears simple, but it requires the 
coordination of several body systems. It involves balance, coordination, muscular 
strength, range of motion in the lower limb joints and tolerance for exercise. Physical 
frailty is often indicated by a person’s inability to get up from a chair without using 
arm rests. From a sitting position in a firm chair, participants were asked to stand up 
without the use of their arms. If successful in this task, respondents had to stand up 
and sit down as fast as possible five consecutive times, and a record was made of the 
time taken (Figure 2.4). Participants had to keep their arms folded across their chest 
and feet on the floor during the test. When the participant was fully standing with her 
back straight, the rise was counted as complete and counted out loud (Guralnik et al..
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2000; Lusardi et al., 2003). Ail of the respondents attempting this test could stand up 
without assistance and two trials of this test were performed.
Verbal instructions and encouragement during the tests were standardized. A walking 
aid, such as a walker or cane, was permitted for the 8 FW but not for the GUG or the
5-STS test. Participants were encouraged to rest as needed between different 
functional tests and between repeats of the same test. If the researcher felt worried 
about the participant’s condition, or if the participant became too tired or had 
difficulty breathing, the test was halted. A digital stopwatch was used to time how 
long participants took to undertake each of these tasks, and time was calculated in 
seconds. The mean of the two trials for each test was calculated and used in the 
analysis.
Figure 2.4: 5-times sit-to-stand test
59
2.6 Bone Mineral Densitometry Measurements
Calculating BMD involves measuring the BMC in grams in a projected two- 
dimensional area (in cm^) of the bone(s) being studied. It was performed by a single 
technician for the lumbar spine (L1-L4), at the total hip (femoral neck, ward’s, and 
trochanter), and for the total body by DXA using (LUNAR Prodigy Model, Lunar 
Corp., Madison, WI, USA, available at the Bone Densitometry Unit at CEOR), 
according to standard protocol. Figure 2.5 below presents the DXA scan machine 
used for the BMD measurements at CEOR. Quality control procedures were carried 
out in accordance with the manufacturer’s recommendations. Instrument variation was 
determined regularly by a daily calibration procedure using a phantom supplied by the 
manufacturer. Precision error of the phantom was 0.3% and for in vivo was less than 
1.2% for the spine and less than 2% for femoral regions. There was no significant 
drift over the period of the study using the DXA system. All measurements were 
performed at the Bone Densitometry Unit at the Center of Excellence for 
Osteoporosis Research, King Abdul-Aziz University.
For the purpose of diagnosing osteoporosis, BMD values alone are not used. A 
scientific group of the WHO has proposed, instead, a definition of osteoporosis based 
on the T-score (WHO, 2003). The T-score is the difference between the BMD 
recorded for the patient and the average bone mass of a healthy adult, shown as the 
number of standard deviations (SD) from the mean in a normal population of the same 
ethnic group. The reference range for Saudi Arabia was used. As per the WHO 
recommendations, osteopenia was defined by a T-score between -1 and -2.5 SD, and 
osteoporosis was defined by a T-score less than -2.5 SD at a particular skeletal site.
During a DXA scan, the participant is not enclosed by the equipment at any 
time and feels no pain. While being scanned, the subject lies on a large, fiat table
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underneath which is an X-ray generator. A thin, invisible beam of very low-dose X- 
rays is sent by the DXA machine through the body. Bodily tissues like fat and bone 
absorb the X-rays. Above the table is an arm of the machine which passes over the 
subject during the scan. In this arm is a detector which calculates the quantity of X- 
rays passing through the body of the subject. An image of the body is then produced 
using this information.
The subject first changed into a hospital gown and removed all metal objects from the 
body. When the participant entered the scanning room, the procedure was explained 
briefly by the technologist. The subject was centered on the surface of the machine 
and secured. The subject was told not to move during the scan to ensure a clear, un­
blurred image. Positioning each participant correctly for her scan took a few minutes 
and taking the scans lasted approximately 30 minutes.
Figure 2.5: DXA scan machine
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2.6.1 Measurement Procedures:
2.6.1.1 Lumbar Spine:
The lumbar spine scanning starts in the lower vertebrae, next to the pelvis, and 
proceeds up toward Ll(Leib et al., 2006). The technologist positions the participant in 
the center of the scan table so that the middle of the subject’s body is aligned 
lengthwise with the centerline on the table pad. The subject is positioned with her 
spine straight and centered, and both iliac crests visible. The scan starts sufficiently 
low to include the pelvic brim (usually the level of the L4-L5 inter-space) and 
extends up far enough to show part of the lowest vertebra with ribs. The participant’s 
head is placed right beneath the horizontal line at the top of the table pad and her arms 
are positioned at her sides with palms flat against the table. There is a support block 
near the lower end of the table. The legs of the participant are placed on this block, so 
that her thighs are at a right angle with the table. The support block helps keep the 
lower back straight. The position of the laser light should be two inches beneath the 
navel. A sample of DXA measurement of BMD at the lumbar spine is presented in 
Figure 2.6.
Densitometry Reference: AP Spine L1-L4
BMD (g/crrf) YA T -S core
jb .
Osteopenia
0.82-£W:?'vY;;
20 30 40 50 GO 70 80 90 100
Age [years)
Figure 2.6: DXA measurement of BMD at the spine
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2.6.1.2 Femur:
A scan of the right or left femur starts in the soft tissue around the shaft of the femur 
and extends up to include the femoral neck and greater trochanter. BMD values for 
the trochanter, Ward’s triangle, femoral neck, and total femur regions are given by the 
scan. The participant is placed in the center of the scan table with the middle of her 
body aligned lengthwise with the centerline on the table pad. The participant’s head is 
placed right beneath the horizontal line at the top of the table pad and her arms are 
positioned at her sides with palms flat against the table. Both legs are gently rotated at 
an angle of 25°. A foot-brace keeps the legs in position by strapping the feet to the 
angled side of the brace. The participant’s feet should be perpendicular to the top of 
the table and her toes should point upwards. A sample of DXA measurement of BMD 
at the femur is presented in Figure 2.7.
1
Densitometry Reference; Left Femur Total
BMD (g/cmP) YA T-Score
1.260
20 30 40 50 60 70 80 90 100
Age (years)
Figure 2.7: DXA measurement of BMD at the femur
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2.7 Specimen collection
Subjects reported to the laboratory for a single blood draw by a trained phlebotomist. 
For proper analysis of the serum measures, women were required to fast for at least 10 
hours prior to blood collection. Blood samples were collected from all participants in 
two plain tubes (10 ml) under standardized conditions. Immediately following blood 
collection, the blood was to clot at room temperature for 30 minutes, and then 
underwent centrifugation using Clay Adams Dynac II centrifuge (Block Scientific 
Inc, NY, USA) at 3000 rpm for 10 minutes. The serum extracted after being 
centrifuged was kept in two labeled micro-tubes (1.5ml size) that were stored in a 
-80°C freezer until analyzed. Second void urinary samples were collected under 
standardized conditions from all subjects in the morning between 8 and 11a.m. and 
transferred to tubes and stored at - 80°C until analyzed. Urine samples were 
centrifuged at 3000 rpm for 10 minutes before the analysis was done. All samples 
were stored in tubes labeled with an ID number; no identifying information was 
written on any storage tubes.
2.7.1 Measurements of liver and renal functions
Serum Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and 
Alkaline Phosphatase (ALP) were measured. Women with abnormal liver function 
tests (AST, ALT, and ALP) levels were excluded from the study. Renal function was 
also evaluated by measuring creatinine levels. Women whose creatinine levels were 
above the normal range were excluded. All healthy women included in this study 
showed: normal values for liver function tests (serum AST <30 U/L; ALT <30 U/L; 
ALP between 80 and 280 U/L and normal values for renal creatinine (serum 
creatinine in women <105mmol/L).
Principles of the tests:
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Measurement of liver enzymes was carried out using the colorimetric method, where 
the sample’s enzymatic activity is proportional to the multiple-point rate of changes in 
the density of the end-product dye (as measured by reflectance spectrophotometry). 
Measuring creatinine levels was also involved the colorimetric method, where the 
creatinine concentration in the specimen is proportional to the difference in the 
density of the end-product dye at two fixed times (as measured by reflectance 
spectrophotometry).
VITROS 250 Clinical Chemistry Auto-analyzer (Ortho-Clinical Diagnostics Inc., 
Rochester, NY, USA) was used for the measurements.
2.7.2 Measurements of hormones
Serum FSH was measured by commercially available immunoassays using VITROS 
ECi (Ortho-Clinical Diagnostics Inc., Rochester, NY, USA). Two different antibodies 
bind to serum FSH during incubation. Streptavidin coating on the wells captures this 
antigen-antibody complex. One of the two antibodies is linked to an enzyme. This 
results in a sandwich binding with FSH between two antibodies. After incubation, 
gentle washing is done to remove materials which are not bound. The subsequent 
addition of a substrate (a luminol derivative) to the wells allows catalyzation by the 
enzyme conjugate, which produces light. The VITRO S ECi System reads these light 
signals. The concentration of FSH present in the sample is directly proportionate to 
the amount of bound enzyme conjugate. The intra-and inter-assay coefficient 
variation (CV) were < 4%.
2.7.3 Measurement of Intact Parathyroid Hormone
Intact PTH (1-84) was quantitatively measured by direct sandwich 
chemiluminescence immunoassay using LIASON auto-analyzer (DiaSorin Inc.,
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Stillwater, MN, USA). Two antibodies bind to serum PTH in two different regions 
during the first incubation. The first antibody is coated on the solid phase, while an 
isoluminol derivative is linked to the second antibody. This results in a sandwich 
binding with PTH between two antibodies. After incubation, a washing cycle removes 
materials which are not bound. Then a flash chemiluminescent reaction is set off by 
the addition of a starter reagent. A photomultiplier measures the light signal, which 
indicates proportionally the concentration of PTH in the sample. The intra-and inter­
assay coefficient variation were 5.1% and 4.3%, respectively.
2.7.4 Measurement of 25-hydroxyvitamin D
Serum 25(OH)D was measured with direct competitive chemiluminescence 
immunoassay using LIASON autoanalyzer (DiaSorin Inc, Stillwater, MN, USA), 
which detects both 25(OH)D2 and 25(OH)D3 to estimate the total 25(OH)D 
circulating in the body. It works on the principle of competition between 25(OH)D 
present in the specimen and labeled 25(OH)D tracer for the binding site of vitamin D 
specific antibodies. During the initial incubation, serum 25(OH)D separates from its 
serum-binding protein and binds with the specific antibody coated on the solid phase. 
Following a second incubation, the next step is the addition of a tracer (vitamin D 
linked to an isoluminol derivative) which acts in competition with serum 25(OH)D to 
bind to the antibody coated on the solid phase. After a third incubation, a washing 
cycle is carried out to remove the material which did not bind. A flash 
chemiluminescent reaction is then set off by the addition of a starter reagent. A 
photomultiplier measures the light signal given off, which is inversely proportional to 
the amount of 25(OH)D in the specimen. The intra-and inter-assay coefficient 
variation (CV) were 7.8% and 3.8%, respectively.
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2.7.5 Measurement of other analytes:
Serum Ca and PO4  were measured by kits and reagents supplied by Ortho-Clinical 
Diagnostics, USA using VITROS 250 chemistry System Autoanalyzer (Ortho- 
Clinical Diagnostics- Johnson & Johnson Co., USA). Colorimetric detection was 
used, where the analyte concentration in the specimen was proportional to the 
difference in the density of the end-product dye at two fixed times (as measured by 
reflectance spectrophotometry).
2.8 Measurements of bone turnover markers
Serum OC, PINP, and CTX were measured by a sandwich electrochemiluminescence 
immunoessay (ECLIA) using Cobas-e immunoassay analyzer. During the first 
incubation, the sample and a biotinylated antibody are incubated together. In the 
second incubation, after addition of streptavidin labeled microparticles and specific 
antibody labeled with ruthenium complex, a sandwich complex is formed which 
becomes bound to the solid phase via interaction of biotin and streptavidin. Then the 
reaction mixture is aspirated into the measuring cell where the microparticles are 
magnetically captured onto the surface of the electrode. Unbound substances are then 
removed. Application of voltage to the electrode then induces chemiluminescent 
emission which is measured by a photomultiplier. Results are determined via a 
calibration curve which is an instrument specifically generated by 2 -point calibration 
and a master curve provided via the reagent barcode. The intra- and inter-assay 
coefficients of variations (CVs) were 1.8% and 1.2% for serum OC, and 2.3% and 
2.1% for serum PINP, respectively. The intra- and inter-assay for serum CTX were 
4%.
The measurement of urine NTX was carried out by direct competitive 
chemiluminescence immunoassay using VITROS ECi (Ortho-Clinical Diagnostics
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Inc., Rochester, NY, USA). It works on the principle of competition for the binding 
site of NTX specific antibodies between NTX present in the specimen and a labeled 
NTX tracer. In the initial incubation, urine NTX and its binding protein are 
dissociated, and the NTX binds to the specific antibody coated on the solid phase. 
This is allowed to incubate a second time. The next step is the addition of a tracer 
(NTX linked to an isoluminol derivative), which acts in competition with urine NTX 
to bind to the antibody coated on the solid phase. After a third incubation, a washing 
cycle is carried out to remove the unbound material. A flash chemiluminescent 
reaction is then set off by the addition of a starter reagent. A photomultiplier measures 
the light signal given off, which is inversely proportional to the amount of NTX in the 
specimen. Urine NTX intra- and inter-assay CVs were 7.8% and 4.5%, respectively.
2.9 Musculoskeletal pain Measurements
Pain is a subjective experience, and no objective tests exist to measure it (American 
Pain Society, 2009). Whenever possible, the existence and intensity of pain are 
measured by the patient’s self-report, abiding by the clinical definition of pain that 
states, "Pain is whatever the experiencing person says it is, existing whenever he/she 
says it does" (McCaffery, 1968). Self-reporting of pain verbally, in writing, or by 
other means, such as finger span or blinking their eyes to answer yes or no questions 
is a common way to measure pain (Pasero & McCaffery, 2011). The bone and muscle 
pain questionnaire used in this study was designed to locate the site(s) and the 
intensity on a scale ranging from 0 - 1 0  with 0  indicating no pain and 1 0  indicating the 
worst pain possible (Appendix b).
2.9.1 Back pain
Each woman was asked whether or not she had experienced back pain in the past six 
months. If she answered in the affirmative, she was asked to rate the pain. Women
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were also asked to elaborate on a description of the pain, its causes, how often it 
occurred, any use of medications to relieve the pain, and whether or not medical 
consultation was sought for the pain.
2.9.2 Daily living
The questionnaire answered by the women also included a section about daily 
routines and included questions about any problems faced in doing simple things like 
bending, reaching for an object, getting in or out of a car, walking, or climbing the 
stairs. If women had difficulties with these movements, they were asked if it was 
related to back pain or not.
2.9.3 Bone and Muscle pain
To collect information on pain, the questionnaire included a question: ‘Have you had 
any bone and/or muscle pain in the last six months?’ If the participant’s answer was 
‘Yes’, she was asked to show the location(s) of the pain and its intensity. The subject 
was also asked to describe the pain briefly.
2.10 Statistical analysis
Data entry and analysis of data was achieved using SPSS software package (v .l6  
SPSS Chicago Inc). A probability value of <0.05 was considered statistically 
significant. Raw data from the participants’ questionnaires and results was entered 
into SPSS spread sheet. Testing for normality was determined by Kolmogorov- 
Smimov test to compare the shape of our sample distribution to the shape of a normal 
curve for all variables. Independent sample T-test was used to test significant 
differences between two independent variables. One way ANOVA test was used 
when the independent variables had more than two categories. Bivariate correlations 
were used to test for associations between variables with Pearson’s correlations being
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reported for normally distributed data. When the normality assumption was violated, 
Spearman’s rank order correlations were reported. Independent variables that 
displayed significant associations at the bivariate level (P<0.05) were included in the 
Multivariable statistical analysis to identify independent predictors of the testing 
variable.
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CHAPTER III
GENERAL CHARACTERISTICS OF 
THE STUDIED PRE-AND POST­
MENOPAUSAL HEALTHY SAUDI
WOMEN
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3.1 Subject Characteristics
From April-September 2010, a total of 449 women were eligible and enrolled in the 
present study. Of the total 449 women in this study 50% (n=226) were premenopausal 
and 50% (n=223) were postmenopausal. General characteristics of the studied pre and 
postmenopausal healthy Saudi women are presented in Tables 3.1- 3.6.
3.2 Age and anthropometric
Women’s age and anthropometric data are shown in Table (3.1). The age of 
premenopausal participants ranged from 20-39 years and the mean was 29.1 years (SD 
5.6 years). The age of postmenopausal participants ranged from 50-82 years and the 
mean was 58.8 years (SD 5.9 years). The mean body weight was 65.1 (SD 14.9) for 
premenopausal and 74.8 (SD 13.9) for postmenopausal women. The mean waist-to- 
hip ratio (WHR) was 0.765 (SD 0.07) for premenopausal and 0.855 (SD 0.08) for 
postmenopausal participants. The mean body mass index (BMI) for the 
premenopausal was 25.9 (kg/m^) [SD 5.4 (kg/m^)], while mean BMI for the 
postmenopausal was 31.5 (kg/m^) [SD 5.7(kg/m^)]. The mean total body fat (TBF) for 
the premenopausal was 25.8 (g) [SD 8.4 (g)], while mean TBF for the 
postmenopausal was 31.7 (g) [SD 6.7(g)]. Postmenopausal women exhibited 
increased in all anthropometric measures (except height) as compared to 
premenopausal women (P<0.001).
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Table 3.1: Age & anthropometric characteristics of pre and post-menopausal 
women
Age & anthropometric Premenopausal Postmenopausal P-value
(n=226) (n=223)
Age (years) 29.1 ±5.6 58.8 ±5.9 <0 . 0 0 1
Weight (kg) 65.1 ± 14.9 74.8 ± 13.9 <0 . 0 0 1
Height (cm) 158.4 ±5.5 154.1 ±5.9 <0 . 0 0 1
BMI (kg/m )^ 25.9 ±5.4 31.5 ± 5.7 <0 . 0 0 1
Waist circumference (cm) 74.8 ±11.7 90.9 ±11.8 <0 . 0 0 1
Hip circumference (cm) 97.6 ± 11.1 106.4 ±11.7 <0 . 0 0 1
WHR 0.765 ± 0.07 0.855 ±0.08 <0 . 0 0 1
TBF (g) 25.8 ± 8.4 31.7 ±6.7 <0 . 0 0 1
Data are presented as mean ± SD
Premenopausal and postmenopausal groups were compared with use o f independent samples ?-tests
3.3 Reproductive characteristics
Reproductive characteristics of the premenopausal and postmenopausal groups 
of women are presented in Table 3.2. For all women combined the mean number of 
pregnancies was 5.5±3.1. The maximum number for children bom alive was 14 with 
an overall mean of 4.4± 2.5. The mean duration of lactation in months was 7.9±5.8 for 
premenopausal women and 10.2±6.9 for postmenopausal women. Significant 
differences were found between the two groups of women.
Table 3.2: Reproductive characteristics of pre and post-menopausal women
Variables Premenopausal
(n=226)
Postmenopausal
(n=223)
P-value
Age at menarche (years) 13.2 ± 1.3 12.8 ± 1.5 0 . 0 1
Parity 3.40 ±1.8 6.51 ±3.1 <0 . 0 0 1
Children bom alive (n) 2.69 ±1.4 5.25 ± 2.4 <0 . 0 0 1
Lactation (months)* 7.90 ±5.8 10.2 ±6.9 0.003
Age at menopause (years) 51.4 ± 3.4
Data are presented as mean ± SD
Premenopausal and postmenopausal groups were compared with use o f independent samples Mests. 
* Average o f months o f lactation during the last period prior to recruiting
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3.4 General characteristics
Table 3.3 provides a summary of the general charaeteristics collected for the 
participants as part of the study. Fifty five percent (55%) of the women were married, 
41% had university postgraduate education, 51% were housewives, and about 30% of 
the studied women had a high income (>15,000 SR). Of the studied women 38.5% 
were physically active, 24.9% had a regular sun exposure, 5% used sunscreen, 58% 
were totally eovered wearing a niqab, and 10.7% were current smokers. 
Postmenopausal group of women exhibited inerease use of vitamin D 
supplementations compared to premenopausal women (P<0.001).
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Table 3.3: General characteristics of pre and post-menopausal women
Variables All women 
n(% )
Premenopausal 
n (%)
Postmenopausal 
n (%)
Marital status:
single 118(26.3) 111 (49.1) 7(3.1)
married 248 (55.2) 96 (42.5) 152 (68.2)
widow 55 (12.2) 2 (0.9) 53 (23.8)
divoreed 28 (6 .2 ) 17 (7.5) 11 (4.9)
Education level:
no education 48 (10.6) 1 (0.4) 47 (21.1)
Elementary / 
intermediate
77(17.1) 6  (2 .6 ) 71 (31.8)
secondary 138 (30.7) 85 (37.7) 53 (23.8)
University / 
postgraduate
186(41.4) 134 (59.3) 52 (23.3)
Occupation:
student 55 (24.3) 55 (24.3) -
governmental 8 6  (19.2) 64 (28.3) 22 (9.9)
private sector 39 (8.7) 34 (15.0) 5 (2 .2 )
housewife 269 (59.9) 73 (32.3) 196 (87.9)
Income per month 
(SR):
< 5,000 145 (32.3) 61 (27.0) 84 (37.7)
>5,000-<10,000 99 (22.0) 57 (25.2) 42(18.8)
> 10,000-< 15,000 71 (15.8) 39(17.3) 32 (14.3)
> 15,000 134 (29.8) 69 (30.5) 65(29.1)
Physical activity:
yes 160 (35.6) 8 8  (38.9) 72 (32.3)
no 289 (64.4) 138(61.1) 151 (67.7)
Sun exposure:
yes 112(24.9) 54 (23.9) 58 (26.0)
no 337 (75.1) 172 (76.1) 165 (74.0)
Sun screen use:
yes 23 (5.1) 13 (5.8) 10 (4.5)
no 426 (94.9) 213 (94.2) 213 (95.5)
Vitamin D 
supplements:
yes 108(24.1) 22 (9.7) 8 6  (38.6)
no 341 (75.9) 204 (90.3) 137(61.4)
Veiling type:
niqab+gloves 14(3.1) 7(3.1) 7(3.1)
niqab only 247 (55.0) 130 (57.5) 117(52.5)
hijab 188(41.9) 89 (39.4) 99 (44.4)
Smoking:
yes 48 (10.7) 28 (12.4) 20 (9.0)
no 401 (89.3) 198 (87.6) 203 (91.0)
Values given in parenthesis are percentages (%) out o f total within the group
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3.5 Skin type characteristics
Skin type frequency of the studied women is presented in Table 3.4. None of the 
women in the present study were skin type I (extremely fair) or type VI (black). Skin 
types III and IV made up 82.9% of the overall group.
Table 3.4: Skin types characteristics of pre and post-menopausal women
Fitzpatrick skin Types* All women 
N (%)
Premenopausal 
N (%)
Postmenopausal 
N (%)
Type I (extremely fair) 0(0) 0(0) 0(0)
Type II (fair) 60 (13.4) 32 (14.2) 28 ( 1 2 .6 )
Type III (medium) 174 (38.8) 8 8  (38.9) 8 6  (38.6)
Type rV (olive) 198(44.1) 99 (43.8) 99 (44.4)
Type V (dark brown) 17 (3.8) 7(3.1) 10 (4.5)
Type VI (black) 0(0) 0(0) 0(0)
^(Fitzpatrick, 1975). Values given in parenthesis are percentages (%) out o f total within the group
3.6 Biochemical characteristics
Biochemical characteristics of the studied women are presented in Table 3.5. 
The overall mean (±SD) serum 25(OH)D level was 22.63±19.85 and 35.01±22.08 
nmol/L for premenopausal and postmenopausal women studied (P<0.001); 
respeetively with an overall mean of 28.78±21.86 nmol/L. The mean (±SD) serum 
PTH level was 9.5±3.9 and 8.9±3.3pmol/L for premenopausal and postmenopausal 
women, respectively. No significant differences were found in serum PTH levels in 
the two groups of women studied (P=0.07). No significant differences were found in 
means BTM’s between the two groups of women except for PINP which was 
significantly higher in premenopausal than postmenopausal women (P=0.01).
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Table 3.5: 25(OH)D, hormones, minerais and BTM’s values of the studied 
women
Biochemical parameters Premenopausal
(n=226)
Postmenopausal
(n=223)
P-value
25(OH)D (nmol/L) 22.63 ± 19.85 35.01 ±22.08 <0 . 0 0 1
Intact PTH (pmol/L) 9.47 ±3.98 8.86 ± 3.27 0.07
Calcium (mmol/L) 2.48 ±0.19 2.54 ±0.21 0 . 0 0 1
Phosphate (mmol/L) 1.27 ±0.16 1.34 ±0.17 <0 . 0 0 1
FSH (lU/L) 5.21 ±2.79 57.04 ±26.10 <0 . 0 0 1
PINP (ng/ml) 51.62 ±23.62 45.87 ±23.40 0 . 0 1 0
OC (ng/ml) 18.91 ±7.77 18.23 ±7.47 NS
CTX (pg/ml) 335.3 ± 179.5 319.9 ±188.2 NS
NTX (nmol/mmol creat) 51.51 ±26.43 48.49 ±24.91 NS
Data are presented as mean ± SD. All biochemical was measured in serum except NTX in urine. 
Premenopausal and postmenopausal groups were compared with use o f independent samples Mests
3.7 Discussion
This is a cross-sectional study that covered both healthy Saudi women young 
and old. A total of 449 women, [50.3% (n=226) premenopausal and 49.7% (n=223) 
postmenopausal] took part in the present study. The mean age was 29.1(5.6) and 58.8 
(5.9) years for pre and postmenopausal women, respectively. Postmenopausal women 
were signifieantly shorter (P<0.001), and heavier (P<0.001) than premenopausal 
women. Postmenopausal women had significantly higher BMI (P<0.001), and higher 
waist to hip ratio (P<0.001) than premenopausal women. For all women eombined the 
mean age at menarche was 12.9 years with the range being 9 to 17 years. The 
minimum age at first pregnaney was 14 years in premenopausal women and 1 1  years 
in postmenopausal women. In women who had reaehed menopause, mean parity was 
6.5 children with a range of 1 to 14 ehildren bom alive.
The majority of women in the current study (55.2%) were married, (59.9%) 
and being housewives, (61.5%) not practicing any physical activity, and (75.1%) not
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exposing to the sun. There was a high level of edueation reported, with 41% having 
university and/or postgraduate edueation, and almost 30% can be considered with 
high ineome. At the time of assessment, vitamin D supplement intake was low among 
the participants and even lower in premenopausal group. Only 26.1% were taking 
vitamin D supplementation (11.9% in pre-and40.4% post-menopausal women). 
Despite the inereased prevalence of smoking in the area especially in the younger age, 
only 10.7% of the women were smokers at the time of assessment. As to the veiling 
style (cultural conservative clothing type), about 3.1% of the women were completely 
eovered (niqab+gloves), 55% wearing niqab only, and 41.9% wearing hejab.
Unexpectedly serum 25(OH) D was signifieantly higher in postmenopausal 
women (P<0.001) than in premenopausal women. No signifieant differenees were 
found in serum intact PTH between the two groups however about 69% of women 
had serum PTH above the normal range (>7pmol/L). Bone turnover markers did not 
significantly differ between the two groups of women except for the bone formation 
marker PINP whieh was significantly higher in premenopausal women (P=0.01).
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CHAPTER IV
EXTENT OF VITAMIN D DEFICIENCY 
IN PRE-AND POST-MENOPAUSAL 
HEALTHY SAUDI WOMEN
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4.1 Introduction
Hypovitaminosis D is becoming a rising health concern around the globe, with 
both developed and developing countries reporting elevated rates of vitamin D 
deficiency (Mithal et ah, 2009; van Schoor & Lips, 2011). A reemergence of 
osteomalacia and infantile rickets has been documented in North America, Europe 
and even in countries with sunny climates. With its hot arid climate and its latitudinal 
location (from 12° to 42° N), the Middle East gets more than eight hours of sunlight 
every day almost year round, an ample amount for vitamin D synthesis (El-Hajj 
Fuleihan, 2009). In spite of this abundance of UVB rays, however, the Middle East 
reports some of the highest rates of hypovitaminosis D and the lowest levels of 
vitamin D worldwide (Arabi et al., 2010). Vitamin D ’s significance stems not only 
from its well-known role in osteoporosis but also for the reported links between 
vitamin D deficiency and elevated risks of several chronic diseases such as 
cardiovascular disease, autoimmune disease, and cancer (Holick, 2007).
Vitamin D deficiency is associated with several risk factors. Among them are 
poor diet, obesity, older age, diminished intestinal absorption, metabolism-altering 
medications, and hepatic and renal disease (Tsiaras & Weinstock, 2011). The 
production of vitamin D can be significantly affected by any process that changes the 
amount of UVB radiation absorbed by the skin. One of the key factors affecting the 
synthesis of vitamin D is the season of the year. Most studies carried out in the 
Western hemisphere show that the incidence of vitamin D deficiency rises during the 
winter, indicating the importance of increased vitamin D supplementation during this 
cold season (Gozdzik et al., 2008; Kull et al., 2009). In contrast to this, however, are 
the findings of a recent study on the link between seasonal variations and vitamin D 
status in Saudi adults aged 18-70, in which vitamin D levels were higher during the
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winter than the summer (Ardawi et ah, 2011; Al-Daghri et ah, 2012). Due to the 
pleasant weather in the winter individuals increase their outdoor activity thus 
increasing sun exposure time.
Skin pigmentation is another factor affecting ultra violet radiation mediated 
vitamin D synthesis. People with darkly-pigmented skin need longer exposure to 
UVR compared to individuals with low concentrations of melanin, in order to 
generate the same amount of vitamin D3 (Tsiaras & Weinstock, 2011), although both 
groups have the same capacity to produce vitamin D (Chen et al., 2007).
Some prior reports have focused on the effect of clothing style on serum 
25(OH)D levels and revealed lower serum 25(OH)D in women who wear veils than in 
their unveiled counterparts (El-Sonbaty & Abdul-Ghaffar, 1996; Guzel et al., 2001). 
Mishal (2001) investigated the influence of dress styles in healthy young Jordanian 
women. Cultural and religious differences explained the wide range of women’s dress 
styles, including Westem-style dresses. The most conservative styles are those which 
cover the whole body, including the face and hands known as niqab. Styles that cover 
the whole body except for the hands and face are known as hijab. Women who wear 
hijab or niqab continue doing so at work, but inside their homes they usually free 
themselves from these more conservative clothing styles. The study indicates that 
these more conservatively dressed women are more likely to be vitamin D deficient 
compared to the non-veiled women wearing Westem-style clothing (Mishal, 2001).
Extensive research on 25(OH)D status determination has been conducted on 
Caucasians, but limited studies have been described for Saudi adults (Al-Turki et al., 
2008; Ardawi et al., 2011). One cannot directly compare studies from different 
countries and continents because there are different factors which may have affected 
the results of the particular studies including: seasonal variations, latitude, culture,
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availability of food and diet patterns. Currently, there is a dearth of data on vitamin D 
deficiency in Saudi Arabia. In order to lower health risks related to hypovitaminosis 
D, it is vital to know what determines the levels of serum 25(OH) D, a key circulating 
metabolite of vitamin D which reflects both endogenous synthesis and dietary intake 
and is used as an index of vitamin D status. The aim of this study was to describe 
vitamin D status in a sample of randomly selected healthy pre- and postmenopausal 
Saudi women and to determine the effect of lifestyle factors such as: sun exposure, 
sun screen use, physical activity, extent of veiling, and vitamin D supplementation use 
on serum 25(OH) D levels among these Saudi women.
4.2 Subjects and methods:
In brief a total of 226 premenopausal women aging 20-39 years; and 223 
postmenopausal women aging 50-82 years were studied. Fasting blood samples were 
obtained for the analysis of 25(OH) D and PTH. Lifestyle information such as sun 
exposure, use of sunscreen, veiling type, skin type, and use of vitamin D supplements 
was also obtained. Detailed information about subject’s recruitment, inclusion criteria, 
and data collection are presented in methodology chapter (Chapter II).
4.2.1 Classifications of vitamin D status
For the present analysis, vitamin D deficiency is defined as a serum 25(011) D 
concentration of <50nmol/L, moderate deficiency as <25nmol/L, and severe 
deficiency as a serum 25(OH)D concentration of <12.5nmol/L (Lips, 2004).
4.2.2 Statistical analysis
SPSS version 16.0 (SPSS, Inc. Chicago, IL) was used for statistical analysis. 
Variables were checked for normality using Kolmogorov-Smimov (K-S) test. 
Continuous variables are presented as means ± SD and categorical variables are
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expressed as frequencies and percentages. Spearman’s correlations were applied to 
investigate correlations between not normally distributed variables. Partial 
correlations adjusting for confounding variables were also performed. Subjects were 
grouped according to their skin type, veiling type, sun exposure, physical activity, and 
income per month and intergroup differences in serum 25(OH)D were analyzed using 
one way analysis of variance (ANOVA). The statistical differences among the use of 
vitamin D supplements groups were analyzed by independent t-test. Results were 
considered significant if P<0.05. Independent variables that displayed significant 
associations at the bivariate level were included in the multivariable statistical 
analysis to identify independent predictors of serum 25(OH)D status.
4.3 Results
The mean serum 25(OH)D of the studied women is presented in Table 3.5 (please 
refer to Chapter III). The overall mean (±SD) serum 25(OH)D levels was 
28.78±21.86nmol/L. Postmenopausal women had a significantly higher serum 
25(OH)D levels than premenopausal women (P<0.001), although in both groups the 
mean 25(OH)D level was < 50nmol/L.
Figure 4.1 below shows the distribution frequencies for various 25(OH)D cut-off 
levels among the studied healthy women. Only 3.8% of all women were considered to 
have adequate vitamin D status (serum 25(OH) D >75nmol/L); 2.7% and 4.9% being 
pre-and post-menopausal, respectively. About 20.3% of all women exhibited severe 
vitamin D deficiency (serum 25(011) D<12.5nmol/L); 29.2% and 11.2% being pre- 
and postmenopausal women, respectively. Moreover, 55% of all women exhibited 
moderate vitamin D deficiency; 70.8% premenopausal and 39.0% postmenopausal 
(with serum 25(OH) D<25nmol/L). About 85.5% of women exhibited mild 
deficiency; 93.8% premenopausal and 77.1% postmenopausal (with serum 25(OH)
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D<50nmol/L). Furthermore, about 10.7% of all women studied exhibited vitamin D 
insuffieieney (3.5% premenopausal and 17.9% postmenopausal with serum 25(OH) D 
>50 to <75nmol/L).
pre
post
<12.5
12.5-24.99 
deficiency Suboptimal
50-74.99
Serum 25(OH)D (nmol/L)
Figure 4.1: Serum 25(OH) D levels according to different cutoffs in healthy pre- 
and post menopausal women
4.3.1. Serum 25(OH)D levels in relation to skin type
For all women combined, there was a significant negative correlation between skin 
pigmentation and serum 25(OH)D levels (r=-0.133; P=0.005) and this correlation 
became stronger after controlling for age, and BMI (r=-0.159; P=0.001). Table 4.1 
presents the mean serum 25(OH)D levels among the different skin type groups of 
women studied. There were a significant differences in serum 25(OH)D levels among 
skin types. Women with darker skin (type V) had lower 25(OH)D levels than women 
with lighter skin type. A post-hoe test revealed that women with skin type II had 
significantly higher serum 25(OH)D (37.1 ± 28.0, P= 0.004) compared to women with 
skin type IV (26.2 ± 19.5).
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Table 4.1: Serum 25(OH) D levels among skin type groups in pre-and post­
menopausal studied women
Fitzpatrick skin type*
n (%) Mean 25(OH)D ± SD 
(nmol/L)
P-value 
for trend
Type II (Fair) 60 (13.4) 37.1 ±28.0
0.006Type III (Medium) 174 (38.8) 29.3 ±21.7
Type IV (Olive) 198(44.1) 26.2 ±19.5
Type V (Dark brown) 17 (3.8) 24.1 ±17.4
* (Fitzpatrick, 1975). Mean 25(OH) D levels were compared among skin type groups with the use o f  
ANOVA
4.3.2 Serum 25(OH) D levels in relation to sun exposure
For all women combined, a significant positive correlation was found between serum 
25(OH)D and sun exposure (r=0.107; P= 0.024). The association remained significant 
after controlling for age and BMI (r=0.11; P= 0.025). No significant association was 
found between sunscreen use and serum 25(OH)D in this studied population. Women 
were divided into three groups according to the time they spent in the sun (min/day):
Group I: 0 minute/day 
Group II: < 15 minutes/day 
Group III: >15 minutes/day
The majority of women had nil time spent in the sun. Differences in serum 25(OH)D 
levels among sun exposure groups are presented in Table 4.2. A post-hoc test revealed 
that women who were not exposing to the sun (group I) had significantly lower serum 
25(OH)D compared to women in group III (P= 0.021).
Table 4.2: Serum 25(OH) D levels among sun exposure groups in pre-and post­
menopausal studied women
Sun exposure groups n (%) Mean 25(OH)D ± SD 
(nmol/L)
P-value 
for trend
I (0 min/d) 338(752% 27.3 ± 19.6
0.027II (<15min/d) 95 (21.2) 32.7 ± 27.7
III (>15 min/d) 16(3.6) 37.4 ± 24.3
Mean 25(OH)D levels were compared among sun exposure groups with the use o f ANOVA.
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4.3.3 Serum 25(OH) D levels in relation to veiling
The study participants were subdivided according to their veiling styles into the 
following three groups:
• Group 1 (Hijab): wearing covering dress styles sparing the hands and face.
• Group 2 (Niqab): wearing full covering dress styles, including the face.
• Group 3 (Niqab and gloves): wearing full covering dress styles, including the 
face and hands.
For all women combined serum 25(OH)D was significantly associated with veiling 
(r=0.112; P=0.018). The association remained significant after controlling for age, and 
BMI (r=0.130; P=0.006). The mean serum 25(OH)D levels were significantly lower in 
women who were wearing a niqab with or without gloves than those wearing a hijab 
(serum 25(OH)D values 26.5 ±19.6 vs. 32.0± 24.4 nmol/L) respectively (P=0.011) 
(Table 4.3). No differences were seen in BMI among the groups. A trend was also seen 
for a difference in 25(OH)D levels between women covering their faces only (n=247) 
vs. women covering their faces and hands (n=14) (P=0.086). Post hoc test revealed 
significant difference between women wearing hijab and those wearing niqab 
(P=0.040).
Table 4.3: Serum 25(OH)D levels among veiling groups in pre-and post­
menopausal studied women
Veiling Type n (%) Mean 25(OH)D ± SD 
(nmol/L)
P-value 
for trend
Hijab 188(41.9) 32.0 ± 24.4
0.013Niqab 247 (55.0) 26.9 ±19.9
Niqab & gloves 14(3.1) 19.2 ± 10.5
Mean 25(OH)D levels were compared among veiling groups with the use o f ANOVA.
86
4.3.4 Serum 25(OH) D levels in relation to vitamin D supplements use
For all women combined serum 25(OH)D was significantly associated with vitamin D 
supplementation (r=0.728; P<0.001), and remained significant after adjusting for age 
and BMI (r=0.751; P<0.001). The mean serum 25(OH)D levels was significantly lower 
in women (both pre and postmenopausal) who did not use vitamin D supplements when 
compared to those who used supplements (serum 25(OH)D values of 19.2 ±8.9 vs. 
59.0± 22.9 nmol/L) respectively, (P<0.001) (Table 4.4). Among the premenopausal 
women group the mean serum 25(OH)D in the group who used supplements was 
67.1±34.6 vs. 17.8±8.7 in the group of women who did not use supplements. The same 
was true for postmenopausal with the mean serum 25(OH)D in the group who used 
supplements being 56.9 ± 18.6 vs. 21.2 ± 9.1 in the group of women who did not use 
supplements.
Table 4.4: Serum 25(OH)D levels according to vitamin D supplements use in pre- 
and post- menopausal women
Vitamin D Supplements n (%) Mean 25(OH)D ± SD 
(nmol/L)
P-value
No 341 (75.9) 19.2 ±8.9
<0.001Yes 108(24.1) 59.0 ± 22.9
Mean 25(OH)D levels were compared among vitamin D supplements use with independent f-test
4.3.5 Serum 25(OH) D levels in relation to physical activity
For all women combined serum 25(OH)D was significantly associated with physical 
activity (i=0.123; P=0.009), and remained significant after adjusting for age and BMI 
(r=0.161; P=0.001). Women were divided into three groups according to their physical 
activity levels:
• Group I: inactive.
• Group II: moderate activity (> Ihour -  < 2 hours/week).
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• Group III: highly active (> 2 hours/week).
The majority of women (64.4%) were not physically active. Differences in mean serum 
25(OH)D among physical activity groups are presented in Table 4.5. Post-hoc test 
showed significant difference between group I and III (P=0.021).
Table 4.5: Serum 25(OH)D levels among physical activity groups in pre-and post­
menopausal women
Physical activity groups n(% ) Mean 25(OH)D ± SD 
(nmol/L)
P-value 
for trend
I 289(64.4j 27.18 ±19.6
0.027II 96 (21.4) 29.30 ±23.9
III 64 (14.3) 35.24 ±26.9
Mean 25(OH)D levels were eompared among sun exposure groups with the use o f ANOVA.
4.3.6 Serum 25(OH) D levels in relation to economic status in the studied 
women
For all women combined serum 25(OH)D was significantly and positively associated 
with income (r=0.116; P=0.014), and the correlation became stronger after adjusting 
for age and BMI (r=0.151; P=0.001). Women were divided into three groups according 
to their income per month:
• Group I: Low (< 5000 SR).
• Group II: Moderate (> 5000- < 15,000 SR).
• Group III: High (> 15,000 SR).
Table 4.6 below presents the differences in mean serum 25(OH)D among the different 
income groups. Women with high income had significantly higher serum 25(OH)D than 
other women. Post-hoc test revealed significant difference in serum 25(OH)D 
coneentrations in the low income group compared to the high income group (P=0.036).
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Table 4.6: Serum 25(OH)D levels among income groups in women studied
Income groups (SR) n (%) Mean 25(OH)D ± SD 
(nmol/L)
P-value 
for trend
Low 145 (32.3) 25.4 ± 18.4
0.027Moderate 170 (37.9) 28.7 ±22.7
High 134 (29.8) 32.5 ±23.7
SR: Saudi riyal. Mean 25(OH)D levels were compared among income groups with the use o f ANOVA.
4.3.7 Effect of other factors on 25(OH) D in the studied women
The data were examined for existing assoeiation between 25(OH) D and the following 
factors: age, sun screen use, smoking, and education levels in the studied women. No 
significant associations were found between 25(OH) D and the listed above faetors in 
the two groups of women studied.
4.3.8 Multivariable regression analysis for predictors of serum 25(OH)D  
status
Tables 4.7 & 4.8 present the results of the multivariable regression analysis for pre- and 
post-menopausal women, respectively. The use of vitamin D supplements was the only 
variable to reach statistical significant as a predictor of serum 25(OH)D status in both 
groups of women, contributing 54.2% of the variance in serum 25(OH)D levels in 
premenopausal women and 62.1% of the variance in serum 25(OH)D levels in 
postmenopausal women.
Table 4.7: Possible determinants of serum 25(OH)D status in premenopausal 
women
Predictors B t
Vitamin D Supplements 49.2 16.3
Model summary: R=0.737; Acjusted RW .542; ?<0.001
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Table 4.8: Possible predictors of serum 25(OH)D status in postmenopausal women
Predictors B t
Vitamin D Supplements 35.7 19.1
Model summary: R=0.789; Ac[justed R^=0.621;P<0.001
However, when vitamin D supplements was removed from the multivariable regression
analysis, sun exposure was a significant predictor of serum 25(OH)D status in
premenopausal women while income, skin type, and physieal activity were significant
predictors in the postmenopausal group (Tables 4.9 & 4.10).
Table 4.9: Possible determinants of serum 25(OH)D status in premenopausal 
women
Predictors B t
Sun exposure 0.518 2.92
Model summary: R=0.192; Adjusted R"^=.G32; P=0.004
Table 4.10: Possible predictors of serum 25(OH)D status in postmenopausal 
women
Predictors B t
Economic status 1.14 1.75
Skin type -5.13 -2.66
Physical activity (1038 2.55
Model summary: R=0.310; Ac justed R"^=0.084; P<0.001
4.4 Discussion
One might assume that people living in Saudi Arabia, with its latitude and 
significant amount of sunshine, would have adequate exposure to UVB for sufficient 
synthesis of vitamin D. However, this current study of healthy Saudi women indicates 
that this is not the case, with 85.5% of the women in this randomly selected sample 
found to have vitamin D levels lower than the currently reeommended level, 
indicating a problem in this population. This has potentially worrying implieations in 
regards to a high risk of bone disease in later years as well as a series of other diseases
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which are increasingly associated with vitamin D deficiency (Bikle, 2009). At present, 
there is a great deal of discussion and debates about the use of 50nmol/L as the cut-off 
value for vitamin D sufficiency, and there has been a recent call for this minimum 
value to be inereased to 75nmol/L (Vieth, 2011; Holick, 2012). If this higher cutoff 
value for adequacy were used, only around 4% of the participants in this study would 
meet this criterion for sufficiency. Previous research has highlighted the increased 
prevalence of vitamin D deficiency among Arabian women (Arabi et al., 2010). Low 
dietary consumption of vitamin D and limited or inadequate exposure to the sun were 
linked to the low vitamin D status.
The partieularly low vitamin D concentrations that have been reported in 
Saudi women are due to several factors. Chief among them appears to be a lack of 
exposure to sunlight. Saudi Arabia’s latitude means it gets a great deal of sunlight 
throughout the year. Regrettably, most Saudi women in Jeddah (75%) avoid exposure 
to the sun and heat. Among those who reported regular sun exposure (25%), the 
majority (21%) had less than 15 minutes exposure to sunlight. One reason for this 
may be that the kingdom in general is extremely warm and UV radiation and total 
solar radiation reach a peak between April and October (Elani, 2007). These months 
make up the hottest period in the kingdom, at times exceeding 50°C at midday, with a 
subsequent rise in the ineidenee of heat exhaustion, heat stroke, and even death 
(Noweir et al., 2008). Such high temperatures during the period from April to October 
typically push Saudis to limit their time outside to the nighttime hours. For the same 
reason, most daytime public activities are conducted inside. This contrasts with the 
winter season (October-March), when temperatures fall and become more bearable 
for outdoor activities and sun exposure. The current study found low vitamin D levels
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during the summer, in line with the results of a previous study investigating how 
seasonal variations affect vitamin D status in Saudi adults (Al-Daghri et ah, 2012).
Other reasons to avoid sun exposure are lifestyle, culture and personal 
appearance. In the current study, about 40% of the women were either working or 
students. Being in a classroom or working in an office for long hours, and driving to 
and from work or schools may all explain the inadequate sun exposure and 
consequently low vitamin D status. It is impossible to walk and this has severe 
implications for public health not only in terms of sun exposure but also decreased 
physical activity.
The conservative clothing Saudi women wear in outdoors contributes to the 
amount of sun exposure. The hijab allows part of the face and/or hands to be exposed 
to direct sunlight. The current study has found that women wearing niqab have lower 
25(OH)D plasma levels than their counterparts who wear hijab, indicating that 
clothing is a major blocker of sunlight and subsequently impairs vitamin D synthesis 
and status. Although the difference in the area of exposed parts of the body (i.e., face 
and hands) is small, it may still explain the considerable difference in the degree of 
cutaneous synthesis of vitamin D among these women. The findings of this study are 
in agreement with the results of earlier studies showing that Arabian women who 
wear the veil have lower serum 25(OH)D levels than non-veiled women (El-Sonbaty 
& Abdul-Ghaffar, 1996; Mishal, 2001).
Melanin pigmentation was also found to affect serum 25(OH)D status in this 
group of women. The results indieate a significant association between a woman’s 
skin color and her serum vitamin D concentration. Previous studies showed that 
vitamin D levels differ according to cutaneous melanin concentrations (Shoenfeld et 
al., 2009). As anticipated, subjects with lighter skin had higher serum 25(OH) D
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concentrations than did those with darker skin. Due to melanin’s function as a natural 
sunscreen, people with darker pigmentation need to be exposed to UVB longer in 
order to reach the same rise in serum 25(OH)D concentrations as those with lighter 
skin (Tsiaras & Weinstock, 2011). Armas et al. (2007) found that skin type and the 
amount of UVB exposure, when considered together, accounted for 80% of the 
difference in the serum 25(OH)D response to UVB radiation.
The daily application of sunscreen has also been found to reduce the dermal 
production of vitamin D by blocking the UVB radiation necessary for cutaneous 
vitamin D production (Tsiaras & Weinstock, 2011). As shown by the present study, 
Saudi women who live in Jeddah do not typically use sunscreen. Surprisingly, no 
assoeiation was observed between sunscreen use and vitamin D status in the study 
participants, which could be due to the small number (5%) of women using sunscreen.
The food supply in Saudi Arabia is not fortified with vitamin D, and there is 
minimal intake of vitamin D fi*om the diet, so the only realistic sources of vitamin D 
for this population are supplements. Supplements seem to play a positive role in 
preventing and treating vitamin D deficiency. However, the use of vitamin D 
supplements is not widespread among Saudi Arabian women. For the most part, 
supplements are prescribed for people with health conditions requiring treatment with 
vitamins. Only 24.1% of the Saudi women in this study took vitamin D supplements. 
Of those who did, about 38.6% were postmenopausal, while 9.7% were 
premenopausal. These findings may explain the vitamin D deficiency observed 
among the participants to some extent. Women taking vitamin D supplements had 
significantly higher serum 25(OH)D levels that those who did not. In most cases, 
vitamin D supplements were used together with calcium or multivitamins, but 
sometimes they were taken separately. One reason for these differences may be the
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limited availability of supplements (e.g. lack of single vitamin D products available 
over the counter).
Studies have found that another contributing factor to vitamin D status is age 
since cutaneous production of vitamin D drops with aging (Holick, 2004). However, 
this association was not seen in the present study. This could be because of the overall 
low amounts of sunlight Saudi women are exposed to as they tend to stay indoors to 
avoid the extreme daytime heat. What was unexpected was that premenopausal 
women had lower serum vitamin D levels than their postmenopausal counterparts. 
Postmenopausal women in the study had a mean serum concentration of 25(OH)D of
35.01i22.08 nmol/L, while for premenopausal women it was 22.63Ü9.85 nmol/L. A 
possible explanation for this surprising finding is that as there was not a significant 
difference in the amount of sunlight exposure between the two groups, the higher 
intake of vitamin D supplements by the postmenopausal group resulted in their 
increased serum vitamin D coneentrations. When women with the use of vitamin D 
supplements were excluded, interestingly postmenopausal women also exhibited 
higher serum 25(OH)D (21.23±9.07) than did premenopausal women (17.84±8.70), 
which cannot be explained.
Physieal activity was also associated with variations in serum 25(OH) D levels 
among the study participants. The findings of the present study are in line with prior 
research which has shown a positive link between levels of physical activity and 
25(OH) D concentrations (Brock et al., 2010). This positive association may be 
explained by the likelihood of increased exposure to the sun during physical outdoor 
activity. However, the present study did not collect data on indoor and outdoor 
physical activity.
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Socioeconomic status was another factor associated with variations in serum 
25(OH)D levels among the studied women. The majority of women from higher 
socioeconomic status live in houses with private backyard areas, where they can enjoy 
plenty of sunshine uncover. Siddiqui and Kumfar found that living in small and 
crowded houses where sunlight does not penetrate was affecting vitamin D status 
among girls participated in their study (Siddiqui & Kamfar, 2007). Another 
explanation may be that women from higher soeioeeonomic status have the ability to 
afford the cost of vitamin supplements. Indeed, soeioeeonomic status has been linked 
to vitamin D deficiency in the Middle East (El-Hajj Fuleihan, 2009).
The lack of information of dietary intake of vitamin for the studied women is 
one of the study limitations. Limited analysis might be another limitation for this 
study. There are several known factors affecting vitamin D status and there are quite 
possibly other as yet unknown factors. It is important to carry out further research to 
better understand how each of these factors affects concentrations of vitamin D and its 
metabolites in groups such as Saudi women, who are at risk of vitamin D deficiency 
and insufficiency. Vitamin D deficiency is highly prevalent in the studied women. 
Limited sun exposure, darker skin pigmentation, and obesity are among the factors 
contributing to this high prevalence of deficiency. Supplements of vitamin D may be 
the optimal public health approach to improving vitamin D status for Saudi women as 
the other life style factors are not expected to be changed in the near future.
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CHAPTER V
EXTENT OF OSTEOPENIA AND 
OSTEOPOROSIS IN HEALTHY SAUDI 
PRE-AND POST-MENOPAUSAL
WOMEN
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5.1 Introduction
Osteoporosis, the silent skeletal disease, is characterized by low bone mineral 
density, decreased bone strength and increased fragility fractures (NOF, 2010). 
Globally, osteoporosis in postmenopausal women is a major public health concern. 
Most women with postmenopausal osteoporosis present with a fracture as the first 
indication of the disease (Nichols, 2000). Estrogen deficiency is a key factor in the 
progression of the disease (Riggs et al., 1998). However, in most of the Middle East 
countries, the epidemiology of osteoporosis is not well known. It has only been in the 
last decade that researchers in Saudi Arabia have recognized the prevalence of 
postmenopausal osteoporosis and its associated problems in this country (El-Desouki, 
1999; Greer et al., 2008).
For the prevention of osteoporosis and ensuing fractures, reaching an optimal 
PBM is the main approach (Hernandez et al., 2003; Bonjour et al., 2009). The 
likelihood of developing osteoporosis as age-related bone loss occurs is lower in 
individuals who attain a higher PBM compared to those with lower bone mass 
(Seeman, 1997). Between 60 to 80% of bone mass attainment may be due to genetic 
factors, but environmental and lifestyle factors also play a role in bone mass and bone 
loss (Krall & Dawson-Hughes, 1993). Research in different populations has shown 
various risk faetors of osteoporosis, including older age, early menopause, lack of 
physical activity, low body weight, and insufficient intake of calcium (WHO, 2003; 
Compston et al., 2009). However, data on Saudi women is lacking in this area.
Aging is an important risk factor for osteoporosis and its related fractures 
(Siris et al., 2006). Menopause, clearly results from loss of ovarian function, is 
associated with a rapid loss of bone (Riggs et al., 2002). Estrogens play an important 
role in preserving bone mass (Khosla & Riggs, 2005), but what is less clear is the
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influence of other reproductive factors on bone mass and some researchers, but not all 
have reported that multiple pregnancies and extended lactation are not associated with 
bone mass loss or increased risk of fi*acture (Karlsson et ah, 2001; Paton et ah, 2003). 
Data are also limited on how other relevant reproductive history variables, including 
age of menarche or menopause, are associated with bone mass (Gambacciani et al., 
1995; Ito et al., 1995).
Bone mineral density positively correlates with weight and BMI (Douchi et 
al., 2000). Thinness is related to both osteoporosis and increased fracture risk (Van 
der Voort et al., 2001), so low BMI was added to the set of tools for the assessment of 
osteoporosis and osteoporotic fracture risk (NOF, 2008).
Exercise has been proposed as a possible way of improving BMD (Vainionpaa 
et al., 2005). In cross-seetional studies, physically active participants were found to 
have significantly higher BMD than sedentary controls of the same age (Forwood & 
Burr, 1993). Training programs involving exercise can stop or reverse nearly 1% of 
bone loss annually in both lumbar spine and femoral neck for both premenopausal and 
postmenopausal women (Wolff et al., 1999). Nguyen et al (2000) found the 
prevalence of osteoporosis to be higher in elderly women in the lowest tertile of 
dietary Ca intake and physical activity than women in the highest tertile (Nguyen et 
al., 2 0 0 0 ).
The second objective of this study is in an attempt to address one of the 
important public health problems which can be controlled if preventive measures are 
taken at an early stage. The effects of lifestyle factors including: smoking, parity, 
lactation, sun exposure, and physical activity on BMD in healthy pre-and post­
menopausal Saudi women were assessed. The effects of age, age at menarche.
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menopausal duration, body weight, and BMI on BMD at different skeletal sites were 
also analyzed in these women.
5.2 Subjects and methods
Details on subjects’ recruitment can be found in the methodology chapter (Chapter 
II). In brief a total of 449 women (20-82 years) were studied. All women were healthy 
and were not taking any medications known to affect bone metabolism except vitamin 
D supplements. The exclusion criteria used for the study are shown in Table 2.1 in the 
methodology chapter. Bone mineral density was measured using DXA.
5.2.1 Statistical analysis
SPSS version 16.0 (SPSS, Inc. Chicago, IL) was used for statistical analysis. 
Variables were cheeked for normality using Kolmogorov-Smimov (K-S) test. Results 
are presented as means ± SD for continuous variables and as frequencies and 
percentages for categorical variables. The statistical differences among the two groups 
for different variables were analyzed by independent t-test. Association between 
variables was examined using Spearman’s correlation. Independent variables that 
displayed significant correlations at the bivariate level were included in the 
Multivariable statistical analysis to identify independent predictors of bone mineral 
density at the lumbar spine and femur neck in the two groups of women studied. 
Results were considered significant if P<0.05.
5.3 Results
Summary of BMD measurements at the lumbar spine, three sites of the femur (neck, 
ward, trochanter), total femur, and for the total body are presented in Table 5.1. As 
expected, the BMD measurements were significantly lower in postmenopausal 
women when compared to those of the premenopausal women.
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Table 5.1: BMD values among the studied healthy women
BMD (g/cm^): Premenopausal
(n=226)
Postmenopausal
(n=223)
(P value)
Lumbar spine (L1-L4) 1.136±0.134 0.986 ±0.149 <0 . 0 0 1
Femur : neck 0.933 ±0.128 0.845 ±0.131 <0 . 0 0 1
Ward’s 0.826 ±0.144 0.651 ±0.144 <0 . 0 0 1
trochanter 0.718 ±0.113 0.683 ±0.115 0 . 0 0 1
Total femur 0.926 ±0.122 0.874 ±0.133 <0 . 0 0 1
Total body 1.09 ±0.07 1.05 ±0.08 0.003
T-score:
Lumbar spine (L1-L4) 0.286 ± 1 . 1 0 1 -0.950 ± 1.247 <0 . 0 0 1
Femur neck 0.039 ±1.061 -0.713 ±1.106 <0 . 0 0 1
Data are presented as mean ±  SD
Premenopausal and postmenopausal groups were compared with the use o f independent samples f-tests
5.3.1 Prevalence of osteopenia and osteoporosis in the studied Saudi 
women
Based on WHO criteria, a total of 28.9% of all women (14.3% premenopausal and 
43.6% postmenopausal) were osteopenic at the lumbar spine ( L i _  L 4 )  (Figure 5.1). 
Similar results were found for the femoral neck, where 28.6% of all women combined 
were osteopenie (15.2% premenopausal and 42.1% postmenopausal) (Figure 5.2). 
None of the premenopausal women had osteoporosis at any of the sites studied. The 
percentages of osteoporotic postmenopausal women at the lumbar spine (Li- L 4 )  site 
were higher than that at the femur neck, 9.1% and 4.1% respectively. Only 1.1% of 
postmenopausal women (5 subjects) were osteoporotic at both sites.
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Figure 5.1: Percentages of women classified as normal, osteopenic, and 
osteoporotic according to WHO criteria at the lumbar spine site in pre-and
post-menopausal women
normal
osteopenic
■ pre 
-  post
osteoporotic
Figure 5.2: Percentages of women classified as normal, osteopenic, and 
osteoporotic according to WHO criteria at the femur neck site in pre-and post­
menopausal women
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5.3.2 Factors affecting BMD in premenopausal women
The data were examined for existing association between BMD and the following 
factors: age, age at menarche, weight, height, BMI, physical activity, sun exposure, 
smoking, parity, and duration of lactation in the premenopausal group of women. 
There was a significant negative correlation between age and BMD at the femur neck 
(r=-0.155; P=0.021) (Figure 5.3), and femur ward (r=-0.331; P<0.001). Age at 
menarche was negatively associated with BMD at the lumbar spine (r=-0.136; 
P=0.043) (Figure 5.4), femur ward (r=-0.143; P=0.032), femur trochanter (r=-0.222; 
P=0.001), and total femur (r=-0.172; P=0.01). A significant positive correlation was 
found between weight, height, BMI, and BMD at all skeletal sites measured 
(P<0.001) (Figures 5.5-5.10). Parity was negatively correlated to BMD at the lumbar 
spine (r=-0.231; P=0.019) (Figure 5.11). No significant association was found 
between BMD at any sites measured and physical activity, smoking, sun exposure, 
and lactation duration in this group of women.
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Figure 5.3: Association between age and 
femur neck BMD in premenopausal women
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Figure 5.4: Association between age at 
menarche and lumbar spine BMD in 
premenopausal women
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femur neck BMD in premenopausal women
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Figure 5.10: Association between BMI and 
femur neck BMD in premenopausal 
women
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0.23;P=0.019
Figure 5.11: Association between parity and 
lumbar spine BMD in premenopausal women
5.3.3 Factors affecting BMD in postmenopausal women
The data were examined for existing assoeiation between BMD and the following 
factors: age, age at menarche, menopausal duration, weight, height, BMI, smoking, 
physical activity, sun exposure, parity, and duration of lactation in the postmenopausal 
group of women. A significant negative correlation was found between age and BMD at 
the lumbar spine (r=-0.224; P=0.001) (Figure 5.12), femur neck (r=-0.305; P<0.001) 
(Figure 5.13), femur ward (r=-0.371; P<0.001), and femur trochanter (r=-0.252; 
P<0.001), and total femur (r=-0.329; P<0.001). A significant positive correlation was 
found between BMD at all sites measured and weight, height, and BMI (P<0.001) 
(Figures 5.14-5.19). Menopausal duration was negatively associated with BMD at the 
lumbar spine (r=-0.267; P<0.001) (Figure 5.20), femur neck (r=-Q.378; P<0.001) 
(Figure 5.21), femur ward (r=-Q.429; P<0.001), femur trochanter (r=-Q.345; P<0.001), 
and total femur (r=-Q.413; P<0.001). Physical activity was positively associated with 
femur neck BMD (r=0.135; P=0.045) (Figure 5.22), femur ward (r=0.150; P=0.025), 
femur trochanter (r=0.147; P=0.028), and with total femur (r=0.165; P=0.014). A 
significant positive correlation was found between lactation duration in months and 
lumbar spine BMD (r=0.146; P=0.038) (Figure 5.23). Sun exposure was positively 
associated with BMD at the femur trochanter (r=0.145; P=0.031), and total femur
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(r=0.147; P=0.028). A trend was also found between sun exposure and femur neck 
BMD (r=0.128; P=0.056) and femur ward (r=0.126; P=0.060).No significant 
association was found between smoking, parity, and age at menarche and BMD at any 
sites measured.
-= -0 .22; P=0.001
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-0.30; P<0.001
ag e  (years)
Figure 5.12 rAssociation between age and lumbar Figure 5.13 : Association between age and 
spine BMD in postmenopausal women femur neck BMD in postmenopausal
women
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Figure 5.14: Association between weight and 
lumbar spine BMD in postmenopausal women
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Figure 5.15: Association between weight 
and femur neck BMD in postmenopausal 
women
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Figure 5.16: Association between 
height and lumbar spine 
BMD in postmenopausal women
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height and femur neck BMD in 
postmenopausal women
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Figure 5.23: Association between 
lactation duration and lumbar spine 
BMD in postmenopausal women
5.3.4 Results of multivariable regression analysis for predictors of BMD in 
premenopausal women
Multiple variables that could possibly affect BMD were examined by regression 
analysis. Age, age at menarche, body weight, height, BMI, and parity remained 
independent risk factors for BMD at the lumbar spine and femoral neck in this group 
of women (Tables 5.2 & 5.3). The adjusted value can be interpreted as the model 
explaining 12% and 31.3% of the variances in BMD at the lumbar spine and femur 
neck, respectively.
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Table 5.2: Regression results for possible predictors for lumbar spine in
premenopausal women
Predictors B t P-value
Parity -0.013 -1.9 0.05
Height 0.008 2.8 0.007
Age at menarche - 0 . 0 2 0 - 2 . 2 0.03
Model summary: R=.3S2; Adjusted R.-^ =.120; P=0.0() 1
Table 5.3: Regression results for possible predictors for femur neck in premenopausal 
women
Predictors B t P-value
Weight .005 9.8 <0 . 0 0 1
Age -0.007 -4.9 <0 . 0 0 1
Model summary: R=.565; Adjusted R^=.313;P<0.0C) 1
5.3.5 Results of multivariable regression analysis for predictors of BMD in 
postmenopausal women
Multiple variables that could possibly affect BMD were examined by regression 
analysis. Age, menopausal duration, body weight, height, physical activity, and 
lactation duration remained independent risk factors for BMD at the lumbar spine and 
femoral neck in this group of women (Table 5.4 & 5.5). The adjusted R^ value can be 
interpreted as the model explaining 24.5% and 27.5% of the variances in BMD at the 
lumbar spine and femur neck, respectively.
Table 5.4: Regression results for possible predictors for lumbar spine in 
postmenopausal women
Predictors B t P-value
Weight .004 6.17 <0 . 0 0 1
Age -0.006 -3.99 <0 . 0 0 1
Lactation duration .003 2.03 0.04
Model summary: R=.506; Adjusted R^=.245; ?<0.001
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Table 5.5: Regression results for possible predictors for femur neck in
postmenopausal women
Predictors B t P-value
Weight .003 6.24 <0 . 0 0 1
Menopause duration -0.007 -5.53 <0 . 0 0 1
Model summary: R=.525; Adjusted R^=.275; P<0.001
5.4 Discussion
Osteoporosis is generally a silent and asymptomatic disease until a fracture 
occurs. Estimates suggest that over a third of adult women will have at least one 
osteoporotic fracture in their life time (NOF, 2010), creating a considerable burden to 
health care systems around the globe (Melton, 2003). Osteoporosis and osteopenia are 
common among postmenopausal Arab women and should be considered a matter of 
public health (Maalouf et ah, 2007; Baddoura et ah, 2011). The bone health indices 
for the women in the present study showed that, as expected, all the BMD 
measurement variables were significantly lower in postmenopausal women in 
comparison with premenopausal women. Analysis of bone health at the lumbar spine 
revealed the existence of osteopenia in 14% of the premenopausal and 43% of the 
postmenopausal women. Analysis at the femur neck indicated comparable results, 
with osteopenia found in 15% of the premenopausal and 42% of the postmenopausal 
women. Several studies have found lower BMD in healthy Saudi women than in their 
Caucasian counterparts (Ghannam et ah, 1999; Ardawi et ah, 2005). Factors common 
to the region such as multiple pregnancies, extended breastfeeding, and inadequate 
vitamin D levels help contribute to the lower BMD in our population.
The prevalence of osteoporosis in the postmenopausal women is cause for 
concern given that the mean age of this group is 58.8 years. In our study the impact of 
osteoporosis in postmenopausal women was higher on the lumbar spine (9%) than the
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femoral neck (4%) which is in line with previous studies (Ghannam et ah, 1999; 
Sadat-Ali et ah, 2004). Previous study (Sadat-Ali et ah, 2004) in Al-Khobar (Eastern 
region of Saudi Arabia) revealed that the percentages of postmenopausal women 
classified as osteopenic and osteoporotic at the lumbar spine were 30.5% and 46.7%, 
respectively. Furthermore, the percentages of postmenopausal women classified as 
osteopenic and osteoporotic at the femur neck were 31.6% and 44.1%, respectively. A 
comparison with the present study reveals a lower prevalence of osteoporosis at both 
sites in Jeddah than in Al-Khobar, although the prevalence of osteopenia is higher in 
Jeddah. The differences between the two studies’ findings could be due to the fact that 
our study included healthy women only, while the women in the other study were 
patients with orthopedic problems. Our findings are more in line with the findings of 
a Qatari study of postmenopausal women (Bener et ah, 2007), where 12.3% of 
postmenopausal women (mean age of 57.6 years) had osteoporosis.
In our study, there was an inverse association between age and BMD at all 
skeletal sites measured in postmenopausal women (P<0.001). Bone loss attributed to 
age has been reported by several studies (Burger et ah, 1994; Siris et ah, 2006). As 
aging occurs, osteoblastic activity decreases, affecting bone formation, which is 
further exacerbated by hormone deprivation and an increase in osteoclastic activity. 
The ovaries gradually stop secreting estrogen during menopause setting off a rapid 
period of bone loss in women, affecting trabecular bone in particular (Riggs et ah,
2002). In the present study, age-related changes in BMD of premenopausal women 
were seen only in the femur neck and femur ward (P<0.05) sites. These findings are in 
line with previous results showing that bone loss starts during the premenopausal 
phase (van Beresteijn et ah, 1990; Ho et ah, 2008). Low bone mass at menopause is 
predictive of fractures in later life (Cummings & Black, 1995).
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Research in women has indicated an association between age at the onset of 
puberty and the risk of osteoporosis in later life (Ito et ah, 1995). The present study 
documents a significant negative correlation between age at menarche and spine 
BMD in premenopausal women. In this group of women, age at puberty was a 
significant predictor of spinal bone loss. Starting puberty at an earlier age means a 
higher level or longer period of estrogen exposure. The duration of menopause was 
inversely related to BMD at the lumbar spine and femur neck. Early onset of 
menopause is associated with an increased risk of osteoporosis later on (Gambacciani 
et ah, 1995). In the current study, years since menopause was a key predictor of femur 
neck low BMD in postmenopausal women.
Specific interventions in clinical practice can target women found to be at high 
risk of osteoporosis-related fractures. Even younger women who have low body 
weight and BMI may be at higher risk of fi-actures. It is noteworthy that overweight 
and obesity are common in the Saudi females. In the current study, weight and BMI 
correlated positively with BMD at all skeletal sites in both groups of women. These 
results are in agreement with the associations between weight, BMI and BMD 
previously reported (De Laet et ah, 2005; Villareal et ah, 2008). There are various 
mechanisms through which higher body weight may affect BMD, including higher 
mechanical loading, increased muscle mass, and elevated levels of sex hormones and 
their precursors (Reid, 2002). Compared to women with normal weight, obese women 
have a lower risk of fractures (Cifuentes et ah, 2003). The reference point below 
which the likelihood of hip and any osteoporotic fracture begins to rise has been 
identified as a BMI of 25 kg/m^ (De Laet et ah, 2005).
Besides the customary causes of osteoporosis in women, the assessment of 
osteoporosis, especially in the Saudi population, should address other important
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lifestyle issues. It has been suggested that pregnancy and breastfeeding may be risk 
factors for low BMD due to the considerable changes which take place in bone 
metabolism during pregnancy and lactation (Kovacs, 2001). Existing evidence for this 
hypothesis has come primarily from studies carried out in developed countries, where 
it is relatively rare for women to have frequent pregnancies and breastfeed for 
extended periods (Demir et ah, 2008). In developing countries, where multiple 
pregnancies are common, less research has been conducted (Ghannam et ah, 1999; 
Allah et ah, 2007). In the current study, repeated pregnancies exert a negative effect 
on BMD at lumbar spine. These findings are in agreement with earlier studies 
reporting a negative association of parity on BMD (Ghannam et ah, 1999; Alsaif et 
ah, 2007). It is noteworthy that the minimum age at first pregnancy in the participated 
premenopausal women was 14 years. Low dietary calcium intake although not 
discussed in the current study accompanying repeated pregnancies could be related to 
the current findings. On the other hand, the duration of breastfeeding was positively 
associated to BMD in postmenopausal women in our study. Previous research has 
pointed to a favorable effect of lactation on bone mass in later years (Hansen et ah, 
1991). There is a known correlation between lactation and a lower risk of many 
diseases in mothers and infants (Ip et ah, 2007). The finding in our study may be 
explained by the high quality of the diets that lactating mothers traditionally consume 
during the lactation period or to supplements intake.
Physical activity has been recommended as a non-pharmacological approach 
for maximizing BMD during the younger years (Bass et ah, 1998) in addition to 
improving BMD by augmenting bone density and/or preventing bone loss in later 
years (Engelke et ah, 2006). In the current study physical activity exert a positive 
effect on BMD at the femur site. Among the 38.5% of the women in our study who
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reported engaging in exercise, 35.6% of them listed walking as their mode of activity. 
Krall and Dawson-Hughes (Krall & Dawson-Hughes, 1994) have shown that 
moderate exercise could have a positive effect. Higher BMD was found in women 
who walked about one mile daily. In another study walking for exercise reduced the 
risk of hip fractures in white women 65 years of age and older (Cummings et ah, 
1995). Meta-analysis by Kelly et ah (Kelley, 1998) indicates that physical activity has 
a slowing effect on the rate of bone loss in postmenopausal women and that vertebral 
bone mass may be maintained by aerobic exercise.
Limitations of the current study include limited analysis as we did not adjust 
for supplement users in the analysis. The use of average lactation period instead of 
using the total lactation period in the statistical analysis is another limitation. One 
possible limitation might be the lack of dietary intake information in these women.
In conclusion it is of most importance to achieve an optimal PBM to prevent a 
weak skeleton and its related fractures later in life. Women with multiple risk factors 
and low BMD are at especially high risk. Advanced age, menopausal duration and 
multi-parity are among the factors contributing to low bone mineral density in the 
studied women. The risk of fracture in a woman life could be minimized in a number 
of ways, notably by maintaining healthy weight, engaging in physical activity as a 
daily routine, ensuring sufficient Ca intake, and taking measures that maintain BMD.
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CHAPTER VI
INTERACTION BETWEEN VITAMIN D 
STATUS AND INDICATORS OF BONE 
HEALTH IN PRE-AND POST­
MENOPAUSAL SAUDI WOMEN
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6.1 Introduction
The role of vitamin D in the metabolism of bone and its impact on bone health 
is well established. In severe cases of vitamin D deficiency, overt osteomalacia occurs 
in adults. In less severe cases, secondary hyperparathyroidism, increased bone 
turnover, and progressive bone loss occur, which raises the risk of osteoporosis 
particularly in the elderly (Gamero et ah, 2007). Without adequate vitamin D, the 
absorption of dietary Ca in the intestine will be decreased and PTH concentrations 
will rise, stimulating the renal re-absorption of Ca, and activating the resorption of 
bone and the release of Ca into the bloodstream. Consequently, normal levels of Ca, 
high-normal or elevated levels of PTH, low levels of PO4 , and increased levels of 
BTM’s are usually seen in cases of vitamin D deficiency. High serum PTH levels 
have been associated with increased bone remodeling, excessive bone loss and 
increased fracture risk (Silva et ah, 2011).
A positive association was reported between serum 25(OH)D levels and BMD 
in several studies. In a study on a large group of white postmenopausal women. Lips 
et ah (2001) documented a link between low serum 25(OH)D and low BMD. 
Bischoff-Ferrari et ah (2005) found 25(OH)D levels to be correlated positively with 
BMD of the femoral neck. Subjects in the group with 25(OH)D >80 nmol/L had an 
8.5% higher BMD than those in the deficient group (<40nmol/L) (Bischoff-Ferrari et 
ah, 2005b).
Evidence suggests that older adults with vitamin D inadequacy have a higher 
risk of osteoporosis and related fractures (Van Schoor et ah, 2008). An increased risk 
of hip fractures has also been associated with low vitamin D levels (Feskanich et ah,
2003). Dawson-Hughes et ah reported decreased bone loss in the femoral neck and 
spine and lowered risk of fracture in individuals 65 years of age or older who took
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dietary vitamin D supplementation (often in conjunction with calcium) (Dawson- 
Hughes et ah, 1997). Trivedi et ah showed that the rate of first fi*acture at any major 
osteoporotic site was reduced by 33% with the use of vitamin D supplements than 
placebo in elderly living in the general community (Trivedi et ah, 2003). Gerdhem et 
ah reported that women who had 25(OH)D levels less than 50 nmol/L had double the 
risk of fracture than women with levels above 50 nmol/L (Gerdhem et ah, 2005). 
Bischoff-Ferrari et ah (2005) combined studies into those taking high daily vitamin D 
doses of 700-800 lU and those taking low dose daily supplements of 400IU. The 
authors found a lower incidence of hip and non-vertebral ft-actures with the use of 
higher doses of vitamin D supplementation, whereas the lower doses were ineffective 
(Bischoff-Ferrari et ah, 2005a; Bischoff-Ferrari et ah, 2012).
In general, it is recognized that low vitamin D levels contribute to low BMD, 
and vitamin D deficiency appears to a greater extent among individuals with 
osteoporosis than among those without the disease (Lips et ah, 2001). Considering 
how prevalent vitamin D deficiency is in the Saudi Arabian women population, the 
aim of the present study is to assess the interaction between serum 25(OH)D, calcium 
metabolism marker, BTM’s, and BMD in healthy pre-and post-menopausal Saudi 
Arabian women
6.2 Subjects and methods
A total of 449 healthy women (20-82 years) took part of the present study. Please 
refer to chapter II for detailed information about subject’s recruitment, inclusion 
criteria, and biochemical measurements.
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6.2.1 Statistical analysis
SPSS version 16.0 (SPSS, Inc. Chicago, IL) was used for statistical analysis. 
Variables were checked for normality using Kolmogorov-Smimov (K-S) test. 
Continuous variables are presented as means ± SD and categorical variables are 
expressed as frequencies and percentages. Spearman’s correlations were applied to 
investigate correlations between non-normally distributed variables. Partial 
correlations adjusting for confounding variables were also performed. BMD and 
BTM’s were compared among serum 25(OH)D quartiles in the two studied groups of 
women with the use of ANOVA. Results were considered significant if P<0.05.
6.3 Results
Serum 25(OH)D and PTH values of the studied women are presented in Table 3.5 
(please refer to Chapter III). For all women combined the mean (±SD) of serum 
25(OH)D and PTH values were 28.78±21.86 nmol/L and 9.2±3.6 pmol/L, 
respectively. Postmenopausal women had significantly higher serum 25(OH)D levels 
than premenopausal women (35.0±22.1 vs. 22.6±19.8 nmol/L; P<0.0011), while no 
significant differences were found in serum PTH levels between the two groups of 
women studied (8.86±3.28 vs. 9.48±3.98 pmol/L; P=0.07). Sixty nine percent of the 
population demonstrated serum intact PTH levels above the upper limit of the normal 
range (>7.0 pmol/L), with the remaining 30.7% exhibiting serum intact PTH in the 
normal range (1.6-6.9 pmol/L). The mean (±SD) serum intact PTH level within the 
normal hormonal range was 5.42±1.09 pmol/L with levels ranging between 2.5 and 
6.9pmol/L, whereas the mean (±SD) serum intact PTH level was 10.83 ± 3.12 pmol/L 
in the group with above normal levels, ranging from 7.0 to 25.0 pmol/L. Furthermore 
increased serum PTH were observed in 69.0% and 55.6% of pre-and post-menopausal
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women studied with serum 25(OH) D <50nmol/L. Other biochemical measures 
including serum Ca, P O 4 ,  and BTM’s are also present in Table 3.5.
6.3.1 Serum 25(OH)D and PTH
For all women combined (pre-and post-menopausal women who were taking or not 
taking vitamin D supplements), a decrease in serum 25(OH)D levels were associated 
with an increase in serum PTH levels independent of age and BMI (r=-0.199; 
P<0.001).When women were divided according to their menopausal status the 
association remained significant in premenopausal women (r=-0.23; P=0.001), and 
postmenopausal women (r=-0.22; P=0.001), respectively and remained significant 
after controlling for age and BMI in the two groups (P<0.01). Figures 6.1 and 6.2 
below illustrate the association between 25(OH)D and PTH in pre-and post­
menopausal women, respectively. In both groups, women with increasing mean 
25(OH)D levels their mean PTH level decreased (by ANOVA; P<0.01).
r= -0.23; p=0.001
0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0
S erum  25(OH)D (nmol/L)
Figure 6.1: Correlation between serum 
25(OH)D & PTH in premenopausal 
women
- = - 0 . 2 2 ; p = 0 . 0 0 1
^  15.0-
S erum 25(O H )D  (nmol/L)
Figure 6.2: Correlation between serum 
25(OH)D & PTH in postmenopausal 
women
The analysis was repeated again only on women who were not taking vitamin D 
supplements (n=341). A moderate correlation approaching significance was found 
between serum 25(OH)D and PTH in the premenopausal group (n=204) (r=-0.13;
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P=0.064), and a weak negative, non significant correlation was found in the 
postmenopausal group (n=137) (r=-0.123; P=0.15). After controlling for age and 
BMI the association became stronger in the premenopausal group (r=-0.15; P=0.03), 
while no differences was found in the postmenopausal group (r=-0.109; P=0.21). 
Figures 6.3 and 6.4 below illustrate the correlation between serum 25(OH)D levels 
and PTH in pre-and post-menopausal women who are not using vitamin D 
supplements, respectively.
r=-0.13;P=0.06
0,0 1 0,0 20.0 30.0 40.0 5QD
Serum 25(OH)D (nmol/L)
Figure 6.3: Correlation between 
25(OH)D & PTH in 
premenopausal women who were not 
taking vitamin D supplements
=-0.12; P=0.15
Serum  25(OH)D (nmol/L)
Figure 6.4: Correlation between 
25(OH)D & PTH in postmenopausal 
women who were not taking vitamin 
D supplements
6.3.2 Serum 25(OH)D, PTH and biochemical parameters in 
premenopausal women
Data were analyzed for premenopausal women and a weak positive, non significant 
correlation was found between serum 25(OH)D and Ca (r=0.09; P=0.1) and with PO4  
(r=0.09; P= 0.1). On the other hand, PTH was significantly and inversely correlated 
to serum Ca (r=-Q.25; P<0.001), as well as with PO4 (r=-Q.29; P<0.001) (Figures 6.5 
& 6 .6 ), and remained significant after adjusting for age and BMI (P<0.001).
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— 0.25; P<0.001
cBo
Serum  calcium (mmoi/L)
Figure 6.5: Correlation between PTH 
and Ca in premenopausal women
-=-0.29; P<0.001
1
o
Serum  p h o sp h o ru s  (mmol/L)
Figure 6 .6 : Correlation between PTH 
and PO4  in premenopausal women
The correlation between PTH and Ca and P O 4  remained significant when repeated on 
women who were not taking vitamin D supplements (Figures 6.7 and 6.8).
I
Serum  calcium (mmol/L)
Figure 6.7: Correlation between 
PTH & Ca in premenopausal 
women who were not taking vitamin 
D supplements
-0.25; P<0.001
1
Serum  p h o sp h o ru s  (mmol/L)
Figure 6 .8 : Correlation between PTH & 
PO4  in premenopausal women who were 
not taking vitamin D supplements
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6.3.3 Serum 25(OH) D status and biochemical parameters in
postmenopausal women
In the postmenopausal group a significant positive correlation was found between 
serum 25(OH) D and Ca (r=0.161; P=0.016) (Figure 6.9), and remained significant 
after controlling for age and BMI (r=0.15; P=0.026), while a weak negative, non 
significant correlation was found with PO4 (i^-0.005; P=0.9). Furthermore, a 
significant inverse correlation was found between PTH and PO4  (r=-0.262; P<0.001) 
(Figure 6.10), and a moderate inverse correlation between PTH and Ca approaching 
significance (r=-0.119; P=0.07) (Figure 6.11). After controlling for age and BMI, the 
significant association remained between PTH and PO4  (P<0.001), and became 
stronger with calcium (P<0.05). When the correlations were repeated on women who 
were not taking vitamin D supplements, the significant association remained only 
between PTH and PO4  in this group of women (r=-0.25; P=0.003) (Figure 6.12).
-0.26; P<0.001
S e ru m  p h o s p h o ru s  (mmol/L)S erum  calcium  (mmol/L)
Figure 6.9: Correlation between 
serum 25(OH)D and Ca in 
postmenopausal women
Figure 6.10: Correlation betwe* 
PTH and PO 4  in postmenopaus 
women
1 2 1
r=-0.119;P=0.07
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Figure 6.11 Correlation between PTH 
and Ca in postmenopausal women
0.25; P=0.003
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S erum  p h o sp h o ru s  (mmol/L)
Figure 6.12 Correlation between PTH 
and
PO 4  in women who were not using 
vitamin D supplements
6.3.4 Serum 25(OH)D, PTH and BTM ’s in premenopausal women
The data were examined to see if any association existed between 25(OH) D and 
BTM’s in premenopausal group of women. We observed a significant negative 
correlation between serum 25(OH) D levels and u-NTX (r=-0.20; P=0.003) (Figure 
6.13), CTX (r=-0.13; P=0.045) (Figure 6.14), OC (r=-0.14; P=0.031) (Figure 6.15), 
and with PINP (r=-0.15; P=0.027) (Figure 6.16). The association remained significant 
after controlling for age and BMI (P<0.05). After excluding vitamin D outliers the 
significant association remained between serum 25(OH) D levels and u-NTX (r=-0.19; 
P=0.006), OC (r=-0.13; P=0.049), and with PINP (r=-0.14; P =0.038), and remained 
significant after controlling for age and BMI (P<0.05). PTH was significantly and 
positively associated with u-NTX (r=0.19; P=0.003) (Figure 6.17), and with CTX 
(r=0.25; P<0.001) (Figure 6.18) in this group of women. After adjusting for age and 
BMI, increased serum PTH was positively associated with increased markers of bone 
resorption (P<0.001), and with bone fomiation markers (P<0.01). The association 
remained significant after excluding serum 25(OH) D outliers.
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Figure 6.14: Correlation between 25(OH)D 
and CTX in premenopausal women
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Figure 6.16: Correlation between 
25(OH)D and PINP in premenopausal 
women
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Figure 6.17: Correlation 
between PTH and urine-NTX 
in premenopausal women
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Figure 6.18: Correlation between PTH 
and CTX in premenopausal women
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The correlations were repeated on women who were not taking vitamin D 
supplements, and the significant association remained between PTH and u-NTX 
(r=0.19; P=0.007), and with CTX (r=0.25; P<0.001) (Figures 6.19 and 6.20), and a 
moderate inverse correlation between 25(OH)D and u-NTX, approaching significance 
was also seen (r=-Q.13; P=0.06) (Figure 6.21). After controlling for age and BMI, the 
association remained significant between PTH and markers of bone resorption 
(P<0.001), and became stronger with OC and PINP (P=0.02), while no differences 
were seen with 25(OH)D.
r=0.19; P=0.007
0% ,
1
o O
U-NTX
igure 6.19: Correlation between PTH & 
u-NTX in premenopausal women who 
were not using vitamin D supplements
=-0.25;P<0.001
o °
CTX (pg/ml)
Figure 6.20: Correlation between PTH & 
CTX in premenopausal women who were 
not using vitamin D supplements
r=-0.13;P=0.06
U-NTX
Figure 6.21: Correlation between serum 25(OH)D & 
u-NTX in premenopausal womenwho were 
not using vitamin D supplements
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6.3.5 Serum 25(OH) D, PTH and BTM’s in postmenopausal women
The data were examined to see if association existed between 25(OH)D and BTM’s in 
postmenopausal women. Serum 25(OH)D was significantly inversely associated only 
with OC (r=-0.14; P=0.039), and with PINP (r=-0.15; P=0.021) in this group 
(Figures 6.22 & 6.23). The assoeiation remained significant after controlling for age 
and BMI with OC (r=-0.14; P=0.034). The association became stronger when 
controlling for outliers. No significant association was found between PTH and any of 
BTM’s in this group of women.
-0.14; P=0.039
1
I
I
O steocalcin
=-0.15;P=0.021
P1NP (ng/ml)
Figure 6.22: Correlation between 
25(OH)D and OC in postmenopausal 
women
Figure 6.23: Correlation between 
25(OH)D and PIN ? in postmenopausal 
women
The correlations were repeated on women who were not taking vitamin D 
supplements. A moderate significant assoeiation was found between 25(OH)D and 
OC (r=-0.163; P=0.057). However, the association disappeared after controlling for 
age and BMI.
6.3.6 Serum 25(OH) D, PTH and BMD in the studied women
The data were examined to see if association existed between 25(OH) D, PTH, and 
BMD in the studied women. Serum 25(OH) D was not significantly associated with 
BMD at any site measured in the two groups of women. On the other hand, PTH was 
significantly and inversely associated with femur neck BMD in postmenopausal
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women (r=-0.13; P=0.049), and a trend was seen in premenopausal women (r=-0.12; 
P=0.07) (Figures 6.24 & 6.25, respectively). After adjusting for age and BMI, the 
association became stronger in the premenopausal group (r=-0.181; P=0.007) and in 
postmenopausal group (r=-0.143; P=0.034).
=-0.13; P=0.049
g o  0<P CO
0.800 1.000 
Fem ur neck  BMD (g/cm2)
Figure 6.24: Correlation between PTH 
and femur neck BMD in postmenopausal 
women
=-0.12; P=0.07
0.800 1.000 1.200 1.400 1.600
Fem ur neck  BMD (g/cm2)
Figure 6.25: Correlation between PTH 
and femur neck BMD in premenopausal 
women
6.3.7 BMD according to 25(OH) D quartiles in premenopausal women
Serum 25(OH) D were divided into quartiles and the mean values of BMD at different 
sites are presented in Table 6.1. These data were examined for differences in mean 
BMD between quartiles of 25(OH) D. Significant differences were found only at 
femur trochanter (P=0.028), and total femur (P=0.025). Post Hoc analysis showed a 
significant differences in femur trochanter BMD between women in quartile 1 and 
quartile 2 (P=0.035). The same was true for the total femur BMD (P=0.034). These 
differences disappeared when the analysis was repeated on women who were not on 
vitamin D supplements (Table 6.2).
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Table 6.1: BMD according to 25(OH) D quartiles in premenopausal women
BMD
(g/cm^)
Ql
(<11.77)
(n=56)
Q2
(11.78-17.29)
(n=56)
Q3
(17.3-26.74)
(n=58)
Q4
(>26.75)
(n=56)
P-value
L1-L4 1.12±0.15 1.17±0.12 1.14±0.13 1.12±0.13 0.192
FN 0.91 ±0.15 0.97 ±0.13 0.93 ± 0.09 0.92 ±0.13 0.061
FW 0.81 ±0.17 0.87 ±0.14 0.81 ± 0 . 1 2 0.81 ±0.14 0.061
FT 0.70 ±0.11 0.75 ±0.12 0.71 ±0.09 0.71 ±0.11 0.028
TF 0.89 ±0.13 0.96 ±0.12 0.93 ± 0.09 0.91 ±0.13 0.025
Data are presented as mean ± SD. L1-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur, Q; quartiles.. Means BMD were compared among 25(OH)D quartile groups 
with ANOVA. *Post Hoc
Table 6.2: BMD according to 25(OH) D quartiles in premenopausal women wbo 
were not taking vitamin D supplements
BMD
(g/cm^)
Ql
(<11.20)
(n=52)
Q2
(11.21-15.79)
(n=48)
Q3
(15.8-23.51)
(n=53)
Q4
(>23.52)
(n=51)
P-
value
L1-L4 1.12±0.15 1.16±0.13 1.17±0.12 1.12±0.13 0.057
FN 0.92 ±0.15 0.95 ±0.14 0.95 ±0.10 0.92 ±0.12 0.4
FW 0.83 ±0.16 0.84 ±0.15 0.85 ±0.13 0.79 ±0.14 0 . 2
FT 0.69 ±0.11 0.73 ±0.12 0.74 ±0.10 0.71 ±0.11 0 . 1
TF 0.91 ±0.13 0.94 ±0.13 0.96 ±0.11 0.92 ±0.12 0 . 2
Data are presented as mean ± SD. L1-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur, Q; quartiles.. Means BMD were compared among 25(OH)D quartile groups 
with ANOVA.
6.3.8 BMD according to 25(OH)D quartiles in postmenopausal women
The data were also examined in postmenopausal women to see if differences in BMD 
at different 25(OH)D quartiles exist. No significant differences were found in BMD at 
different 25(OH)D quartiles in this group of women. The means of BMD at different 
25(OH)D levels for postmenopausal group are presented in Table 6.3
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Table 6.3: BMD according to 25(OH) D quartiles in postmenopausal women
BMD
(g/cm^)
Q l
(<17.1)
(n=57)
Q2
(17.2-29.79)
(n=54)
Q3
(29.8-47.59)
(n=56)
Q4
(>47.6)
(n=56)
P-
value
L1-L4 0.97 ±0.13 1.0±0.16 1.0 ±0.17 0.95 ±0.12 0 . 1
FN 0.84 ±0.13 0.84 ±0.12 0.87 ±0.15 0.83 ±0.12 0.3
FW 0.64 ±0.13 0.66 ±0.14 0.68 ±0.17 0.62 ±0.13 0 . 2
FT 0.67 ±0.10 0 . 6 8  ± 0 . 1 2 0.70 ±0.13 0 . 6 6  ± 0 . 1 1 0 . 2
TF 0 . 8 6  ± 0 . 1 2 0.88 ±0.14 0.90 ±0.15 0.85 ±0.12 0 . 1
Data are presented as mean ± SD. L1-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur. Means BMD were compared among 25(OH)D quartile groups with 
ANOVA.
However, when women on vitamin D supplements were excluded BMD values were 
significantly different among the vitamin D quartiles (Table 6.4). Post-Hoc analysis 
showed that women in the lower quartile of serum 25(OH)D had significantly lower 
BMD at all sites than did women in the highest quartile.
Table 6.4: BMD according to 25(OH) D quartiles in postmenopausal women wbo 
were not taking vitamin D supplements
BMD
(g/cm^)
Q l
(<14.30)
(n=34)
Q2
(14.31-21.49)
(n=34)
Q3
(21.5-28.44)
(n=35)
Q4
(>28.45)
(n=34)
P-
value
L1-L4 0.93 ±0.13 1.03 ±0.16 1.01 ±0.15 1.03 ±0.19 0.026
FN 0.79 ±0.11 0.86 ±0.14 0.84 ±0.12 0.89 ±0.16 0.035
FW 0.60 ± 0 . 1 2 0.67 ±0.13 0.65 ±0.12 0.72 ±0.19 0 . 0 1 1
FT 0.65 ±0.10 0.70 ±0.10 0 . 6 8  ± 0 . 1 1 0.73 ±0.14 0.029
TF 0.83 ±0.12 0.89 ±0.12 0.87 ±0.14 0.93 ±0.16 0.029
Data are presented as mean ± SD. L1-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur. Means BMD were compared among quartile groups with ANOVA.
6.3.9 BTM’s according to 25(OH) D quartiles in premenopausal women
The data were examined to see any differences in means BTM’s and serum 25(OH)D 
quartiles in the studied premenopausal women. Tables 6.5 and 6 . 6  present BTM’s 
values according to serum 25(OH)D quartiles in all premenopausal women and in
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those were not taking vitamin D supplements, respectively. No significant differences 
were found in this group of women.
Table 6.5: BTM’s according to 25(OH) D quartiles in premenopausal women
BTM’s
Ql
(<11.77)
(n=56)
Q2
(11.78-17.29)
(n=56)
Q3
(17.3-26.74)
(n=58)
Q4
(>26.75)
(n=56)
P-value
NTX (nMcrea) 56.1 ±22.9 50.8 ±21.8 53.4 ±33.0 45.7 ±25.7 0.2
CTX (pg/ml) 347.1 ± 179.7 349.9 ±169.3 341.9 ±185.4 300.9 ±180.0 0.4
OC (ng/ml) 19.3 ±7.0 19.9 ±8.5 18.8 ±7.0 17.6 ±8.4 0.4
PINP (ug/ml) 51.4 ±19.2 54.3 ±19.4 49.7 ±20.5 51.1 ±33.0 0.7
Data are presented as mean ± SD. U-NTX; urine N-terminal telopeptide o f type I collagen, CTX; C- 
terminal telopeptide o f type I collagen , OC; osteocalcin, PINP; N-terminal propeptide o f type I 
collagen, Q; quartiles. Comparisons o f means among 25(OH)D quartile groups were done with 
ANOVA.
Table 6.6: BTM’s according to 25(OH) D quartiles in premenopausal women 
who were not taking vitamin D supplements
BTM’s
Ql
(<11.20)
(n=52)
Q2
(11.21-15.79)
(n=48)
Q3
(15.8-23.51)
(n=53)
Q4
(>23.52)
(n=51)
P-value
NTX (nMcrea) 56.4 ±23.3 51.9 ±22.4 55.2 ±33.6 47.7 ±25.4 0.3
CTX (pg/ml) 356.3 ±180.8 343.2 ± 167.8 346.1 ± 193.7 325.6 ±167.8 0.8
OC (ng/ml) 19.4 ±7.2 20.2 ±8.1 18.4 ±7.4 18.7 ±8.4 0.7
PINP (ug/ml) 52.6 ±19.3 53.1 ±18.8 51.4 ±20.9 50.9 ±27.7 0.9
Data are presented as mean ± SD. U-NTX; urine N-terminal telopeptide o f type I collagen, CTX; C- 
terminal telopeptide of type I collagen , OC; osteocalcin, PINP; N-terminal propeptide o f type I 
collagen, Q; quartiles. Comparisons of means among 25(OH)D quartile groups were done with 
ANOVA.
6.3.10 BTM’s according to 25(OH) D quartiles in postmenopausal women
The data were examined to see any differences in means BTM’s and serum 25(OH)D 
quartiles in the studied postmenopausal women. Tables 6.7 and 6 . 8  present BTM’s 
values according to serum 25(OH)D quartiles in all postmenopausal women and in 
those were not taking vitamin D supplements, respectively. No significant differences 
were found in this group of women.
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Table 6.7: BTM’s according to 25(OH)D quartiles in postmenopausal women
BTM’s
Ql
(<17.1)
(n=57)
Q2
(17.2-29.79)
(n=54)
Q3
(29.8-47.59)
(n=56)
Q4
(>47.6)
(n=56)
P-value
U-NTX (nMcrea) 51.7 ±23.5 49.8 ±29.8 45.6 ±23.7 46.8 ± 22.4 0.5
CTX (pg/ml) 337.7 ±180.4 333.1 ±192.9 283.4 ±178.4 324.9 ± 197.3 0.4
OC (ng/ml) 20.3 ±8.1 18.2 ± 8 . 1 16.6 ± 6 . 2 17.7 ±7.0 0.06
PINP (ug/ml) 50.4 ±19.4 46.9 ± 26.4 42.9 ± 22.2 42.9 ± 24.9 0:3
Data are presented as mean ± SD. U-NTX; urine N-terminal telopeptide o f type I collagen, CTX; C- 
terminal telopeptide o f type I collagen , OC; osteocalcin, PINP; N-terminal propeptide o f type I 
collagen, Q; quartiles. Comparisons o f means among 25(OH)D quartile groups were done with 
ANOVA. * Post Hoc
Table 6.8: BTM’s according to 25(OH)D quartiles in postmenopausal women 
who were not taking vitamin D supplements
BTM’s
Ql
(<14.30)
(n=34)
Q2
(14.31-21.49)
(n=34)
Q3
(21.5-28.44)
(n=35)
Q4
(>28.45)
(n=34)
P-value
U-NTX (nMcrea) 55.6 ±22.3 45.3 ±22.6 47.5 ±31.6 46.1 ±21.9 0.3
CTX (pg/ml) 334.3 ±160.1 338.5 ± 194.8 304.6 ±171.7 303.7 ±171.8 0.7
OC (ng/ml) 21.1 ±7.9 19.3 ±9.2 16.8 ± 6 . 0 18.3 ±6.4 0 . 1
PINP (ug/ml) 50.1 ± 18.2 50.8 ± 24.8 43.2 ±23.8 46.3 ± 17.4 0.4
Data are presented as mean ± SD. U-NTX; urine N-terminal telopeptide o f type I collagen, CTX; C- 
terminal telopeptide of type I collagen, OC; osteocalcin, PINP; N-terminal propeptide o f type I 
collagen, Q; quartiles. Comparisons o f means among 25(OH)D quartile groups were done with 
ANOVA.
6.4 Discussion
Chapter IV clearly demonstrated that there is a high prevalence of vitamin D 
deficiency and/or insufficiency among healthy Saudi young and old women living in 
Jeddah during the summer season. This study was carried out to investigate the 
interaction between serum 25(OH)D levels, PTH, BTM’s and BMD in these women. 
There is still no consensus on the serum 25(OH)D levels that define sufficient vitamin 
D status. However, it is generally agreed that sufficient levels of 25(OH)D maintain 
maximum Ca absorption, suppress PTH, increase BMD, and reduce the risk of
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fractures (Dawson-Hughes et al., 2005). Sufficient 25(OH)D levels have been 
suggested to be between 75-150 nmol/L (Holick et al., 2011). The majority of women 
in the present study are far below these values. In agreement with previous studies 
(Peppe et al., 2005; Lu et al., 2012), the results of the present study present a 
significant inverse association between serum 25(OH)D and PTH levels independent 
of age and BMI. Identifying such a relationship suggest that serum 25(OH)D level 
could be an important mediator in PTH stimulating bone resorption, which may 
contribute to low bone mass. Sufficient serum 25(OH)D may maintain low serum 
PTH concentrations in these women. Interestingly hypercalcemia was prevalent in the 
studied healthy women that cannot be explained in the current study.
Biochemical markers of bone provide an indication of the rate of bone 
turnover. Increased bone turnover is associated with a high rate of bone loss and 
osteoporotic fractures (Glendenning, 2011). As reported in several previous studies 
(Gannage-Yared et al., 2000; Diamond et al., 2002; Lu et al., 2012), low serum 
25(OH)D level was associated with higher BTM’s independently of age and BMI in 
the studied women. Furthermore, a significant positive association was found between 
PTH and BTM’s independently of age and BMI; identifying that higher PTH levels 
are associated with more bone turnover. The biochemical picture of our results 
suggest that increased PTH concentrations may play a role in accelerated bone 
remodeling and subsequent bone loss in women with insufficient serum 25(OH)D 
levels. Several studies have indicated that secondary hyperparathyroidism associated 
with 25(OH)D insufficiency is the cause of increased bone resorption and fractures 
(Lips et al., 2001; Allali et al., 2009).
The association between 25(OH) D and BMD is still debatable. Some studies 
suggest that a low serum 25(OH)D level is associated with low BMD (Lips et al.,
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2001; Bischoff-Ferrari et al., 2004a). However, no such association has been found in 
other studies (Gamero et al., 2007; Hosseinpanah et al., 2008; Allali et al., 2009). The 
present study demonstrated 85.5% of the studied women to have low vitamin D 
levels. Interestingly, even though a significant proportion of the studied sample had 
low BMD (76%), low serum 25(OH)D levels were not associated with decreased 
BMD at any site measured. On the other hand, a negative correlation between PTH 
and BMD of femoral neck, a common site of fracture, was observed in spite of the 
absence of any correlation between serum 25(OH)D and BMD of all sites. 
Furthermore, various studies reported the inverse correlation between serum PTH 
level and BMD, particularly in the femoral neck site (Hosseinpanah et al., 2008). 
Moreover, other studies have shown higher levels of PTH in individuals with hip 
fracture (Benhamou et al., 1995). The inverse relationship between 25(OH) D and 
PTH, and between PTH and femur neck BMD; suggesting that vitamin D status could 
still be an important part of bone health in these women. The relationships between 
2 5 (OH) D and bone health outcomes may be better elucidated if vitamin D status is 
known over a period of time; conceivably it is not vitamin D status today that is 
associated with BMD today. The serum measurement of 25(OH)D at one time may 
not be representative of lifetime vitamin D status, and may be exceptionally high or 
low depending on factors such as history of vitamin D supplements use, sun exposure, 
as well as season of measurement.
In conclusion, it seems that there is no association between serum 25(OH)D 
and BMD at different sites of bone densitometry in healthy Saudi Arabian women 
living in the Jeddah area. Low 25(OH)D was associated with both secondary 
hyperparathyroidism and increased bone remodeling. Differences in serum PTH 
levels, but not 25(OH)D levels, predicted low BMD at the hip in both younger and
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older Saudi women who had low serum vitamin D levels. Aiming at normalizing 
PTH, as opposed to targeting specific 25(OH)D levels, may be the best approach to 
optimize skeletal health in subjects with low 25(OH)D levels.
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CHAPTER VII
EXTENT OF OVERWEIGHT AND 
OBESITY AND THE ASSOCIATION 
WITH 25(OH)D AND BONE MINERAL 
DENSITY IN HEALTHY PRE-AND 
POSTMENOPAUSAL SAUDI WOMEN
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7.1 Introduction
More than one billion people around the world are either overweight or obese 
with a body mass index (BMI) of 25 kg/m^ or more (WHO, 2000). The prevalence 
rates are continuing to increase, and obesity is occurring in all socio-economic classes 
and all age groups as a result of the over consumption of energy and decreased 
physical activity (Drewnowski & Popkin, 1997). In Saudi Arabia, nutrition is in a 
stage of transition, with fast food high in fat and sugar taking the place of customary 
and traditional food. Simultaneously, changes in lifestyle with reduced physical 
activity are occurring. A previous study conducted in Saudi Arabia revealed that 
72.5% of Saudis are either overweight or obese, and obesity was significantly higher 
in women than men (Al-Nozha et al., 2005). Accompanying the growing problem of 
obesity is the increase in the prevalence of associated co-morbidities such as heart 
diseases, strokes, diabetes, and hypertension (WHO, 2000).
It may appear contradictory to have a correlation between nutritional 
deficiency and obesity, especially with high calorie consumption, but increasing 
studies have shown that overweight and obese adults, especially the extremely obese 
(BMI > 40kg/m^^ have a higher prevalence of deficiencies of several micronutrients. 
More and more studies indicate a link between obesity and changes in the vitamin D- 
endocrine system. Vitamin D status can be predicted by BMI and body composition. 
Many studies have found an association between low vitamin D levels, measured by 
serum 25(OH)D levels, and increased BMI (Arunabh et al., 2003; Snijder et al., 
2005), and elevated PTH levels (Kamycheva et al., 2004; Parikh et al., 2004).
There are additional challenges involved in investigating the connection 
between vitamin D status and body composition. Vitamin D is a fat-soluble vitamin, 
so one might conclude that those with more adipose tissue would have greater vitamin
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D stores. However, reports do not substantiate this expectation. In fact, obese subjects 
are among groups at risk for vitamin D deficiency and its related symptoms and health 
risks (Holick, 2007a). This may be explained by a higher volumetric dilution of 
vitamin D in adipose tissues instead of being released into the circulation and its 
deposition in the adipose tissue (Wortsman et al., 2000; Drincic et al., 2012). This 
phenomenon was demonstrated well by a study in which both obese and non-obese 
subjects were given equal amounts of oral vitamin D3 supplements and exposed to 
identical amounts of UVB. The hypothesis was that higher 25(OH)D serum levels 
would be seen in the obese subjects due to the greater fat stores for vitamin D, in 
addition to increased body surface area resulting in more UV light absorption. 
However, the opposite was found. Significantly lower vitamin D levels were found in 
the obese subjects than the non-obese ones despite equal levels of 7-DHC, UV 
exposure time, and vitamin D intake (Wortsman et al., 2000). The study concluded, 
“obesity did not affect the capacity of the skin to produce vitamin D3, but may have 
altered the release of vitamin D3 from the skin into the circulation” (Wortsman et al., 
2000).
Increased bone mass, and decreased bone turnover and loss is associated with 
obesity (Reid, 2002), whereas reduced bone mass and an higher fracture risk is 
associated with a low body weight (Shapses & Cifuentes, 2004). In the Study of 
Osteoporosis Fractures, twice as many hip fi*actures were seen among white women 
aged 65 years and older who were in the lowest quartile for weight than in their 
counterparts in the other quartiles (Cummings et al., 1995).
Little data exist on the relationship between 25(OH)D and adiposity measures 
in our community. The aims of this study were to describe the extent of overweight 
and obesity in healthy pre-and postmenopausal Saudi women, to assess the
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association between serum 25(OH) D and PTH and adiposity, and to assess the 
association between adiposity and BMD in these women.
7.2 Subjects and methods
Information about subjects’ recruitment and inclusion criteria can be found in Chapter 
II. Body mass index (BMI; kilograms per meter squared), waist circumference (WC; 
centimeters), hip circumference (HC; centimeters), and waist-to-hip circumference 
ratio (WHR) were recorded. Overweight is defined as BMI > 25 kg/m^, and obese as 
BMI > 3 0  kg/m^ on the basis of international obesity classification (WHO, 2000). 
Total body fat (TBF) was measured in grams on total body scan using dual-energy X- 
ray absorptiometry (DXA) (Lunar Prodigy Model, Lunar Corp., Madison, WI, USA). 
Fasting venous blood samples were drawn in the morning under standardized 
conditions. Centrifuged blood was analyzed for the determination of serum 25(OH) D 
and PTH as described previously (Chapter II).
7.2.1 Statistical analysis
All analyses were performed with SPSS version 16.0 (SPSS, Inc. Chicago, IL), and 
statistical significance was set as P < 0.05. Continuous variables are presented as 
means ± SD and categorical variables are expressed as frequencies and percentages. 
Participants were stratified into the following subgroups by BMI: normal weight 
(18.5- <25 kg/m^); overweight (25- <30 kg/m^ ); and obese (> 30 kg/m^) (WHO, 
2000). Correlations were performed with Spearman’s correlation coefficient. Partial 
correlation adjusting for confounding variables was also performed. Differences in 
serum levels of 25(OH) D and PTH between BMI subgroups were tested using 
analysis of variance ANOVA.
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7.3 Results
Age, anthropometric, and biochemical characteristics of the study population 
according to menopausal status arc presented in Table 3.1 (please refer to chapter III). 
The mean TBF in grams measured by DXA for all women was 28.4 ± 8.2. The 
women ranged from lean to morbidly obese with a mean BMI of 28.7 kg/m^ (range, 
16-54.5 kg/m^). Postmenopausal women exhibited increased BMI (P<0.001), and 
WHR (P<0.001) as compared to premenopausal women. Although mean serum 
25(OH) D was low in both groups of women, postmenopausal women had 
significantly higher 25(OH)D levels compared to premenopausal women with an 
overall mean of 28.8±21.8nmol/L (P<0.001).
Figure 7.1 presents BMI status of pre and post-menopausal women studied. A total of 
30.1% of the women were overweight (27.4% pre, 32.7% post), and 38.5% were 
obese (21.2% pre, 56.1% post).
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Figure 7.1: BMI status among pre-and post-menopausal women studied (n=449)
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7.3.1 Association between 25(OH) D, PTH and anthropometric measures
in premenopausal women
A l t h o u g h  n o t  s t a t i s t i c a l l y  s i g n i f i c a n t ,  s e r u m  2 5 ( O H ) D  w a s  i n v e r s e l y  a s s o c i a t e d  w i t h  
W C  ( r = - 0 . 1 1 3 ;  P = 0 . 0 9 0 )  ( F i g u r e  7 . 2 ) ,  a n d  w i t h  B M I  ( r = - 0 . 1 2 4 ;  P = 0 . 0 6 2 )  ( F i g u r e
7 . 3 )  i n  p r e m e n o p a u s a l  w o m e n .  C o n v e r s e l y ,  s e r u m  P T F I  w a s  s i g n i f i c a n t l y  a n d  
p o s i t i v e l y  a s s o c i a t e d  w i t h  B M I  i n  t h i s  g r o u p  o f  w o m e n  ( r = 0 . 1 3 7 ;  P = 0 . 0 4 0 )  ( F i g u r e
7 . 4 ) ,  a n d  r e m a i n e d  s i g n i f i e a n t  a f t e r  a d j u s t i n g  f o r  a g e  ( r = 0 . 1 3 3 ;  P = 0 . 0 4 6 ) .
-=-0.11;P=0.09
I
I
W aist c ircu m feren ce  (cm)
Figure 7.2 Correlation between 25(OH)D 
and WC in premenopausal women
^r=-0.12; P=0.06
I
I
BMI (kg/m2)
Figure 7.3 Correlation between 
25(OH)D and BMI in premenopausal 
women
r=0.137; P=0.04
15.00 20 DO 30 DO 35.00
BMI (kg/m2)
40.00 45.00
Figure 7.4 Correlation between PTH and BMI 
in premenopausal women
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7.3.2 Association between 25(OH)D, PTH and anthropometric measures in
postmenopausal women
A n t h r o p o m e t r i c  m e a s u r e s  w e r e  i n v e r s e l y  r e l a t e d  t o  2 5 ( O H )  D ,  b u t  t h i s  c r u d e  
a s s o c i a t i o n  w a s  o n l y  s t a t i s t i c a l l y  s i g n i f i c a n t  f o r  B M I  ( r = - 0 . 3 4 0 ;  P = 0 . 0 0 5 )  ( F i g u r e
7 . 5 ) ,  a n d  W C  r = - 0 . 1 4 0 ;  P = 0 . 0 3 7 )  ( F i g u r e  7 . 6 ) .  B M I  w a s  s i g n i f i c a n t l y  a n d  p o s i t i v e l y  
a s s o c i a t e d  w i t h  s e r u m  P T H  ( r = 0 . 1 3 8 ;  P = 0 . 0 4 0 )  ( F i g u r e  7 . 7 ) ,  a n d  h i g h e r  B M I  w a s  
a s s o c i a t e d  w i t h  h i g h e r  P T H  a f t e r  a d j u s t i n g  f o r  a g e ,  s u n  e x p o s u r e ,  s e r u m  C a ,  a n d  
2 5 ( O H )  D  ( r = 0 . 1 3 6 ;  P = 0 . 0 4 6 ) .  T o t a l  b o d y  f a t  w a s  i n v e r s e l y  a s s o c i a t e d  w i t h  2 5 ( O H ) D  
( r = - 0 . 2 0 3 ;  P = 0 . 0 0 2 )  ( F i g u r e  7 . 8 ) ,  b u t  n o  a s s o c i a t i o n  w a s  f o u n d  w i t h  P T H .  A f t e r  
a d j u s t m e n t  f o r  a g e ,  a n d  s u n  e x p o s u r e ,  h i g h e r  T B F ,  a n d  W C  w e r e  s t a t i s t i c a l l y  
s i g n i f i c a n t l y  a s s o c i a t e d  w i t h  l o w e r  2 5 ( O H )  D  ( P < 0 . 0 1 ) .
-=-0.34; P=0.005
I
Figure 7.5 Correlation between 25(OH)D 
and BMI in postmenopausal women
■=-0.14; P=0.037
I
W aist c ircum ference  (cm)
Figure 7.6 Correlation between 25(OH)D 
and WC in postmenopausal women
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Figure 7.7 Correlation between 
PTH and BMI in 
postmenopausal women
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Figure 7.8 Correlation between 
25(OH)D and TBF 
in postmenopausal women
7.3.3 Serum 25(OH) D and PTH levels according to BMI category in 
premenopausal women
T h e  m e a n  s e r u m  2 5 ( O H )  D  o r  P T H  l e v e l s  w e r e  n o t  s i g n i f i c a n t l y  d i f f e r e n t  b e t w e e n  t h e
B M I  c a t e g o r i e s  i n  t h e  p r e m e n o p a u s a l  w o m e n  g r o u p  ( P =  0 . 1 2 4 )  ( P = 0 . 1 9 9 )  ( T a b l e  7 . 1 ) .
Table 7.1: Mean 25(OH) D and PTH levels by BMI categorical in premenopausal 
women
BMI category n (%) 25(OH)D (nmol/L) PTH (pmol/L)
Normal weight 1 1 6 ( 5 1 . 3 ) 2 4 . 5  ±  1 9 . 7 9 . 0  ± 3 . 9
Overweight 62 (27.4) 1 8 . 3  ±  1 2 . 1 9 . 7  ± 4 . 2
Obese 48(21.2) 23.8 ±26.5 1 0 . 2  ± 3 . 7
Differences in 25(OH) D and PTH between BMI groups were tested with the use o f ANOVA. 
Table 7.2: Serum 25(OH) D levels by BMI categorical in premenopausal women
BMI category Serum 25(OH)D (nmoI/L)
<25
n
25-49.99
n
50-74.99
n
>75
n
Total
Normal weight 7 3 3 2 8 3 1 1 6
Overweight 5 2 9 0 1 6 2
Obese 3 5 11 0 2 48
Total 1 6 0 5 2 8 6 226
N= number of women.
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7.3.4 Serum 25(OH)D and PTH levels according to BMI category in
postmenopausal women
Serum 25(OH) D was significantly higher in normal weight postmenopausal women 
than in overweight (44.2±26.0 vs. 39.8±25.5nmol/L) and obese women (44.2±26.0 vs. 
30.3± 17.6nmol/L respectively (P= 0.001) (Table 7.2). A trend for differences in PTH 
levels among the groups was also found (P=0.054). PTH was higher in obese women 
(9.3 ± 3.5) than in normal weight (8.0 ± 2.6).
Table 7.2: Mean 25(OH)D and PTH levels by BMI categorical in postmenopausal 
women
BMI category n (%) 25(OH)D (nmol/L) PTH (pmoI/L)
Normal weight 25 (11.2) 44.1 ±26.0 8.0 ±2.6
Overweight 73 (32.7) 39.8 ±25.5 8.4 ± 2.9
Obese 125 (56.1) 30.3 ± 17.6 9.3 ±3.5
Differences in 25(OH)D and PTH between BMI groups were tested with the use o f ANOVA.
Table 7.2: Serum 25(OH) D levels by BMI categorical in postmenopausal women
BMI category Serum 25(OH)D (nmol/L)
<25
n
25-49.99
n
50-74.99
n
>75
n
Total
Normal weight 7 8 6 4 25
Overweight 25 26 17 5 73
Obese 55 51 17 2 125
Total 87 85 40 11 223
N= number o f women.
7.3.5 Bone mineral density in relation to BMI category
Significant differences in means of BMD at different skeletal sites were observed 
according to BMI categories in premenopausal women (Table 7.3), and 
postmenopausal women (Table 7.4), respectively. Obese women had significantly 
higher BMD at all sites than did the normal and overweight women in the two groups 
studied (P<0.01).
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Table 7.3: Effect of adiposity on BMD in premenopausal women
BMD
(g/cm^)
Normal weight 
n=116
Overweight
n=62
Obese
n=48
P-
value
L1-L4 1.10±0.13 1.15±0.13 1.19±0.13 <0.001
FN 0.89 ±0.12 0.95 ±0.11 1.02 ±0.13 <0.001
FW 0.79 ±0.14 0.83 ±0.13 0.89 ±0.15 <0.001
FT 0.68 ± 0.09 0.72 ± 0.09 0.81 ±0.12 <0.001
TF 0.88 ±0.10 0.93 ±0.11 1.02 ±0.12 <0.001
Data are presented as mean ± SD. L1-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur. BMD were compared among BMI groups with the use o f ANOVA.
Table 7.4: Effect of adiposity on BMD in postmenopausal women
BMD (g/cm^) Normal weight 
n=25
Overweight
n=73
Obese
n=124
P-
value
L1-L4 0.92 ±0.15 0.96 ±0.13 1.0 ±0.15 0.003
FN 0.80 ±0.14 0.82 ±0.13 0.87 ±0.12 0.003
FW 0.59 ±0.15 0.63 ±0.14 0.68 ±0.14 0.006
FT 0.61 ±0.12 0.67 ±0.11 0.70 ±0.11 0.001
TF 0.79 ±0.13 0.85 ±0.13 0.90 ±0.13 <0.001
Data are presented as mean ± SD. LI-L4; lumbar spine, FN; femur neck, FW; femur ward, FT; femur 
trochanter, TF; total femur. BMD were compared among BMI groups with the use o f ANOVA
7.3.6 Association between BMI and BTM ’s in the studied women
Body mass index was inversely related to u-NTX (r=-0.168; P=0.013), CTX 
(r=-0.155; P=0.02), OC (r=-0.212; P=0.001), and with PINP (r=-0.154; P=0.021) in 
premenopausal women (Figures 7.9-7.12). This crude association between BMI and 
BTM’s was only statistically significant for CTX (r=-0.132; P=0.049) (Figure 7.13), 
and OC (r=-0.167; P=0.013) (Figure 7.14).
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Figure 7.9 Correlation between u-NTX and 
BMI in premenopausal women
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7.3.7 Multivariable regression analysis for predictors of BMD
Tables 7.5-7.8 present the results of the multivariable regression analysis for pre- and 
post-menopausal women, respectively. Body mass index and PTH were the two 
variables to reach statistical significant as predictors of LS and FN BMD in both 
groups of women.
Table 7.5: Possible determinants of lum bar spine BMD in premenopausal 
women
Predictors B t
BMI 0.008 4.79
Model summary: R=0.307; Adjusted R"^=0.090; ?<0.001
Table 7.6: Possible determinants of lum bar spine BMD in postmenopausal 
women
Predictors B t
BMI 0.010 5.55
PTH -0.007 -2.43
Model summary: R=0.365; Adjusted R^=0.125; ?<0.001
Table 7.7: Possible determinants of femur neck BMD in premenopausal women
Predictors B t
BMI 0.011 7.53
PTH -0.005 -2.75
Model summary: R=0.464; Adjusted R"^=0.208; ?<0.001
Table 7.8: Possible determinants of femur neck BMD in postmenopausal women
Predictors B t
BMI 0.008 5.48
PTH -0.007 -2.72
Model summary: R=0.365; Adjusted R"^=0.126; P<0.001
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7.4 Discussion
Obesity is the most widespread nutritional disorder in developed countries and 
is increasingly so in developing countries as well (Ng et ah, 2011). Genetic and 
environmental factors, along with social, physiological and psychological factors are 
linked to obesity. It is well accepted that diseases such as diabetes, hypertension, and 
metabolic syndrome have become critical problems in the Gulf region (El-Hazmi & 
Warsy, 1999; Al-Mahroos et al., 2000). In particular, these are diseases that have been 
highly associated with overweight and obesity (WHO, 2000). In the present study the 
BMI data revealed that 68.6% of the women were either overweight or obese. The 
high prevalence of overweight and obesity was confirmed in previous studies 
conducted on Saudi subjects (Al-Nuaim et al., 1997; Al-Nozha et al., 2005). In Saudi 
Arabia, there is a gender differential in the prevalence of overweight and obesity, with 
women having notably higher rates than men, particularly starting firom their mid-20s 
(Ng et al., 2011). Major factors which may contribute to this high prevalence, are 
higher income, sedentary lifestyle, and lack of nutritional awareness (El-Hazmi et al., 
1996; Martorell et al., 2000). In addition, women tend to spend a large part of their 
time indoors, while indoor activities (such as TV watching) and socializing fi*equently 
involve eating and snacking.
The results from the current study show a strong inverse association between 
BMI, TBF and serum 25(OH) D levels and a positive association between body mass 
index and serum PTH levels in postmenopausal women, independent of age, and sun 
exposure. Previous studies showed that serum 25(OH)D levels were lower in obese 
subjects compared with non obese individuals, and serum PTH levels were higher 
(Parikh et al., 2004; Snijder et al., 2005). In our sample we found statistically 
significant associations between BMI and 25(OH)D and between BMI and PTH
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levels. When TBF (in grams) was measured by DXA, the association with 25(OH)D 
was even stronger, a phenomenon also found in younger women (mean age 47.6 
years) (Arunabh et al., 2003). These findings suggest that adiposity and not merely 
body weight or BMI may be linked to serum 25(OH)D levels.
The present study shows a significant positive correlation between PTH and 
BMI, which has been documented in previous studies (Kamycheva et al., 2004; 
Shapses et al., 2013). Increased BMI as a consequence of elevated serum PTH can be 
explained. Increased PTH promotes an increased intracellular calcium concentration 
in adipocytes, which in turn enhances lipogenesis (McCarty & Thomas, 2003). In 
several cross-sectional epidemiological surveys, subjects whose PTH was in the 
reference range, have been found to have lower body weight than subjects with 
elevated PTH (Zemel et al., 2000). Insufficient calcium and vitamin D were 
associated with increased adiposity in premenopausal women than women with higher 
intake women (Tidwell & Valliant, 2011).
Increased body weight has a protective function for bones, whereas low 
weight, especially in older people, is a key risk factor for fractures (Reid, 2002). Our 
study confirmed that obese women, both young and old, had higher BMD at all 
skeletal sites measured than did women of normal weight. The protective effect of 
obesity on bone mass has been well described in cross-sectional studies (Reid, 2008). 
Several mechanisms through which a higher body weight may affect BMD, including 
increased mechanical loading, elevated concentrations of sex hormones and their 
precursors, and lower bone turnover (Reid, 2002). In our cross sectional study, 
increased BMI was associated with decreased BTM’s levels. Albala et al investigated 
the effect of obesity on obese and non-obese Caucasian postmenopausal women. They 
reported a higher bone mass after menopause in obese women than in normal weight
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women of the same age, especially at the sites of the lumbar spine and femoral neck 
(Albala et al., 1996). Dennison et al. showed that a lower BMI predicted bone loss in 
elderly aged 60-75 years followed up for 4 years (Dennison et al., 1999). Zhai et al. 
showed a protective role of increasing weight on the long term bone loss in 
postmenopausal women (Zhai et al., 2008). Estrone, the most plentiful circulating 
estrogen in postmenopausal women, is higher in obese postmenopausal women than 
in their lean counterparts (Albala et al., 1996; Zhai et al., 2008).
In conclusion, although there seems to be a beneficial effect of higher body 
mass on bone health, being obese increases the likelihood of several other health 
problems, including Type 2 diabetes and heart disease. Consequently, it is important 
for public health organizations to continue to concentrate on weight reduction in 
individuals who are overweight or obese and maintenance of body weight in 
individuals of normal weight, especially in later life. For those who are overweight, 
the goal is to lose weight while preserving skeletal integrity. The answer may be to 
lower caloric intake while raising levels of physical activity. Increasing intakes of Ca 
and/or vitamin D during energy restriction, is a better strategy for weight and fat loss 
(Soares et al., 2011).
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CHAPTER VIII
INTERACTION BETWEEN VITAMIN D 
AND PHYSICAL PERFORMANCE 
MEASURES AND MUSCULOSKELTAL 
PAIN IN PRE-AND POST MENOPAUSAL
SAUDI WOMEN
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8.1 Introduction
Vitamin D deficiency can lead to muscle weakness principally of the proximal 
muscle groups. Signs of this weakness are difficulty lifting objects, rising from a 
seated position, and ascending a flight of stairs (Girgis et al., 2013). A combined 
effect of bone and muscle pain, and proximal muscle weakness may also account for 
the widely reported changes in gait, which are frequently portrayed as waddling or 
penguin-like. Muscle weakness due to inadequate levels of vitamin D is common in 
the elderly (Janssen et al., 2010).With ageing muscle weakness increases the risk of 
falls, and the weaker bones increase the risk of bone fractures during falling. 
Measures to reduce the risk of falls and its related fractures in the elderly are of most 
important for individuals at high risk (Francis, 2001). Therefore, the link between 
sufficient vitamin D status and the lower risk of fractures may not only be due to the 
role of the vitamin D in maintaining bone mass and reducing the likelihood that a fall 
will result in bone fracture, but also by actually decreasing the risk of a fall in the first 
place as vitamin D acts to preserve muscle strength and balance.
The association between vitamin D and muscle tissue function has been 
recognized for a many years, and is both genomic and non-genomic in nature. 
Genomic effects start with the binding of l,25(OH)2D to its nuclear receptor, resulting 
in the activation of the VDRs. This activation induces the formation of VDR/RXR 
cofactor complex. This complex binds vitamin D response elements in DNA causing 
alterations in gene transcription and ensuing synthesis of protein. Vitamin D's non- 
genomic effects occur quickly and are mediated through a vitamin D receptor bound 
to the membrane (Girgis et al., 2013). Vitamin D in muscles activates protein kinase C 
and results in Ca release, increasing the calcium pool, which is essential for muscle 
contraction (Ceglia & Harris, 2012).
150
Numerous recent studies have investigated the role vitamin D plays in muscle 
strength and function. In their study on elderly women (mean age 75.6 years), 
Toffanello et al. (2012) found an association between lower serum 25(OH)D levels 
and impaired coordination and weaker strength. Houston et al. (2007) studied 
community-dwelling older adults (mean age 76.7 years) to investigate the connection 
between 25(OH)D, as well as change in 25(OH)D, and physical performance. They 
found that impaired physical performance was linked to inadequate vitamin D status 
among community-dwelling older men and women. Furthermore, baseline-deficient 
subjects whose vitamin D status was no longer deficient at follow-up exhibited 
significantly improved physical performance. It seems, then, that reaching 25(OH)D 
levels of at least 50 nmol/L may slow down the decrease in physical performance in 
the elderly and even postpone disability (Houston et al., 2007). In their population- 
based study of ambulatory individuals in the U.S. aged 60 and above, Bischoff-Ferrari 
et al. (2004b) found that serum 25(OH)D levels below 40 nmol/L correlated to 
reduced muscular function in the lower extremities. Another study on individuals 65 
years and older demonstrated an association between serum 25(OH)D levels below 50 
nmoFL and poor physical performance accompanied by a greater decline in muscle 
function (Wicherts et al., 2007).
Moreover, a great deal of research has found a lower risk of falls to be linked 
to adequate serum 25(OH)D levels or supplemental vitamin D. In their meta-analysis 
of randomized controlled studies of vitamin D supplementation, Bischoff-Ferrari et al. 
(2009) demonstrated that daily vitamin D supplements of 700-1000 lU lowered the 
risk of falls in older adults. On the other hand, supplemental doses of vitamin D of 
less than 700 lU or serum 25(OH)D levels of less than 60 nmol/1 may not lower the 
fall risk among older people.
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Frequently misdiagnosed as fibromyalgia, chronic musculoskeletal pain has 
been mainly linked to osteomalacia (Plotnikoff & Quigley, 2003). Vitamin D 
deficiency sets off a sequence of mechanisms which exert a negative influence on 
bone metabolism and skeletal integrity (Holick, 2005). When vitamin D falls below 
adequate levels, PTH secretion is stimulated. In conjunction with l,25(OH)2D, PTH 
trigger the mobilization of calcium from the bone, which over a long period of time 
can lead to diminished bone density. Furthermore, elevated PTH causes excess 
urinary excretion of phosphorus. In fact, serum calcium concentrations may maintain 
normal levels because calcium is being taken from the bone, but the mineralization of 
bone still deteriorates because the calcium phosphate compound is inadequate. When 
levels of calcium phosphate are low, osteoblasts continue their deposition of collagen 
matrix on both inner bone surfaces and under membranes covering the bone. This 
rubbery matrix does not offer structural support. Instead, it can absorb fluid, become 
spongy, and may expand under the periosteal coverings. Outward pressure on the 
periosteal tissues can result fi*om this osteomalacic condition and aches or pains can 
ensue, as these tissues are filled with pain-sensing fibers (Holick, 2003).
The relationship between vitamin D deficiency and musculoskeletal pain has 
drawn attention of many investigators. Plotnikoff and his coworkers showed that up to 
93% of the subjects (n=150) in their study who reported nonspecific musculoskeletal 
pain were vitamin D deficient (serum 25(OH)D <50nmol/L) (Plotnikoff & Quigley, 
2003), suggesting that insufficient levels of this hormone may contribute to the 
etiology of musculoskeletal pain. In another study conducted by Study of A1 Faraj and 
A1 Mutairi (2003) on 360 subjects with chronic back pain, reported the disappearance 
of low back pain in 95% of subjects after vitamin D therapy (A1 Faraj & A1 Mutairi, 
2003).
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Vitamin D deficiency and insufficiency is prevalent in Saudi Arabian women. 
Therefore, the aims of the present study were to determine if any associations exist 
between serum 25(OH)D and lower extremity performance measures. Further the 
study examined for verification if non-specific musculoskeletal pain is associated with 
vitamin D deficiency in these randomly selected healthy women.
8.2 Subjects and Methods
Please refer to Chapter II for complete information about subject’s recruitment, 
inclusion criteria anthropometric and biochemical measurements. In brief a total of 
449 healthy women were included in the present study.
The lower extremity performance was measured which included an assessment of 
eight feet walk (8FW), get up and go (GUG), and 5 times sit to stand (5-STS). ‘Self 
report’ musculoskeletal pain questionnaire was used in this study to locate pain in the 
body and pain intensity by using 0-10 numerical rating scale with 0 indicating no pain 
and 10 the worse pain ever (Appendix b). Non-specific musculoskeletal pain is 
defined in this thesis as pain perceived to be related to the musculoskeletal system 
which was not secondary to other diseases or injuries or known conditions causing 
pain (Littlejohn, 2005).
8.2.1 Statistical analysis
SPSS version 16.0 (SPSS, Inc. Chicago, IL) was used for statistical analysis. 
Continuous variables are presented as means ± SD and categorical variables are 
expressed as frequencies and percentages. Independent t-test was also used to assess 
menopausal differences (premenopausal versus postmenopausal). Association 
between variables was examined by Spearman’s correlation. Partial correlation 
adjusting for confounding variables was also performed. Tertiles of 25(OH)D levels 
were calculated and the differences in lower extremity performance were compared
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between women in the upper and those in the lower tertiles using Student t-test. 
Results were considered significant if P<0.05.
8.3 Results
8.3.1 Descriptive distribution of lower extremity performance
The means (SD) for the performed lower extremity performance tests and muscle pain 
scores according to menopausal status are presented in Table 8.1. There was a 
significant difference between premenopausal women and postmenopausal women in 
all parameters measured (P<0.001). Premenopausal women exhibited decreased time 
in performing all physical performance tests and lower muscle pain scores than did 
postmenopausal women.
Table 8.1: Lower extremity performance and muscle pain
variable Premenopausal
(n=226)
Postmenopausal
(n=219)
P-value
8-Feet walk 2.4 ± 0.45 3.1 ±1.9 <0.001
Get-up-go 8.1 ±1.2 11.0 ±4.4 <0.001
5-Sit-to-stand 7.8 ±1.7 11.9 ±4.2 <0.001
Muscle pain score 2.1±4.2 6.2± 7.9 <0.001
Data are presented as mean ± SD
Premenopausal and postmenopausal groups were compared with use of independent samples Mests
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8.3.2 Association between 25(OH) D and lower extremity performance and 
muscle pain
Data were analyzed to assess if a relationship exists between serum 25(OH) D and 
muscle function in the studied women. A significant positive eorrelation was found 
between 25(OH) D and 5-STS in premenopausal group of women (r=0.13; P=0.047). 
In postmenopausal women group no signifieant eorrelations were found, however a 
weak inverse correlation approaching significance was evident between serum 
25(OH)D levels and timed GUG score (r= -0.132; P= 0.051). Correlations between 
muscle functions and muscle pain scores and serum 25(OH) D for the studied women 
are presented in Table 8.2. After adjusting for age and BMI the correlation 
disappeared in the two groups of women.
Table 8.2: Relationship between 25(OH) D and muscle function in the studied 
pre and postmenopausal women (n=449)
Variable Premenopausal 
25(OH)D 
r P
Postmenopausal 
25(OH)D 
r P
8-Feet walk 0.01 0.9 -0.09 0.2
Get-up-go 0.05 0.4 -0.13 0.051
5-Sit-to-stand 0.13 0.047 -0.11 0.1
Muscle pain score 0.03 0.5 -0.062 0.3
r = eorrelation coefficient; P= significance value; Spearman correlation was used
8.3.3 Muscle function measures among 25(OH) D tertiles of the studied 
women
The differences in mean muscle function between women in the upper and lower 
tertiles of serum 25(OH)D level in pre and postmenopausal women are presented in 
Tables 8.3 & 8.4, respectively. There was no significant difference in the mean of 
muscle function measures between women in lower and upper tertiles in either group 
of women.
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Table 8.3: Muscle function means among tertiles of 25(OH) D in premenopausal
women
Variable Lower tertile 
(n=76)
Upper tertile 
(n=74)
P-
value
8-Feet walk 2.41 ±0.6 2.39 ± 0.4 0.8
Get-up-go 7.97 ± 1.12 8.16 ±1.33 0.5
5-Sit-to-stand 7.61 ±1.6 8.07 ±1.9 0.2
Muscle pain score 1.80 ±4.0 2.46 ± 4.5 0.3
Lower tertile (25(OH)D<13.0mnol/L); upper tertile (25(OH)D>23.1nmol/L)
Table 8.4: Muscle function means among tertiles of 25(OH)D in postmenopausal 
women
Variable Lower tertile 
(n=74)
Upper tertile 
(n=71)
P  value
8-Feet walk 3.06 ±0.89 3.28 ± 3.28 0.5
Get-up-go 11.03 ±3.33 11.05 ±6.04 0.9
5-Sit-to-stand 12.10 ±4.68 11.37 ±3.89 0.3
Muscle pain score 6.81 ±8.8 5.65 ± 7.6 0.3
Lower tertile (25(OH)D<22.9mnol/L); upper tertile (25(OH)D>38.8nmol/L)
8.3.4 Bone pain
Baek pain and bone pain frequency distribution information of the studied pre and 
post-menopausal women are present in Tables 8.5 & 8.6, respectively. For all women 
eombined a total of 61.7% of women complained from back pain and 55.9% of them 
had the pain in the lower back area. The percentages of women who visited the 
physician for consultations were 34.1% and 50.6% of women were using medications 
for pain relief.
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Table 8.5: Back pain information in pre and postmenopausal women
Variable Premenopausal 
n (%)
Postmenopausal 
n (%)
P-value
Back pain 129 (57.1) 148 (66.4) 0.043
Lower back pain 114(50.4) 137 (61.4) 0.025
Use of pain relief 96 (42.5) 132 (59.2) 0.002
Physician consultation 57 (25.2) 96 (43.0) 0.001
N: subjects. Values given in parenthesis are percentages (%) out o f total within the group 
Premenopausal and postmenopausal groups were compared with use o f chi-squared
Table 8.6: Bone pain locations in the studied women
Variable Premenopausal Postmenopausal P-value
n (%) n (%)
Bone pain 115(50.9) 189 (84.8)
Collar 22 (9.7) 31 (13.9) 0.009
Shoulder 28 (12.4) 35 (15.7) <0.001
Arms 17 (7.5) 29 (13.0) 0.023
Hands 17 (7.5) 34 (15.2) 0.015
Wrist 8 (3.5) 3 (1.3) NS
Legs 42 (18.6) 65 (29.1) 0.011
Knee 70 (31.0) 164 (73.5) <0.001
Ankle 8 (3.5) 21 (9.4) NS
Foot 23 (10.2) 51 (22.9) 0.028
Thigh 21 (9.3) 26(11.7) 0.006
N; number o f subjects .Values given in parenthesis are percentages (%) out o f total within the group 
Premenopausal and postmenopausal groups were compared with use o f chi-squared
8.3.5 Bone pain scores
Descriptive distribution of pain scores of the women is presented in Table 8.7. 
Postmenopausal women exhibited significantly higher pain scores than 
premenopausal women (P< 0.001).
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Table 8.7: Bone pain scores among the studied healthy pre and postmenopausal
women
Pain score
Premenopausal Postmenopausal P-value
(n=226) (n=223)
Back 3.2 ±3.1 4.5 ±3.6 <0.001
Bone 9.8±11.1 19.8 ±16.6 <0.001
Daily activity 1.0 ±1.9 4.1 ±3.2 <0.001
All types of pain 16.1 ± 16.6 34.6 ± 25.3 <0.001
Data are presented as mean±[SD
Premenopausal and postmenopausal groups were compared with use o f independent samples /-tests
8.3.6 Relationship between 25(OH)D and musculoskeletal pain in the 
studied women
Data were analyzed to see if an association exists between 25(OH)D and bone pain in 
the studied women. None of the pain categories correlated significantly with serum 
25(OH)D in the premenopausal group. On the other hand, a significant inverse 
correlation was found between serum 25(OH)D and bone pain (r=-0.141; P=0.036), 
with daily life activity (p=-0.140; P= 0.037), and with sum of all types of pain 
(r=-0.142; P=0.034) in postmenopausal women. Furthermore, a trend was found 
between serum 25(OH)D and back pain (i=-0.116; P=0.085). The significant 
correlation between pain categories and serum 25(OH)D disappeared however after 
controlling for age and BMI.
Table 8.8: Relationship between 25(OH)D and musculoskeletal pain in 
postmenopausal women (n=223)
Pain categories Postmenopausal 
25(OH)D 
r P
Back -0.116 0.085
Bone -0.141 0.036
Daily life activity -0.140 0.037
All types pain -0.142 0.034
r = correlation value; P= significant value
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8.4 Discussion
The connection between vitamin D status and physical performance measures 
which examine impaired mobility has become the subject of much clinical debate in 
the last two decades (Wicherts et ah, 2007; Toffanello et al., 2012). Reduced muscle 
strength and impaired functional performance are significant contributors to the risk 
of falls in older individuals, and several studies have demonstrated the link between 
low serum 25(OH)D levels, diminished muscle strength and functional capacity 
(Bischoff-Ferrari et al., 2004b; Bischoff-Ferrari et al., 2009). As vitamin D deficiency 
is associated with a higher risk of osteoporosis and consequently, an increased risk of 
fracture after a fall, it appears that low vitamin D status is involved in raising the risk 
of both falls and osteoporotic fractures.
One of the objectives for this study was to test whether serum 25(OH) D was 
correlated with simple physical performance measures (8-FW, GUG, and 5-STS). 
These measures were used to assess the muscle strength and lower extremity function 
in our sample of ambulatory pre- and post-menopausal women. Despite the high 
prevalence of vitamin D deficiency in our population, this was not associated with 
impaired physical performance measures, a strong predictor of future disability, in the 
studied healthy women. Bivariate correlation between serum 25(OH)D levels and 
functional measures showed a trend toward decreased time in seconds to complete the 
timed GUG test and higher serum 25(OH)D levels (Spearman’s rho= -0.132; P= 
0.051). Although we accept the null hypothesis in that physical performance measures 
are not significantly correlated with serum 25(OH) D levels, there is a definite trend 
apparent between GUG and serum levels of 25(OH) D.
Previous studies have found a relationship between serum levels of 25(OH) D 
and muscle strength and physical performance in older subjects (Bischoff-Ferrari et
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al., 2004b). However other studies failed to show any associations (Annweiler et al.,
2009) and are in line with our results. The observation of a trend toward significant 
correlation at the bivariate level between increased timed GUG test and lower serum 
25(OH)D levels is important from a public health position as higher timed GUG have 
been associated with increased fall risk in community dwelling adults (Lusardi et al., 
2003). Several reasons for the lack of an observed association between serum 25(OH) 
D and muscle strength in the current study should be considered. The study 
population was one of overall good health. However, the majority of the women 
suffered from vitamin D deficiency, and an insufficient number with higher 25(OH)D 
levels were available to deduce a meaningful relationship. Further investigation of the 
link between vitamin D and musculoskeletal health in pre and post-menopausal 
women is highly recommended and is suggested to include subjects with a range of 
vitamin D levels.
Musculoskeletal pain is common in the general population and may be looked 
upon as one of our daily life harassments, and one of the most common reasons for 
primary care consultation (Brooks, 2006b). Results of the current study showed that 
67.7% and 39.9% of women reported pain in bone and muscle, respectively. Some 
authors have suggested some specific character for the pain associated with vitamin D 
deficiency (Holick, 2003). They believed that the pain is usually sensed on the bone 
or muscle. In present study 86.5% and 86.0% of women who complained from bone 
pain, and muscle pain respectively, suffered from vitamin D deficiency (serum 
25(OH) D >50nmol/L). However, low serum 25(OH)D concentrations were not 
associated with increased pain in these women and our results are in line with 
previous studies that failed to show the association between vitamin D status and 
musculoskeletal pain (Block, 2004; Warner & Amspiger, 2008). The majority of
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women in our study were vitamin D deficient, which is why we had not appreciated 
the relationship between vitamin D and musculoskeletal pain. Furthermore, conditions 
that encourage vitamin D deficiency such as obesity and sedentary life, which are 
evident in the current study, also predispose subjects to musculoskeletal pain.
In conclusion vitamin D deficiency is a condition that causes muscle 
weakness and musculoskeletal pain. Although 25(OH) D concentrations were not 
associated with muscle strength and pain in this group of women, corrections of 
vitamin D levels may preserve muscle strength and reduce pain. Further research is 
required to determine whether hypovitaminosis D is causally linked to increased 
musculoskeletal pain, and whether supplementation can improve muscle function in 
these women.
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CHAPTER IX
GENERAL DISCUSSION
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9.1 Discussion
The main purpose of this thesis was to describe the vitamin D status in a 
sample of healthy pre- and post-menopausal Saudi women living in the city of Jeddah. 
The objectives were to 1) investigate the impact of lifestyle factors on serum 
25(OH)D levels; 2) to assess the extent of osteopenia and osteoporosis and factors 
affecting bone health in these women; 3) to assess the interaction between vitamin D 
status and marker of bone health; 4) to describe the extent of overweight and obesity 
and its association with vitamin D status and bone density; 5) and to assess the 
relationship between serum 25(OH)D and non-specific musculoskeletal pain and 
measures of physical performance. Two hundred twenty six women aged 20-39 years 
and 223 women aged 50-82 years participated in the study.
The results of the research conducted for this thesis were presented in five 
chapters. This type of research is useful for a number of reasons, one of which being 
that it will contribute to the assessment of the vitamin D status and exploring factors 
that contribute to poor vitamin D status of Saudi women residing in the Western 
region of Saudi Arabia, which is an under-researched area. Vitamin D, not only has 
an important role in bone health but it may also affect overall health outcomes. To 
reduce health risks associated with vitamin D deficiency, knowing the determinants of 
25(OH) D concentrations, a major circulating metabolite of vitamin D, is critical. An 
interesting dimension to this study is that it allows comparison of two different age 
groups living in similar environmental and cultural conditions and thus allows the 
impact of these factors on vitamin D status and bone health to be examined. As 
previously mentioned, little data is available in the literature regarding the vitamin D 
status among Saudi women, young and old, living in Jeddah and even less 
information is available regarding the associated risks of developing deficient and
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insufficient levels of this vitamin. Thus, understanding factors associated with 
25(OH)D levels is important and can be a key factor in prevention and management 
of vitamin D deficiency.
Jeddah is located on the Western coast of Saudi Arabia, with an arid climate 
and at latitude of 21°N, vitamin D deficiency was assumed not to be a problem due to 
the abundant sunshine. However, the results of the present study challenge this 
assumption and they clearly demonstrated that there is a high prevalence of vitamin D 
deficiency and/or insufficiency among healthy women living in Jeddah. About 85.5% 
of women exhibited vitamin D deficiency (serum 25(OH) D<50 nmol/L) and only 
3.8% were considered to have optimal vitamin D status (serum 25(OH)D >75 
nmol/L). Unexpectedly, higher percentages of the deficiency and/or insufficiency 
were present in the premenopausal group of women.
The vitamin D status of a person depends on the endogenous production of 
vitamin D by the skin in the presence of sunlight and dietary intake of vitamin D. 
Factors affecting vitamin D synthesis include seasonal variation, latitude, time of the 
day, air pollution, aging, skin pigmentation, use of sunscreens and concealing clothing 
(veils). Analysis of the characteristics of the Saudi women studied showed that they 
had limited sun exposure and darker skin, both well-known risk factors for vitamin D 
deficiency. Cutaneous synthesis is the most efficient natural source of vitamin D and 
80-90% of vitamin D requirements are obtained through sun exposure (Holick et al., 
2007; Tsiaras & Weinstock, 2011). It would seem that women in the current study are 
not getting sufficient cutaneous vitamin D synthesis. Melanin pigmentation and 
conservative clothes worn while being outdoors may be factors affecting vitamin D 
synthesis and therefore status in these women. More time spent indoors due to work 
schedule or excessive heat has resulted in reduced sun exposure and less vitamin D
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production. The obvious solution to the lack of sunlight on skin is not a workable one, 
given Saudi attitudes toward women’s dress. The lack of any sporting activities in 
girls’ school does not help the situation (Siddiqui & Kamfar, 2007). It is going to take 
a major shift in cultural attitudes to make sunshine a viable source for vitamin D. The 
irony, of course, in a country with over 350 days of sunshine every year (El-Hajj 
Fuleihan, 2009), is apparent.
To conclude, although other factors may contribute to vitamin D deficiency in 
different populations, plausible explanations for the high prevalence of 25(OH)D 
deficiency among Saudi women is reduced cutaneous synthesis which is due to: 1) 
limited sun exposure (limited outdoor activities due to excessive heat, and 
conservative clothing, 2) higher skin pigmentation than that of Caucasians that 
reduces the UVR-mediated synthesis of vitamin D per the same dose of sun exposure. 
For the previously mentioned reasons, women are at higher risk of vitamin D 
deficiency.
Adequate levels of vitamin D have an important effect on bone mass in the 
young and old. Maintaining serum calcium and phosphorus concentrations within the 
normal range is vitamin D ’s major biologic function. Vitamin D deficiency is 
associated with secondary hyperparathyroidism and bone loss. As mentioned earlier, 
85.5% of women were vitamin D deficient and 69% had serum PTH levels above the 
normal range. Low BMD was prevalent in the studied women with more women in 
the postmenopausal group, as expected. Compared to premenopausal women with 
normal BMD, those with low bone mass tend to have a faster process of losing BMD 
at an older age and are more likely to develop osteoporosis (Hernandez et al., 2003; 
Bonjour et al., 2009).
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Osteoporosis is a major global health problem with an increasing prevalence 
and a high impact on mortality and morbidity. This condition is influenced by genetic 
and environmental factors. Aging increases the risk of developing osteoporosis, which 
affects millions of postmenopausal women. Menopause is associated with an 
imbalance in bone metabolism. The decline in ovarian estrogen production is the main 
determinant of this imbalance; however, many other factors seem to be involved. In 
our study, osteoporosis was evident in postmenopausal women at the lumbar spine 
(9%) and femoral neck (4%) sites. Although genetic information are not known for 
the studied women, plausible explanations for the low bone mass among Saudi 
women are as follows: 1) high prevalence of vitamin D deficiency with secondary 
hyperparathyroidism; 2) multiple pregnancies perhaps with little or no use of calcium 
and vitamin D supplements.
It will not be surprising to see more and more subjects with osteoporosis in the 
coming years, unless preventive steps are seriously considered. The importance of 
understanding modifiable risk factors that contribute to bone mass is critical for 
improving public health. The importance of achieving peak bone mass, to prevent a 
weak skeleton later in life, should not be underestimated. The most effective 
prevention strategy is maximizing both the public’s understanding of bone health as 
well as implementing public health programs that increase BMD during childhood 
and young adulthood. It is through this understanding that the course of the disease 
can be altered.
Obesity, an imbalance between energy intake and expenditure over a 
prolonged period of time, is the disease of the twenty-first century and is rising 
worldwide (Ng et al., 2011). It has been estimated that more than 1 billion people are 
overweight, with 300 million meeting the criteria for obesity (WHO, 2000). Despite a
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known genetic contribution, the increase in obesity prevalence has been largely 
attributed to lifestyle changes, which means that it is amenable to modification 
through public health awareness and other interventions (Vimaleswaran & Loos,
2010). Compared to people with a healthy weight, obese individuals have a higher 
risk of vitamin D deficiency. The low levels of circulating 25(OH)D in obese subjects 
have been attributed to multiple factors like decreased exposure to sunlight because of 
limited mobility, negative feedback from elevated l,25(OH)2D and PTH levels on 
hepatic synthesis of 25(OH)D, and excessive storage of vitamin D in the adipose 
tissue (Arunabh et al., 2003).
It is widely recognized that obesity has a protective effect on the bone tissue 
(Reid, 2008). Obese women have a lower risk of fi*actures compared with normal 
body weight women (Albala et al., 1996; Zhai et al., 2008). The positive effect of 
obesity on bone is multi-factorial, as it is associated not only with the mechanical load 
but also with the secretion of bone-active hormones such as estrogens fi*om the 
adipocyte (Reid, 2002). In obese post-menopausal women, increased estrogen 
synthesis by adipose tissue has been suggested as one of the potential mechanisms for 
the protective effect of fat mass on bone (Albala et al., 1996).
Estrogens play a pivotal role in the maintenance of skeletal homeostasis, protecting 
against osteoporosis by reducing bone resorption and stimulating bone formation 
(Reid, 2008). This extra-gonadal estrogen synthesis in fat tissue becomes the 
dominant estrogen source in postmenopausal women, due to the lack of ovarian 
function (Reid, 2008).
Despite the positive effect of obesity on bone mass, people who are 
overweight and obese are more likely to develop a number of potentially serious 
health problems (WHO, 2000; Conway & Rene, 2004). Vitamin D deficiency is
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emerging as a risk factor for several co-morbidities commonly found in obesity. 
Given Vitamin D’s association with obesity and its co-morbidities, recommendations 
on how to optimize weight loss are warranted and may include achieving an optimal 
vitamin D status.
Historically the association between vitamin D and bone health is well 
accepted. Vitamin D deficiency leads to proximal muscle weakness, which may 
increases the risk of falls in older adults. In the current study despite their vitamin D 
status, premenopausal women performed all the physical measures faster than older 
women as anticipated. We could not demonstrate any association between 25(OH)D 
serum levels and physical performance measures. One reason for the lack of 
association could be because the majority of the women in the study were vitamin D 
deficient, and an inadequate number with sufficient vitamin D levels were available to 
deduce a meaningful relationship. Another reason for the lack of association is that it 
may be a reflection of muscle adaptation to prolonged duration of vitamin D 
deficiency.
Bone discomfort and muscle aches are other symptoms of vitamin D 
deficiency. Because the symptoms of deficiency are non-specific, it often goes 
untreated. The percentages of women complaining of non-specific musculoskeletal 
pain in the current study were 67.7% of whom 86% were vitamin D deficient. 
However, increased intensity of this non-specific musculoskeletal pain was not 
correlated to low 25(OH)D levels in the current study. Increased BMI and decreased 
physical activity may be some of the important factors causing insidious 
musculoskeletal pain in these women. Maintaining a healthy weight may reduce the 
symptoms of pain and increase 25(OH)D levels in these women.
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It is important to note that studies from different continents and countries 
cannot exactly be compared to one another as they have different population 
characteristics and methodologies that may have influenced the results of the 
particular studies. Factors such as culture, latitude, seasonal variations, availability of 
food and dietary patterns are some of the important contributing factors that differ 
from one country to another. Currently, in Saudi Arabia the data on vitamin D 
deficiency are scarce. Limited sun exposure and obesity are among the factors 
contributing to poor vitamin D status in Saudi women. Since vitamin D plays an 
important role not only in bone health but in almost all body’s systems, early 
detecting and treatment of this deficiency is highly recommended. Urgent measures 
are needed to avoid long-term complications related to severe vitamin D deficiency.
9.2 Strengths and limitations
The current study has some strengths and limitations, which should be considered in 
the interpretation of the results. The use of a large randomly selected population of 
adult women minimizes bias errors (explained in Chapter II), and the study sample is 
believed to represent a cross-sectional sample of the general female population in 
Jeddah. It is, however, not clear whether the results can be generalized to other female 
populations in different regions in Saudi Arabia. It was not easy to recruit Saudi 
women to the study, and the premenopausal women were the hardest group to recruit 
because of the early morning appointments conflicting with their work and/or school 
commitments. The construct validity of most of the variables, including the 
anthropometric, physical performance, and BMD measurements, was strong as it was 
done by one subject for the whole subjects studied. The use of self-administered 
questionnaires in assessing independent variables may induce personal 
misclassifications as it allows for subjective interpretation of the questions. The study
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is also limited by demographic bias toward the high income and more educated 
subjects of the community, which will eliminate the more with much lower income 
and less educated women who may have worse results. It was also a challenge to 
choose the most applicable ways to measure the study variables in this research. The 
bone and muscle pain questionnaire, for example, was not the best way to assess bone 
pain, with clinical assessment being a more reliable method for the obtainment of 
accurate data (Fink, 2000). However, the bone/muscle pain questionnaire was the 
fastest and best way to achieve the outcome given the time restraints and equipment 
available for this study. A review of the quality of the questionnaire by professionals 
would have been a further advantage. Another limitation is the lack of dietary intake 
information of these women.
The cross-sectional design of the current study did not allow for any 
conclusions regarding the chronology of any observation made, nor causality of the 
relationships. The results cannot distinguish between newly occurring or longstanding 
suboptimal 25(OH)D levels or low BMD. Thus, prospective studies must be 
performed to elucidate any causality of the associations. Limited analysis, the use of 
average lactation period in months instead of using the total months period, and the 
lack of dietary intake information are other limitations of the current study.
Cross-sectional study design is particularly problematic when assessing bone 
health outcomes due to the length of time of the bone turnover cycle. The 
physiological process of bone resorption could be initiated months before lower BMD 
is detected on a DXA. Therefore, the serum 25(OH)D level at the time of BMD 
measurement may not reflect the true relationship between it and the bone quality 
parameters assessed. To establish an actual causal relationship between 25(OH)D and 
bone health and muscle function outcomes, it would have to be demonstrated that
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variation in the bone health outcomes could only be due to the variation in serum 
25(OH)D levels, and that no other variables are causing them to co-vary. 
Additionally, assessments of vitamin D status over time could reveal the importance 
of vitamin D to bone and muscle health in the Saudi population.
One final potential source of bias comes from measurement uncertainty. It is 
suggested that serum 25(OH)D assays can measure vitamin D levels 10% lower or 
higher than the true serum level (Cavalier et al., 2010). Therefore, someone measuring 
near the optimal 25(OH)D cutoff level may be misplaced in either the optimal or 
suboptimal group, either overestimating or underestimating the number of participants 
presenting with optimal vitamin D levels. In the current study, all samples were 
measured at the same laboratory, with the same technique, in an attempt to limit bias 
introduced from the serum 25(OH)D assessment techniques. International quality 
assurance standards were used in all laboratory analysis. With respect to vitamin D 
status, our results were consistent with previous studies in Middle Eastern population, 
which increases confidence in our findings.
9.3 Areas for further research
9.3.1 Short time objectives
Further research is needed to study the influence of habitual nutrition on vitamin D 
status and bone health. Optimum sun exposure times for vitamin D synthesis vary 
with individuals and environmental characteristics (Tsiaras & Weinstock, 2011). It 
would be interesting to assess the time and the level of sun exposure sufficient to 
maintain 25(OH) D concentrations. Another interesting area which needs further 
research is to investigate how changes in 25(OH) D over time affecting muscle 
function and performance activity in the elderly. Additional research on the effect of 
modifiers such as age, and BMI on 25(OH)D status is needed. Another possible area
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for research is to investigate the role of dietary calcium intake in relation to body 
composition and its affect on vitamin D status.
9.3.2 Long time objectives
Guidelines for vitamin D supplementation and sun exposure are required in order to 
improve vitamin D status, both on individual and population levels. Vitamin D intake 
and sun exposure should be reconsidered and, according to the present work, 
increased significantly. Vitamin D fortification of the commonly used food in Saudi 
Arabia will reduce the deficiency and/or insufficiency of this vitamin in our 
population. We aim to continue our work in developing these recommendations.
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Appendix (a) General & lifestyle data questionnaire
Name:
Basic data
Age: File #:
Phone: District:
Socio-demographic data
Marital Status: □  Single □  Married
□  Divorced O  Widow
Education: □  no education □  Elementary /intermediate
□Secondary □University □Postgraduate
Occupation: □  Student □  Governmental
□  Private sector □  House wife
Income per-month:
□  <5000 SR □  > 5 0 0 0 -<  10,000 SR
□  >10,000-<15,000 SR □  >15,000 SR
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Lifestyle Information
1. Smoking habits:
□  No
□  Yes At what age did you start: 
(years) :______________
Duration
How many cigarettes per day: per week
How many shisha (jurak) per day: per week
How many bubbly bubbly per day: per week
2. Physical Activity:
a) At present, are you practicing any physical activity?
□  No reason:
□  Yes 
exercise:
list type (s) of
Duration minutes day / week?
b) How often are you physically active for at least 20 minutes during which time you 
become short of breath and sweat?
□  Less than once a week □  2-3 times a week
^  Once a week □  more than 3times a week
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3. Sun exposure:
In the past month have you had any sun exposue?
□  No □  Yes If yes: Sites exposed
Duration: □  less than 15 minutes □  15 min-30 min □  30
min- 1 hour
□  1 hour- 2 hours □  2 hours- 3 hours □  more than 3
hours
Do you use sunscreen: Yes □  No □
4. Veiling type:
Are you: □  fully veiled (niqab + gloves) □  fully veiled (niqab only)
□  partly veiled (hijab)
5. Skin type:____________
6. Reproductive history:
Parity:________________
Age at first pregnancy:________________  Age at last
pregnancy:____________
Number of pregnancies:_____________  Number of
children:_____________
Lactation: Yes □  No □  Average lactation:_________ Months
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6.1 Menstrual history:
Age at menarche:_____
Age at menopause:
6.2 Menopausal symptoms:
Hot flashes: Yes □  No □
Trouble sleeping: Yes □  No □
Night sweat: Yes □  No □
Menstrual irregularities: Yes □  No □
7. Fractures history:
Did you have DEXA done before? □  Yes □  No 
Previous diagnosis with osteoporosis: Yes □  No □  When?
Fracture: Yes □  No □  Site(s):___________________
At what age?_______  Cause:
Mother had fracture? Yes O  No O  Site(s):
At what age?________________________
Father had fracture: Yes □  No O  Site(s):
At what age?________________________
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Appendix (b) Bone and Muscle Pain Questionnaire
The purpose of this questionnaire is to assess bone and muscle pain and their 
effects on everyday living. This will provide us with important information 
about how common bone and muscle pain are and how they impact on 
women’s everyday lives. Therefore it is important that you answer it as fully as 
possible. Unless instructed otherwise, please mark only one answer for each 
question.
Section 1- Back pain
1. In the past 6 months, have you had any back pain?
a. Yes □ (go to question 2) b. No □ (go to question 12)
2. What are the causes of this back pain?
(Please give details in the space provided below)
3. How bad is the back pain on average? (please circle one answer)
0 1 2 3 4 5 6 7 8 9  10
No pain Moderate pain Worst
pain ever
4. In what part of the back is the pain usually located?
Please use the chart as your 
guide
Upper back (Area 1) □
Mid area of back (Area 2) □
Lower back (Area 3) □
5. How frequently have you experienced this back pain?
Less than once a month □
One to three times a month □
One to three times per week □
Daily □
6. How would you describe the type of back pain? (Tick all that apply)
‘Shooting’ □
Dull □
Tender □
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Spasmodic
Aching
Sharp
Prickly
Sore
□
□
□
□
□
7. Do you do anything to relieve this pain?
Yes □ (go to question 8)
No □ (go to question 11 )
8. What do you do to relieve this pain?
(Please tick all answers which apply)
Nothing
Rest (lie down, sit down, sleep etc)
Home remedies (heat pad, heat lamp, cold compresses etc) 
Medication (i.e.' pain killers', analgesics)
9. If you use medication, please list the name/s and doses of the
medication/s in the table below  e.g. Paracetamol, Xmg, 3 times per
day____
Name Dose Frequency
10. How often do you use this pain medication?
Less than once a month □
One to three times per month □
One to three times per week □
Daily □
11. Have you ever consulted your GP (Doctor) about your back pain?
Yes □ No o
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Section 2- Daily living
Please tick the option which best describes your experience of the 
following tasks in the last 6 months:
12. (a) Bending down to pick up lightweight objects (like clothing)
from the floor
No difficulty □ go to question 13
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
13. (a) Lifting a ten-pound object (like 10 bags of sugar) from the floor
No difficulty □ go to question 14
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
14. (a) Reaching for an object just above your head, such as ajar on 
the shelf
No difficulty □ go to question 15
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
15. (a) Putting on socks or tights on either foot
No difficulty □ go to question 16
Some difficulty □
Much difficulty □
Unable to do □
198
(b) Is this due to back pain?
Yes □ No □ Don’t know □
16. (a) Getting in and out of a car
No difficulty □ go to question 17
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
17. (a) Standing up for 30 minutes
No difficulty □ go to question 18
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
18. (a) Climbing stairs at a moderate pace
No difficulty □ go to question 19
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know □
19. (a) Walking at a moderate pace on flat ground
No difficulty- □ go to question 20
Some difficulty □
Much difficulty □
Unable to do □
(b) Is this due to back pain?
Yes □ No o Don’t know
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Section 3- Bone and muscle pain
The following questions relate to the past 6 months
PART A- BONE PAIN
20. (a) Have you had any pain in your bones?
Yes □ No □ (go to question 21 )
(b) On the table below, please tick the boxes for any areas where you 
have had bone pain and then rates the severity of the pain on the 
horizontal line (where 1 = no pain and 10 = severe pain):
Location 
of the pain
The severity of the pain Location of 
the pain
The severity of the pain
1. collar
Example
no pain
T  10
severe
pain
2 .
sh rn(s) no pain
Example
— Vio
severe
pain
1. collar 1 f
no pain
T  10
severe
pain
2 .
she s)
1 f
no pain
T  10
severe
pain
3. rib(s)
1 r
no pain
T  10
severe
pain
4. back
no pain
T  10
severe
pain
5. Arm(s) 1 I
no pain
T  10
severe
pain
6. hand(s) 1 f
no pain
T  10
severe
pain
7. wrist s) 1 f
no pain
T  10
severe
pain
8. hip 1 r
no pain
T  10
severe
pain
9. leg 1 r
no pain
T  10
severe
pain
10. knee(s)
no pain
T  10
severe
pain
11
ai
1 F
no pain
T  10
severe
pain
12. foot/feet 1 r~
no pain
T  10
severe
pain
13. thighs 1 r
no pain
T  10
severe
pain
14. other 
(specify
1 r
no pain
T  10
severe
pain
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21. Have you had pain in the back of your thighs?
Yes □ (go to question 22) No □ (go to question 23)
22. How would you describe this thigh pain? {Tick all that apply)
‘Shooting’ □
Dull □
Tender □
Spasmodic □
Aching □
Sharp □
Prickly □
Sore □
23. Have you had symptoms of pain, aching, or stiffness in or around a joint? 
Yes □ No o Don’t know □
PART B- MUSCLE PAIN
The following questions relate to the past 6 months
24. (a) Have you had any pain in your muscles?
Yes □ No o (go to question 26)
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(b) On the table below, please tick the boxes for any areas where you 
have had bone pain and then rates the severity of the pain on the 
horizontal line (where 1 = no pain and 10 = severe pain):
Location 
of the pain
The severity of the pain Location of 
the pain
The severity of the pain
1. arms
Examp/e
1
no pain
T  10
severe
pain
2 .
sh (s) 1 Ino pain
Example
^ -----V10
severe
pain
1. arm(s) 1 I
no pain
T  10
severe
pain
2 .
she s)
1 f
no pain
T  10
severe
pain
3. leg(s) 1 I
no pain
I f 10
severe
pain
4. back 1 I
no pain
T  10
severe
pain
5. thighs 1 f
no pain
T  1 0
severe
pain
6. hand(s) 1 f
no pain
T  10
severe
pain
7. foot/feet 1 I
no pain
"V 10
severe
pain
8. other 
(specify 
 )
1 T
no pain
“T  10
severe
pain
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25. How would you describe the type of muscle pain? {Tickall that apply)
a. ‘Shooting’
b. Dull
0. Tender
d. Spasmodic
e. Aching
f. Sharp
g- Prickly
h. Sore
i. Burning
26. In the last 6 months have you had any feelings of muscle weakness 
in the back of the thighs?
Yes □ No □ Don’t know □
Thank you for answering our questionnaire
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Appendix (c) Health history questionnaire
1. MEDICAL HISTORY;
.1 Hepatic: [ ] Yes [ ]No [ ] DN 2.2 Ricket in childhood: [ ] Yes [ ]No
] DN
(Specify:____________________________ )
.3 Renal: [ ] Yes [ ] No [ ] DN 2.4 Other endoctrine disorders: [ ]Yes [ ]No
]DN
(Specify:____________________________ )
specify:__________________________________ )
5 Hypertension: [ ] Yes [ ] No [ ] DN 2.6 Rheumatic disorder: [ ] Yes [ ] No
] DN
(Specify:
 )
7 Blood disorder(s): [ ]Yes [ ]No [ ]DN 2.8 Thyroid disorder : [ ] Yes [ ]No
] DN
9 Diabetes: [ ] Yes [ ] No
9.1 Type of diabetes: [ ] Non-insulin dependent [ ] Insulin dependent [ ] History of GDM
9.2 Therapy: [ ] Diet alone [ ] Diet + oral [ ] Oral alone [ ] Diet + insulin
10 Cancer: [ ] Yes [ ] No
11 Previous diagnosis of Osteoporosis: [ ] Yes [ ]No [ ] DN (When? 
 )
11.1 Did you have DEXA done? [ ] Yes [ ]No [ ] DN
12 Oophorectomy: [ ] Yes [ ] No
What age?______________________
13 Menstrual irregularities? [ ] Yes [ ] No
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2. DRUG HISTORY:
. 1  D o  y o u  u s e  r e g u l a r  m e d i c a t i o n ?
C a l c i u m
V i t a m i n  D
S t e r o i d s
P h e n y t o i n
A n t a c i d s
[  ] Y e s  [  ] N o
]  Y e s  
]  Y e s  
]  Y e s  
]  Y e s
] N o
] N o
] N o
] N o
]  Y e s  [  ]  N o
O t h e r  d r u g s  ( s p e c i f y )
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Appendix (e) Study brochure
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